Methods for editing DNA methylation
Patent Information
- Application Number
- JP2024119444
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2016-08-19
- Filing Date
- 2024-07-25
- Publication Date
- 2024-11-01
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current methods lack the ability to efficiently and targetedly edit DNA methylation, making it difficult to study the functional significance of methylated variable regions (DMRs) in biological processes.
The use of catalytically inactive site-specific nucleases, such as dCas9-Tet1 and dCas9-Dnmt3a, fused with effector domains to target and modify DNA methylation or demethylation at specific genomic sequences, allowing for precise editing of methylation status in cells.
Enables targeted activation or silencing of gene expression, reprogramming cell fate, and altering chromatin structures, providing insights into epigenetic regulation and facilitating the identification of functionally significant DMRs.
Smart Images

Figure 00000096_0000 
Figure 00000096_0001 
Figure 00000096_0002
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application No. 62 / 377,520, filed Aug. 19, 2016, the entire contents of which are incorporated herein by reference.
[0002] government support This invention was made with Government support under Grant No. HD045022 awarded by the National Institutes of Health. The Government has certain rights in this invention. [Background technology]
[0003] Mammalian DNA methylation at 5-cytosine plays an important role in many biological processes, including genomic imprinting, cell fate determination, organization of chromatin structure, maintenance of cell identity, and regulation of gene expression (Bird, 2002; Cedar and Bergman, 2012; Jaenisch and Bird, 2003; Smith and Meissner, 2013). Genetic studies have revealed that DNA methylation is essential for mammalian development and adaptation to environmental signals (Jaenisch and Bird, 2003; Li et al., 1992; Smith and Meissner, 2013). Aberrant DNA methylation has been observed in cancer and neurological disorders (Laird and Jaenisch, 1996; Robertson, 2005). Advances in sequencing technologies have resulted in the generation of single-nucleotide resolution methylation maps for numerous types of human and mouse cells and tissues (Lister et al., 2009; Schultz et al., 2015). Importantly, these maps have enabled the identification of variably methylated regions (DMRs) at base pair resolution during various processes in normal development (Lister et al., 2013) as well as disease (De Jager et al., 2014; Doi et al., 2009; Landau et al., 2014). However, the study of the functional significance of these DMRs remains challenging due to the lack of suitable molecular tools that can efficiently edit DNA methylation in a targeted manner. Summary of the Invention [Means for solving the problem]
[0004] Mammalian DNA methylation is an epigenetic mechanism that orchestrates gene expression networks in many biological processes. However, it remains difficult to investigate the function of specific methylation events. It has been demonstrated that fusion of Tet1 or Dnmt3a with catalytically inactive Cas9 (dCas9) allows targeted DNA methylation editing. Targeting of dCas9-Tet1 fusion proteins to methylated promoter sequences or dCas9-Dnmt3a fusion proteins to unmethylated promoter sequences caused activation or silencing of endogenous reporters, respectively. Targeted demethylation of BDNF promoter IV by dCas9-Tet1 induced BDNF expression in postmitotic neurons, and targeted demethylation of the MyoD distal enhancer activated MyoD-promoted reprogramming of fibroblasts to myoblasts. De novo methylation targeting CTCF loop anchor sites with dCas9-Dnmt3a blocked CTCF binding, disrupted DNA looping, and caused changes in gene expression in neighboring loops. Finally, these tools have been shown to be capable of editing DNA methylation in mice, demonstrating broad utility in functional studies of epigenetic regulation. These tools will be useful to gain insight into the functional significance of DNA methylation in diverse biological processes such as gene expression, cell fate determination, and organization of higher-order chromatin structures. Furthermore, these tools will be useful in combination with different sgRNA libraries to build screening platforms to identify functionally specific methylation variable regions (DMRs) and in generating transgenic mice to study specific DNA methylation events in vivo.
[0005] Disclosed herein is a method for modifying one or more genomic sequences in a cell, the method comprising introducing into the cell a catalytically inactive site-specific nuclease fused to an effector domain having methylation activity, and one or more guide sequences, thereby modifying one or more genomic sequences in the cell.
[0006] Also disclosed herein is a method of modifying one or more genomic sequences in a cell, comprising introducing into a cell a catalytically inactive site-specific nuclease fused to an effector domain having demethylation activity, and one or more guide sequences, thereby modifying one or more genomic sequences in the cell.
[0007] Also disclosed herein is a method of modulating methylation of one or more genomic sequences in a cell, comprising introducing into a cell a catalytically inactive site-specific nuclease fused to an effector domain having methylation or demethylation activity, and a guide sequence or a nucleic acid encoding a guide sequence, thereby modulating methylation of one or more genomic sequences in the cell.
[0008] In certain embodiments, the genomic sequence comprises a methylation variable region, an enhancer (e.g., an enhancer of MyoD), a promoter (e.g., the BDNF promoter), or a CTCF binding site. In some embodiments, the effector domain comprises Tet1. In other embodiments, the effector domain comprises Dnmt3a.
[0009] In some embodiments, the catalytically inactive site-specific nuclease is a catalytically inactive Cas protein (e.g., a Cas9 protein or a Cpf1 protein). The guide sequence may be a ribonucleic acid guide sequence. In certain embodiments, the guide sequence is about 10 base pairs to about 150 base pairs in length. The one or more guide sequences may include two or more guide sequences.
[0010] In some embodiments, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 genomic sequences are modified in the cell. The cell can be a stem cell, a neuron, a postmitotic cell, or a fibroblast. In some aspects, the cell is a human cell or a mouse cell.
[0011] In some embodiments, one or more nuclear localization sequences are fused between the catalytically inactive site-specific nuclease and the effector domain. In certain embodiments, one or more of the genomic sequences is associated with a disease or condition.
[0012] In certain embodiments, the method further comprises contacting the cell with an agent that inhibits or enhances DNA methylation. The agent can be a small molecule. For example, the agent is 5-azacytidine or 5-azadeoxycytidine.
[0013] In certain embodiments, the method further comprises introducing the cell into a non-human mammal. The non-human mammal can be a mouse.
[0014] Also disclosed are isolated modified cells produced by the methods described herein.
[0015] Also disclosed herein are methods of treating a patient in need of treatment, comprising administering the modified cells described herein to a patient in need of such cells.
[0016] Also disclosed is a method of modulating methylation of one or more disease-causing genomic sequences in an individual in need of such modulation, comprising introducing into the individual a catalytically inactive site-specific nuclease fused to an effector domain having methylation or demethylation activity, and one or more guide sequences, thereby modulating methylation of one or more disease-causing genomic sequences in the individual.
[0017] Also disclosed are modified cells having a modified genome comprising a first genomic modification in which methylation of a genomic sequence is modulated by contacting the cell with a catalytically inactive site-specific nuclease fused to an effector domain having methylation or demethylation activity, and one or more guide sequences.
[0018] Also disclosed herein is a method of modulating methylation of one or more genomic sequences in a cell, comprising contacting a cell with a nucleic acid encoding a polypeptide comprising a catalytically inactive site-specific nuclease fused to an effector domain having methylation or demethylation activity, and a guide sequence or a nucleic acid encoding a guide sequence.
[0019] Also disclosed herein is a method of modulating methylation of one or more genomic sequences in an individual, comprising administering to the individual a nucleic acid encoding a polypeptide comprising a catalytically inactive site-specific nuclease fused to an effector domain having methylation or demethylation activity, and a guide sequence or a nucleic acid encoding a guide sequence.
[0020] In some embodiments, the guide sequence targets the polypeptide to one or more genomic sequences. The genomic sequences may include a methylation variable region, an enhancer, a promoter, or a CTCF binding site. In certain embodiments, the method includes regulating the methylation of at least two genomic sequences in the cell, where the genomic sequences are selected from a methylation variable region, an enhancer, a promoter, and a CTCF binding site.
[0021] In some embodiments, the effector domain comprises Tet1 or Dnmt3a. In some aspects, the catalytically inactive site-specific nuclease is a catalytically inactive Cas protein (e.g., a dCas9 protein).
[0022] In certain embodiments, the method further comprises administering to the individual an agent that inhibits or enhances DNA methylation. The agent can be a small molecule. For example, the agent is 5-azacytidine or 5-azadeoxycytidine.
[0023] Also disclosed herein is a method of treating a patient in need of treatment, comprising administering to the patient a nucleic acid encoding a polypeptide comprising a catalytically inactive site-specific nuclease fused to an effector domain having methylation activity, and a guide sequence or a nucleic acid encoding a guide sequence.
[0024] Also disclosed is a method of modulating expression of one or more genes of interest in a cell, the method comprising contacting the cell with a nucleic acid encoding a polypeptide comprising a catalytically inactive site-specific nuclease fused to an effector domain having methylation or demethylation activity, wherein the methylation variable region is located within 50 kB of the transcription start site of the gene; a guide sequence or a nucleic acid encoding the guide sequence, wherein the guide sequence targets the polypeptide to the methylation variable region.
[0025] In some aspects, the methylation variable region is hypermethylated in the cell and the effector domain (e.g., Tet1) has demethylation activity. In other aspects, the methylation variable region is unmethylated in the cell and the effector domain (e.g., Dnmt3a) has methylation activity. In some embodiments, the cell is a stem cell, a postmitotic cell, a neuron, or a fibroblast.
[0026] Also disclosed herein is a method for identifying a genomic sequence whose methylation state affects expression of a gene of interest, comprising contacting a cell with a nucleic acid encoding a polypeptide comprising a catalytically inactive site-specific nuclease fused to an effector domain having methylation or demethylation activity; a guide sequence or a nucleic acid encoding the guide sequence, wherein the guide sequence targets the polypeptide to a candidate genomic sequence, and measuring expression of the gene, wherein the genomic sequence is identified as one whose methylation state affects expression of a gene of interest if expression of the gene in the cell contacted with the nucleic acid differs from the level of methylation of that genomic region in a control cell not contacted with the nucleic acid.
[0027] In some embodiments, the genomic sequence comprises a methylation variable region, an enhancer, a promoter, or a CTCF binding site. In certain embodiments, the method comprises modulating methylation of at least two genomic sequences selected from a methylation variable region, an enhancer, a promoter, and a CTCF binding site. The one or more genomic sequences may be located within 50 kB of the transcription start site (TSS) of the gene.
[0028] In certain embodiments, the effector domain has methylation activity. For example, the effector domain is Dnmt3a. In other embodiments, the effector domain has demethylation activity. For example, the effector domain is Tet1. In some embodiments, the cell is a stem cell, a postmitotic cell, a neuron, or a fibroblast. In certain embodiments, one or more nuclear transport sequences are fused between the polypeptide comprising catalytically inactive site-specific nuclease and the effector domain.
[0029] Also disclosed herein are methods that include identifying a genomic region whose methylation status affects expression of a gene of interest according to the methods described herein; contacting a cell with a test agent; and measuring methylation of the identified genomic region in the cell, where the test agent is identified as a modulator of methylation of the genomic region if the level of methylation of the genomic region in a cell contacted with the test agent differs from the level of methylation of that genomic region in a control cell that has not been contacted with the test agent (e.g., a small molecule).
[0030] The above-discussed and many other features and attendant advantages of the present invention will become more fully understood by reference to the following detailed description of the invention.
[0031] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be available from the Office upon request and payment of the necessary fee. The present invention also provides the following: (Item 1) 1. A method for modifying one or more genomic sequences in a cell, comprising: a. a catalytically inactive site-specific nuclease fused to an effector domain having methylation activity; and b. introducing one or more guide sequences into the cell; thereby modifying one or more genomic sequences in said cell. (Item 2) 2. The method of claim 1, wherein the genomic sequence comprises a methylation variable region, an enhancer, a promoter, or a CTCF binding site. (Item 3) 3. The method of claim 1 or 2, wherein the genomic sequence comprises a CTCF binding site. (Item 4) 4. The method according to any one of items 1 to 3, wherein the effector domain comprises Tet1. (Item 5) 1. A method for modifying one or more genomic sequences in a cell, comprising: a. a catalytically inactive site-specific nuclease fused to an effector domain having demethylation activity; and b. introducing one or more guide sequences into the cell; thereby modifying one or more genomic sequences in said cell. (Item 6) 6. The method of claim 5, wherein the genomic sequence comprises a methylation variable region, an enhancer, a promoter, or a CTCF binding site. (Item 7) 7. The method of claim 5 or 6, wherein the genomic sequence comprises an enhancer or promoter. (Item 8) 8. The method according to any one of items 5 to 7, wherein the genomic sequence comprises a BDNF promoter. (Item 9) 8. The method according to any one of items 5 to 7, wherein the genomic sequence comprises an enhancer of MyoD. (Item 10) 10. The method according to any one of items 5 to 9, wherein the effector domain comprises Dnmt3a. (Item 11) 11. The method according to any one of items 1 to 10, wherein the catalytically inactive site-specific nuclease is a catalytically inactive Cas protein. (Item 12) 12. The method of any one of items 1 to 11, wherein the catalytically inactive site-specific nuclease is a catalytically inactive Cas9 protein. (Item 13) 12. The method according to any one of items 1 to 11, wherein the catalytically inactive site-specific nuclease is a catalytically inactive Cpf1 protein. (Item 14) 14. The method according to any one of items 1 to 13, wherein the guide sequence is a ribonucleic acid guide sequence. (Item 15) 15. The method according to any one of items 1 to 14, wherein the guide sequence is from about 10 base pairs to about 150 base pairs in length. (Item 16) 16. The method of any one of items 1 to 15, wherein the one or more guide sequences comprise two or more guide sequences. (Item 17) 17. The method according to any one of items 1 to 16, wherein 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 genomic sequences are modified in the cell. (Item 18) 18. The method according to any one of items 1 to 17, wherein the cell is a stem cell, a neuron, a postmitotic cell, or a fibroblast. (Item 19) 19. The method according to any one of items 1 to 18, wherein the cell is a human cell. (Item 20) 20. The method according to any one of items 1 to 19, wherein the cell is a mouse cell. (Item 21) 21. The method of any one of items 1 to 20, further comprising one or more nuclear localization sequences fused between the catalytically inactive site-specific nuclease and the effector domain. (Item 22) 22. The method according to any one of items 1 to 21, wherein one or more of the genomic sequences is associated with a disease or pathology. (Item 23) 22. The method according to any one of items 1 to 21, further comprising introducing the cell into a non-human mammal. (Item 24) 23. The method of claim 22, wherein the non-human mammal is a mouse. (Item 25) An isolated modified cell produced by the method of any of the preceding items. (Item 26) 1. A method for modulating methylation of one or more genomic sequences in a cell, comprising: a. a catalytically inactive site-specific nuclease fused to an effector domain having methylation or demethylation activity; and b. introducing a guide sequence or a nucleic acid encoding a guide sequence into the cell; thereby modulating methylation of one or more genomic sequences in the cell. (Item 27) 27. The method of claim 26, wherein the genomic sequence comprises a methylation variable region, an enhancer, a promoter, or a CTCF binding site. (Item 28) 28. The method of item 26 or 27, wherein the genomic sequence comprises a CTCF binding site. (Item 29) 29. The method of any one of items 26 to 28, wherein the effector domain comprises Tet1. (Item 30) 28. The method of claim 26 or 27, wherein the genomic sequence comprises an enhancer or promoter. (Item 31) 31. The method of any one of items 26 to 27 or 30, wherein the genomic sequence comprises a BDNF promoter. (Item 32) 31. The method of any one of items 26 to 27 or 30, wherein the genomic sequence comprises an enhancer of MyoD. (Item 33) 33. The method of any one of items 26 to 27 or 30 to 32, wherein the effector domain comprises Dnmt3a. (Item 34) 34. The method of any one of items 26 to 33, wherein the catalytically inactive site-specific nuclease is a catalytically inactive Cas protein. (Item 35) 35. The method of any one of items 26 to 34, wherein the catalytically inactive site-specific nuclease is a catalytically inactive Cas9 protein. (Item 36) 36. The method according to any one of items 26 to 35, wherein the catalytically inactive site-specific nuclease is a catalytically inactive Cpf1 protein. (Item 37) 37. The method according to any one of items 26 to 36, wherein the guide sequence is a ribonucleic acid guide sequence. (Item 38) 38. The method according to any one of items 26 to 37, wherein the guide sequence is from about 10 base pairs to about 150 base pairs in length. (Item 39) 39. The method of any one of items 26 to 38, wherein the one or more guide sequences comprise two or more guide sequences. (Item 40) 40. The method of any one of items 26 to 39, wherein 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 genomic sequences are modified in the cell. (Item 41) 41. The method according to any one of items 26 to 40, wherein the cell is a stem cell, a neuron, a postmitotic cell, or a fibroblast. (Item 42) 42. The method according to any one of items 26 to 41, wherein the cells are human cells. (Item 43) 43. The method according to any one of items 26 to 42, wherein the cell is a mouse cell. (Item 44) An isolated modified cell produced by the method of any of the preceding items. (Item 45) 45. A method of treating a patient in need of treatment, said method comprising administering the modified cells of item 44 to a patient in need of such cells. (Item 46) 1. A method of modulating methylation of one or more disease-causing genomic sequences in an individual in need thereof, comprising: a. a catalytically inactive site-specific nuclease fused to an effector domain having methylation or demethylation activity; and b. introducing one or more guide sequences into the individual; This method thereby regulates methylation of one or more disease-causing genomic sequences in the individual. (Item 47) 1. A modified cell having a modified genome comprising a first genomic modification in which methylation of a genomic sequence is regulated, The modified cell, wherein the modulation occurs by contacting the cell with a catalytically inactive site-specific nuclease fused to an effector domain having methylation or demethylation activity, and one or more guide sequences. (Item 48) 1. A method for modulating methylation of one or more genomic sequences in a cell, the method comprising: a. a nucleic acid encoding a polypeptide comprising a catalytically inactive site-specific nuclease fused to an effector domain having methylation or demethylation activity; and b. The method, comprising contacting the nucleic acid with a guide sequence or a nucleic acid encoding a guide sequence. 49. The method of claim 48, wherein the guide sequence targets the polypeptide to the one or more genomic sequences. (Item 50) 50. The method of claim 48 or 49, wherein the genomic sequence comprises a methylation variable region, an enhancer, a promoter, or a CTCF binding site. (Item 51) 50. The method of claim 48 or 49, wherein the method comprises modulating methylation of at least two genomic sequences in the cell, the genomic sequences being selected from a methylation variable region, an enhancer, a promoter, and a CTCF binding site. (Item 52) 52. The method of any one of items 48 to 51, wherein the effector domain comprises Tet1 or Dnmt3a. (Item 53) 53. The method of any one of items 48 to 52, wherein the catalytically inactive site-specific nuclease is a catalytically inactive Cas protein. (Item 54) 54. The method of any one of items 48 to 53, wherein the catalytically inactive site-specific nuclease is a catalytically inactive Cas9 protein. (Item 55) 1. A method of modulating methylation of one or more genomic sequences in an individual, the method comprising administering to the individual: a. a nucleic acid encoding a polypeptide comprising a catalytically inactive site-specific nuclease fused to an effector domain having methylation or demethylation activity; b. The method comprising administering a guide sequence or a nucleic acid encoding a guide sequence. (Item 56) 56. The method of claim 55, wherein the guide sequence targets the polypeptide to the one or more genomic sequences. (Item 57) 57. The method of claim 55 or 56, wherein the genomic sequence comprises a methylation variable region, an enhancer, a promoter, or a CTCF binding site. (Item 58) 57. The method of claim 55 or 56, wherein the method comprises modulating methylation of at least two genomic sequences in the cell, the genomic sequences being selected from a methylation variable region, an enhancer, a promoter, and a CTCF binding site. (Item 59) 59. The method of any one of items 55 to 58, wherein the effector domain comprises Tet1 or Dnmt3a. (Item 60) 60. The method of any one of items 55 to 59, wherein the catalytically inactive site-specific nuclease is a catalytically inactive Cas protein. (Item 61) 61. The method of any one of items 55 to 60, wherein the catalytically inactive site-specific nuclease is a catalytically inactive Cas9 protein. (Item 62) 1. A method of treating a patient in need of treatment, said method comprising: a. a nucleic acid encoding a polypeptide comprising a catalytically inactive site-specific nuclease fused to an effector domain having methylation activity; b. The method comprising administering to the patient a guide sequence or a nucleic acid encoding a guide sequence. (Item 63) 1. A method for modulating expression of one or more genes of interest in a cell, wherein a methylation variable region is located within 50 kB of a transcription start site of said genes, said method comprising: a. a nucleic acid encoding a polypeptide comprising a catalytically inactive site-specific nuclease fused to an effector domain having methylation or demethylation activity; b. The method of claim 64, further comprising contacting the cell with a guide sequence or a nucleic acid encoding a guide sequence, wherein the guide sequence targets the polypeptide to the methylation variable region. 64. The method of claim 63, wherein the methylation variable region is hypermethylated in the cell and the effector domain has demethylation activity. (Item 65) 65. The method of claim 63 or 64, wherein the effector domain is Tet1. (Item 66) 64. The method of claim 63, wherein the methylation variable region is unmethylated in the cell and the effector domain has methylation activity. (Item 67) Item 68. The method according to item 63 or 66, wherein the effector domain is Dnmt3a. 68. The method according to any one of items 63 to 67, wherein the cell is a stem cell, a postmitotic cell, a neuron, or a fibroblast. (Item 69) 69. The method of any one of items 63 to 68, wherein the cell is a postmitotic neuron. (Item 70) 69. The method according to any one of items 63 to 68, wherein the cells are fibroblasts. (Item 71) 69. The method according to any one of items 63 to 68, wherein the cells are stem cells. (Item 72) 1. A method for identifying genomic sequences whose methylation status influences expression of a gene of interest, the method comprising: a. a nucleic acid encoding a polypeptide comprising a catalytically inactive site-specific nuclease fused to an effector domain having methylation or demethylation activity; b. contacting the cell with a guide sequence or a nucleic acid encoding a guide sequence, said guide sequence targeting said polypeptide to a candidate genomic sequence; c. measuring the expression of said gene; The method identifies the genomic sequence as one whose methylation status affects expression of the gene of interest if expression of the gene in the cell contacted with the nucleic acid differs from the level of methylation of the genomic region in a control cell not contacted with the nucleic acid. (Item 73) 73. The method of claim 72, wherein the genomic sequence comprises a methylation variable region, an enhancer, a promoter, or a CTCF binding site. (Item 74) 73. The method of claim 72, wherein the method comprises modulating methylation of at least two genomic sequences selected from a methylation variable region, an enhancer, a promoter, and a CTCF binding site. (Item 75) 75. The method of any one of items 72 to 74, wherein the one or more genomic sequences are located within 50 kB of a transcription start site (TSS) of the gene. (Item 76) 76. The method according to any one of items 72 to 75, wherein the effector domain has a methylation activity. (Item 77) 77. The method according to any one of items 72 to 76, wherein the effector domain is Dnmt3a. (Item 78) 76. The method according to any one of items 72 to 75, wherein the effector domain has demethylation activity. (Item 79) 79. The method of any one of items 72 to 75 or 78, wherein the effector domain is Tet1. (Item 80) 80. The method of any one of items 72 to 79, wherein the cell is a stem cell, a postmitotic cell, a neuron, or a fibroblast. (Item 81) 81. The method of any one of items 72 to 80, wherein the cell is a postmitotic neuron. (Item 82) 81. The method according to any one of items 72 to 80, wherein the cells are fibroblasts. (Item 83) 81. The method according to any one of items 72 to 80, wherein the cells are stem cells. (Item 84) 84. The method of any one of items 72 to 83, further comprising one or more nuclear localization sequences fused between the catalytically inactive site-specific nuclease-containing polypeptide and the effector domain. (Item 85) a. Identifying genomic regions whose methylation status affects the expression of a gene of interest according to any of the methods described in items 72 to 84; b. contacting the cell with a test agent; and c. measuring methylation of the identified genomic region in the cell; The method of claim 1, wherein the test agent is identified as a regulator of methylation of the genomic region if the methylation level of the genomic region in the cell contacted with the test agent differs from the methylation level of the genomic region in a control cell not contacted with the test agent. (Item 86) 86. The method of claim 85, wherein the test agent is a small molecule. (Item 87) 22. The method of any one of items 1 to 21, further comprising contacting the cell with an agent that inhibits or enhances DNA methylation. (Item 88) 88. The method of claim 87, wherein the agent is a small molecule. (Item 89) 89. The method of claim 87 or 88, wherein the agent is 5-azacytidine or 5-azadeoxycytidine. (Item 90) 62. The method of any one of items 55 to 61, further comprising administering to the individual an agent that inhibits or enhances DNA methylation. (Item 91) 91. The method of claim 90, wherein the agent is a small molecule. (Item 92) 92. The method of claim 90 or 91, wherein the agent is 5-azacytidine or 5-azadeoxycytidine. [Brief description of the drawings]
[0032] [Figure 1-1]Figure 1A-1F show activation of the Dazl-Snrpn-GFP reporter by dCas9-Tet1. The top panel of Figure 1A shows a schematic of catalytically inactive mutant Cas9 (dCas9) fused with Tet1, which erases DNA methylation of specific sequences, and Dnmt3a, which de novo methylates specific sequences. The bottom panel shows an optimized dCas9-effector construct with a nuclear localization signal (NLS) linking dCas9 to Tet1, and a guide RNA construct with puro and Cherry cassettes. Figure 1B shows a schematic of targeting the Snrpn promoter region by dCas9-Tet1 with a specific gRNA, which erases methylation and activates GFP expression. Figure 1C shows Dazl-Snrpn-GFP mESCs infected with lentivirus expressing scrambled gRNA (sc gRNA) or four gRNAs (target gRNAs) targeting the Snrpn promoter region and dCas9-Tet1 (dC-T). The percentage of GFP-positive cells was calculated by flow cytometry analysis of these cells 3 days after infection and is shown as the average percentage of GFP-positive cells ± SD of two biological replicates. The percentage of GFP-positive cells is expressed as the percentage of infected Cherry-positive cells. Figure 1D, left: Representative fluorescent images of Cherry-positive cells in Figure 1C sorted after 1 week of culture. Scale bar: 250 um. Right: The percentage of GFP-positive colonies was quantified and is shown as the average percentage of GFP-positive cells ± SD of two biological replicates. Figure 1E shows bisulfite sequencing of the cells described in Figure 1C. Figure 1F shows the methylation levels of individual CpGs in the Snrpn promoter region and the adjacent Dazl locus. Shown as mean ratios ± SD of two biological replicates. [Figure 1-2]Figure 1A-1F show activation of the Dazl-Snrpn-GFP reporter by dCas9-Tet1. The top panel of Figure 1A shows a schematic of catalytically inactive mutant Cas9 (dCas9) fused with Tet1, which erases DNA methylation of specific sequences, and Dnmt3a, which de novo methylates specific sequences. The bottom panel shows an optimized dCas9-effector construct with a nuclear localization signal (NLS) linking dCas9 to Tet1, and a guide RNA construct with puro and Cherry cassettes. Figure 1B shows a schematic of targeting the Snrpn promoter region by dCas9-Tet1 with a specific gRNA, which erases methylation and activates GFP expression. Figure 1C shows Dazl-Snrpn-GFP mESCs infected with lentivirus expressing scrambled gRNA (sc gRNA) or four gRNAs (target gRNAs) targeting the Snrpn promoter region and dCas9-Tet1 (dC-T). The percentage of GFP-positive cells was calculated by flow cytometry analysis of these cells 3 days after infection and is shown as the average percentage of GFP-positive cells ± SD of two biological replicates. The percentage of GFP-positive cells is expressed as the percentage of infected Cherry-positive cells. Figure 1D, left: Representative fluorescent images of Cherry-positive cells in Figure 1C sorted after 1 week of culture. Scale bar: 250 um. Right: The percentage of GFP-positive colonies was quantified and is shown as the average percentage of GFP-positive cells ± SD of two biological replicates. Figure 1E shows bisulfite sequencing of the cells described in Figure 1C. Figure 1F shows the methylation levels of individual CpGs in the Snrpn promoter region and the adjacent Dazl locus. Shown as mean ratios ± SD of two biological replicates. [Figure 1-3]Figure 1A-1F show activation of the Dazl-Snrpn-GFP reporter by dCas9-Tet1. The top panel of Figure 1A shows a schematic of catalytically inactive mutant Cas9 (dCas9) fused with Tet1, which erases DNA methylation of specific sequences, and Dnmt3a, which de novo methylates specific sequences. The bottom panel shows an optimized dCas9-effector construct with a nuclear localization signal (NLS) linking dCas9 to Tet1, and a guide RNA construct with puro and Cherry cassettes. Figure 1B shows a schematic of targeting the Snrpn promoter region by dCas9-Tet1 with a specific gRNA, which erases methylation and activates GFP expression. Figure 1C shows Dazl-Snrpn-GFP mESCs infected with lentivirus expressing scrambled gRNA (sc gRNA) or four gRNAs (target gRNAs) targeting the Snrpn promoter region and dCas9-Tet1 (dC-T). The percentage of GFP-positive cells was calculated by flow cytometry analysis of these cells 3 days after infection and is shown as the average percentage of GFP-positive cells ± SD of two biological replicates. The percentage of GFP-positive cells is expressed as the percentage of infected Cherry-positive cells. Figure 1D, left: Representative fluorescent images of Cherry-positive cells in Figure 1C sorted after 1 week of culture. Scale bar: 250 um. Right: The percentage of GFP-positive colonies was quantified and is shown as the average percentage of GFP-positive cells ± SD of two biological replicates. Figure 1E shows bisulfite sequencing of the cells described in Figure 1C. Figure 1F shows the methylation levels of individual CpGs in the Snrpn promoter region and the adjacent Dazl locus. Shown as mean ratios ± SD of two biological replicates. [Figure 2-1]Figure 2A-2H show silencing of Gapdh-Snrpn-GFP reporter by dCas9-Dnmt3a. Figure 2A shows a schematic diagram of targeting of Snrpn promoter region by dCas9-Dnmt3a using specific gRNA to methylate the promoter and silence GFP expression. Figure 2B shows the case where Gapdh-Snrpn-GFP mESC was infected with lentivirus expressing scrambled gRNA (sc gRNA) or gRNA targeting Snrpn promoter region (target gRNA) and dCas9-Dnmt3a (dC-D). The ratio of GFP-negative cells was calculated by flow cytometry analysis 3 days after infection and shown as the average ratio of GFP-negative cells ± SD of two biological replicates. The ratio of GFP-positive cells is expressed as the ratio of infected Cherry-positive cells. Figure 2C, left: Representative fluorescent images of Cherry-positive cells in B, sorted after 1 week of culture, are shown. Scale bar: 250 um. Right: The percentage of GFP-negative colonies was quantified and is shown as the average percentage of GFP-negative cells ± SD of two biological replicates. Figure 2D shows bisulfite sequencing of cells described in Figure 2B. Figure 2E shows the methylation levels of individual CpGs in the Snrpn promoter region and the adjacent Gapdh locus. Shown as the average percentage of two biological replicates ± SD. Figure 2F shows Gapdh-Snrpn-GFP mESCs carrying doxycycline-inducible dCas9-Dnmt3a were infected with lentivirus expressing gRNA targeting the Snrpn promoter region in the presence of doxycycline (2ug / ml). The percentage of GFP-negative cells was calculated by flow cytometry analysis 3 days after infection and is shown as the average percentage of GFP-negative cells ± SD of two biological replicates. The percentage of GFP-positive cells is expressed as the percentage of infected Cherry-positive cells. Figure 2G, left: Representative fluorescence images of Cherry-positive populations from Figure 2F sorted after 1 week of culture with or without doxycycline. Scale bar: 250 um. Right: The proportion of GFP-negative colonies was quantified and is shown as the mean proportion of GFP-negative cells ± SD of two biological replicates.Figure 2H shows the methylation levels of each individual CpG in the Snrpn promoter region and the adjacent Gapdh locus from the cells in Figure 2G, shown as the mean ratio of two biological replicates ± SD. [Figure 2-2]Figure 2A-2H show silencing of Gapdh-Snrpn-GFP reporter by dCas9-Dnmt3a. Figure 2A shows a schematic diagram of targeting of Snrpn promoter region by dCas9-Dnmt3a using specific gRNA to methylate the promoter and silence GFP expression. Figure 2B shows the case where Gapdh-Snrpn-GFP mESC was infected with lentivirus expressing scrambled gRNA (sc gRNA) or gRNA targeting Snrpn promoter region (target gRNA) and dCas9-Dnmt3a (dC-D). The ratio of GFP-negative cells was calculated by flow cytometry analysis 3 days after infection and shown as the average ratio of GFP-negative cells ± SD of two biological replicates. The ratio of GFP-positive cells is expressed as the ratio of infected Cherry-positive cells. Figure 2C, left: Representative fluorescent images of Cherry-positive cells in B, sorted after 1 week of culture, are shown. Scale bar: 250 um. Right: The percentage of GFP-negative colonies was quantified and is shown as the average percentage of GFP-negative cells ± SD of two biological replicates. Figure 2D shows bisulfite sequencing of cells described in Figure 2B. Figure 2E shows the methylation levels of individual CpGs in the Snrpn promoter region and the adjacent Gapdh locus. Shown as the average percentage of two biological replicates ± SD. Figure 2F shows Gapdh-Snrpn-GFP mESCs carrying doxycycline-inducible dCas9-Dnmt3a were infected with lentivirus expressing gRNA targeting the Snrpn promoter region in the presence of doxycycline (2ug / ml). The percentage of GFP-negative cells was calculated by flow cytometry analysis 3 days after infection and is shown as the average percentage of GFP-negative cells ± SD of two biological replicates. The percentage of GFP-positive cells is expressed as the percentage of infected Cherry-positive cells. Figure 2G, left: Representative fluorescence images of Cherry-positive populations from Figure 2F sorted after 1 week of culture with or without doxycycline. Scale bar: 250 um. Right: The proportion of GFP-negative colonies was quantified and is shown as the mean proportion of GFP-negative cells ± SD of two biological replicates.Figure 2H shows the methylation levels of each individual CpG in the Snrpn promoter region and the adjacent Gapdh locus from the cells in Figure 2G, shown as the mean ratio of two biological replicates ± SD. [Figure 2-3]Figure 2A-2H show silencing of Gapdh-Snrpn-GFP reporter by dCas9-Dnmt3a. Figure 2A shows a schematic diagram of targeting of Snrpn promoter region by dCas9-Dnmt3a using specific gRNA to methylate the promoter and silence GFP expression. Figure 2B shows the case where Gapdh-Snrpn-GFP mESC was infected with lentivirus expressing scrambled gRNA (sc gRNA) or gRNA targeting Snrpn promoter region (target gRNA) and dCas9-Dnmt3a (dC-D). The ratio of GFP-negative cells was calculated by flow cytometry analysis 3 days after infection and shown as the average ratio of GFP-negative cells ± SD of two biological replicates. The ratio of GFP-positive cells is expressed as the ratio of infected Cherry-positive cells. Figure 2C, left: Representative fluorescent images of Cherry-positive cells in B, sorted after 1 week of culture, are shown. Scale bar: 250 um. Right: The percentage of GFP-negative colonies was quantified and is shown as the average percentage of GFP-negative cells ± SD of two biological replicates. Figure 2D shows bisulfite sequencing of cells described in Figure 2B. Figure 2E shows the methylation levels of individual CpGs in the Snrpn promoter region and the adjacent Gapdh locus. Shown as the average percentage of two biological replicates ± SD. Figure 2F shows Gapdh-Snrpn-GFP mESCs carrying doxycycline-inducible dCas9-Dnmt3a were infected with lentivirus expressing gRNA targeting the Snrpn promoter region in the presence of doxycycline (2ug / ml). The percentage of GFP-negative cells was calculated by flow cytometry analysis 3 days after infection and is shown as the average percentage of GFP-negative cells ± SD of two biological replicates. The percentage of GFP-positive cells is expressed as the percentage of infected Cherry-positive cells. Figure 2G, left: Representative fluorescence images of Cherry-positive populations from Figure 2F sorted after 1 week of culture with or without doxycycline. Scale bar: 250 um. Right: The proportion of GFP-negative colonies was quantified and is shown as the mean proportion of GFP-negative cells ± SD of two biological replicates.Figure 2H shows the methylation levels of each individual CpG in the Snrpn promoter region and the adjacent Gapdh locus from the cells in Figure 2G, shown as the mean ratio of two biological replicates ± SD. [Figure 3-1] Figures 3A-E show targeted demethylation of BDNF promoter IV by dCas9-Tet1 to activate BDNF in neurons. Figure 3A shows a schematic diagram of targeting BDNF promoter IV by dCas9-Tet1 (dC-T) with a specific gRNA to erase methylation and activate BDNF expression. Figure 3B shows mouse cortical neurons cultured for 3 days in vitro (DIV3) infected for 2 days with lentivirus expressing dC-T with or without gRNA targeting BDNF promoter IV, or lentivirus expressing a catalytically silent form of Tet1 (dC-dT, with H1672Y and D1674A mutations) and BDNF gRNA, and then harvested with or without treatment for 6 h with KCl (50 mM) for RT-qPCR analysis. Bars are the mean ± SD of three biological replicates. Figure 3C shows representative confocal images for BDNF induction in Figure 3B. Top panel: BDNF expression was induced by 50 mM KCl treatment for 6 hours. Bottom panel: Co-expression of gRNA targeting the BDNF promoter IV region with dC-T significantly induced BDNF expression. Note that co-expression of dC-dT with BDNF gRNA did not activate BDNF expression. MAP2 (top two panels) or Cherry (bottom two panels) are stained red, BDNF green, DAPI blue, and dCas9 grey. Scale bar: 50 um. Figure 3D shows bisulfite sequencing of the neurons in Figure 3C. Figure 3E shows the methylation levels of each individual CpG in the BDNF promoter IV region. Shown as the mean ratio ± SD of two biological replicates. [Figure 3-2]Figures 3A-E show targeted demethylation of BDNF promoter IV by dCas9-Tet1 to activate BDNF in neurons. Figure 3A shows a schematic diagram of targeting BDNF promoter IV by dCas9-Tet1 (dC-T) with a specific gRNA to erase methylation and activate BDNF expression. Figure 3B shows mouse cortical neurons cultured for 3 days in vitro (DIV3) infected for 2 days with lentivirus expressing dC-T with or without gRNA targeting BDNF promoter IV, or lentivirus expressing a catalytically silent form of Tet1 (dC-dT, with H1672Y and D1674A mutations) and BDNF gRNA, and then harvested with or without treatment for 6 h with KCl (50 mM) for RT-qPCR analysis. Bars are the mean ± SD of three biological replicates. Figure 3C shows representative confocal images for BDNF induction in Figure 3B. Top panel: BDNF expression was induced by 50 mM KCl treatment for 6 hours. Bottom panel: Co-expression of gRNA targeting the BDNF promoter IV region with dC-T significantly induced BDNF expression. Note that co-expression of dC-dT with BDNF gRNA did not activate BDNF expression. MAP2 (top two panels) or Cherry (bottom two panels) are stained red, BDNF green, DAPI blue, and dCas9 grey. Scale bar: 50 um. Figure 3D shows bisulfite sequencing of the neurons in Figure 3C. Figure 3E shows the methylation levels of each individual CpG in the BDNF promoter IV region. Shown as the mean ratio ± SD of two biological replicates. [Figure 3-3]Figures 3A-E show targeted demethylation of BDNF promoter IV by dCas9-Tet1 to activate BDNF in neurons. Figure 3A shows a schematic diagram of targeting BDNF promoter IV by dCas9-Tet1 (dC-T) with a specific gRNA to erase methylation and activate BDNF expression. Figure 3B shows mouse cortical neurons cultured for 3 days in vitro (DIV3) infected for 2 days with lentivirus expressing dC-T with or without gRNA targeting BDNF promoter IV, or lentivirus expressing a catalytically silent form of Tet1 (dC-dT, with H1672Y and D1674A mutations) and BDNF gRNA, and then harvested with or without treatment for 6 h with KCl (50 mM) for RT-qPCR analysis. Bars are the mean ± SD of three biological replicates. Figure 3C shows representative confocal images for BDNF induction in Figure 3B. Top panel: BDNF expression was induced by 50 mM KCl treatment for 6 hours. Bottom panel: Co-expression of gRNA targeting the BDNF promoter IV region with dC-T significantly induced BDNF expression. Note that co-expression of dC-dT with BDNF gRNA did not activate BDNF expression. MAP2 (top two panels) or Cherry (bottom two panels) are stained red, BDNF green, DAPI blue, and dCas9 grey. Scale bar: 50 um. Figure 3D shows bisulfite sequencing of the neurons in Figure 3C. Figure 3E shows the methylation levels of each individual CpG in the BDNF promoter IV region. Shown as the mean ratio ± SD of two biological replicates. [Figure 4-1]Figure 4A-H show targeted demethylation of the MyoD distal enhancer by dCas9-Tet1 to promote fibroblast-to-myoblast conversion. Figure 4A shows a schematic of targeting the MyoD distal enhancer (DE) of DMR-5 by dCas9-Tet1 (dC-T) with a specific gRNA. Figure 4B shows C3H10T1 / 2 mouse embryonic fibroblast cells infected for 2 days with lentivirus expressing dC-T and a target gRNA or lentivirus expressing a catalytically-quiescent form of Tet1 (dC-dT) and a target gRNA. Cherry-positive cells were sorted by FACS and subjected to RT-qPCR analysis. Bars represent the mean ± SD of three experimental replicates. Figure 4C is bisulfite sequencing of the cells in Figure 4B. Figure 4D shows the methylation levels of individual CpGs in the MyoD DE region. Shown as the mean ratio ± SD of two biological replicates. Figure 4E shows representative confocal images of C3H10T1 / 2 cells at day 14 in the fibroblast-to-myoblast conversion assay. C3H10T1 / 2 cells were seeded at 1 × 104 cells per well in 6-well plates and then infected with lentivirus expressing dC-T and gRNA targeting DMR-5 or lentivirus expressing catalytically-quiescent form of Tet1 (dC-dT) and gRNA targeting DMR-5. 24 hours after infection, cells were treated with vehicle control (HEPES buffer) or 5-azacytidine (1 uM) for 24 hours and then harvested 14 days later for immunofluorescence staining. MyoD is stained in green, MHC in magenta, and DAPI in blue. Scale bar: 200 um. Figure 4F shows quantification of the MyoD-positive cell ratio 14 days after infection with lentivirus expressing dC-T alone, lentivirus expressing gRNA targeting DMR-5 and dC-T, and lentivirus expressing dC-dT and gRNA targeting DMR-5. Figure 4G shows the distribution profile of MHC-positive cell clusters based on the number of nuclei per MHC+ cluster (classified as 2-5, 6-10, 11-20, and >20 nuclei per MHC+ cluster) 14 days after infection.When treated with 5-Aza, co-expression of dC-T and targeting gRNA, but not other combinations, significantly promotes the formation of more mature and larger MHC+ clusters compared to mock controls or dC-T alone. Figure 4H shows quantification of myotube density in MHC-positive clusters with more than 2 or more than 5 nuclei 14 days after infection. Addition of 5-Aza induces MHC+ myotube formation. Co-expression of dC-T and targeting gRNA significantly synergizes with 5-Aza to induce larger myotubes with higher nuclei (MHC+ clusters with more than 5 nuclei). Data in F-H are quantified from 3-5 representative images. Bars represent mean ± SD. [Figure 4-2]Figure 4A-H show targeted demethylation of the MyoD distal enhancer by dCas9-Tet1 to promote fibroblast-to-myoblast conversion. Figure 4A shows a schematic of targeting the MyoD distal enhancer (DE) of DMR-5 by dCas9-Tet1 (dC-T) with a specific gRNA. Figure 4B shows C3H10T1 / 2 mouse embryonic fibroblast cells infected for 2 days with lentivirus expressing dC-T and a target gRNA or lentivirus expressing a catalytically-quiescent form of Tet1 (dC-dT) and a target gRNA. Cherry-positive cells were sorted by FACS and subjected to RT-qPCR analysis. Bars represent the mean ± SD of three experimental replicates. Figure 4C is bisulfite sequencing of the cells in Figure 4B. Figure 4D shows the methylation levels of individual CpGs in the MyoD DE region. Shown as the mean ratio ± SD of two biological replicates. Figure 4E shows representative confocal images of C3H10T1 / 2 cells at day 14 in the fibroblast-to-myoblast conversion assay. C3H10T1 / 2 cells were seeded at 1 × 104 cells per well in 6-well plates and then infected with lentivirus expressing dC-T and gRNA targeting DMR-5 or lentivirus expressing catalytically-quiescent form of Tet1 (dC-dT) and gRNA targeting DMR-5. 24 hours after infection, cells were treated with vehicle control (HEPES buffer) or 5-azacytidine (1 uM) for 24 hours and then harvested 14 days later for immunofluorescence staining. MyoD is stained in green, MHC in magenta, and DAPI in blue. Scale bar: 200 um. Figure 4F shows quantification of the MyoD-positive cell ratio 14 days after infection with lentivirus expressing dC-T alone, lentivirus expressing gRNA targeting DMR-5 and dC-T, and lentivirus expressing dC-dT and gRNA targeting DMR-5. Figure 4G shows the distribution profile of MHC-positive cell clusters based on the number of nuclei per MHC+ cluster (classified as 2-5, 6-10, 11-20, and >20 nuclei per MHC+ cluster) 14 days after infection.When treated with 5-Aza, co-expression of dC-T and targeting gRNA, but not other combinations, significantly promotes the formation of more mature and larger MHC+ clusters compared to mock controls or dC-T alone. Figure 4H shows quantification of myotube density in MHC-positive clusters with more than 2 or more than 5 nuclei 14 days after infection. Addition of 5-Aza induces MHC+ myotube formation. Co-expression of dC-T and targeting gRNA significantly synergizes with 5-Aza to induce larger myotubes with higher nuclei (MHC+ clusters with more than 5 nuclei). Data in F-H are quantified from 3-5 representative images. Bars represent mean ± SD. [Figure 4-3]Figure 4A-H show targeted demethylation of the MyoD distal enhancer by dCas9-Tet1 to promote fibroblast-to-myoblast conversion. Figure 4A shows a schematic of targeting the MyoD distal enhancer (DE) of DMR-5 by dCas9-Tet1 (dC-T) with a specific gRNA. Figure 4B shows C3H10T1 / 2 mouse embryonic fibroblast cells infected for 2 days with lentivirus expressing dC-T and a target gRNA or lentivirus expressing a catalytically-quiescent form of Tet1 (dC-dT) and a target gRNA. Cherry-positive cells were sorted by FACS and subjected to RT-qPCR analysis. Bars represent the mean ± SD of three experimental replicates. Figure 4C is bisulfite sequencing of the cells in Figure 4B. Figure 4D shows the methylation levels of individual CpGs in the MyoD DE region. Shown as the mean ratio ± SD of two biological replicates. Figure 4E shows representative confocal images of C3H10T1 / 2 cells at day 14 in the fibroblast-to-myoblast conversion assay. C3H10T1 / 2 cells were seeded at 1 × 104 cells per well in 6-well plates and then infected with lentivirus expressing dC-T and gRNA targeting DMR-5 or lentivirus expressing catalytically-quiescent form of Tet1 (dC-dT) and gRNA targeting DMR-5. 24 hours after infection, cells were treated with vehicle control (HEPES buffer) or 5-azacytidine (1 uM) for 24 hours and then harvested 14 days later for immunofluorescence staining. MyoD is stained in green, MHC in magenta, and DAPI in blue. Scale bar: 200 um. Figure 4F shows quantification of the MyoD-positive cell ratio 14 days after infection with lentivirus expressing dC-T alone, lentivirus expressing gRNA targeting DMR-5 and dC-T, and lentivirus expressing dC-dT and gRNA targeting DMR-5. Figure 4G shows the distribution profile of MHC-positive cell clusters based on the number of nuclei per MHC+ cluster (classified as 2-5, 6-10, 11-20, and >20 nuclei per MHC+ cluster) 14 days after infection.When treated with 5-Aza, co-expression of dC-T and targeting gRNA, but not other combinations, significantly promotes the formation of more mature and larger MHC+ clusters compared to mock controls or dC-T alone. Figure 4H shows quantification of myotube density in MHC-positive clusters with more than 2 or more than 5 nuclei 14 days after infection. Addition of 5-Aza induces MHC+ myotube formation. Co-expression of dC-T and targeting gRNA significantly synergizes with 5-Aza to induce larger myotubes with higher nuclei (MHC+ clusters with more than 5 nuclei). Data in F-H are quantified from 3-5 representative images. Bars represent mean ± SD. [Figure 4-4]Figure 4A-H show targeted demethylation of the MyoD distal enhancer by dCas9-Tet1 to promote fibroblast-to-myoblast conversion. Figure 4A shows a schematic of targeting the MyoD distal enhancer (DE) of DMR-5 by dCas9-Tet1 (dC-T) with a specific gRNA. Figure 4B shows C3H10T1 / 2 mouse embryonic fibroblast cells infected for 2 days with lentivirus expressing dC-T and a target gRNA or lentivirus expressing a catalytically-quiescent form of Tet1 (dC-dT) and a target gRNA. Cherry-positive cells were sorted by FACS and subjected to RT-qPCR analysis. Bars represent the mean ± SD of three experimental replicates. Figure 4C is bisulfite sequencing of the cells in Figure 4B. Figure 4D shows the methylation levels of individual CpGs in the MyoD DE region. Shown as the mean ratio ± SD of two biological replicates. Figure 4E shows representative confocal images of C3H10T1 / 2 cells at day 14 in the fibroblast-to-myoblast conversion assay. C3H10T1 / 2 cells were seeded at 1 × 104 cells per well in 6-well plates and then infected with lentivirus expressing dC-T and gRNA targeting DMR-5 or lentivirus expressing catalytically-quiescent form of Tet1 (dC-dT) and gRNA targeting DMR-5. 24 hours after infection, cells were treated with vehicle control (HEPES buffer) or 5-azacytidine (1 uM) for 24 hours and then harvested 14 days later for immunofluorescence staining. MyoD is stained in green, MHC in magenta, and DAPI in blue. Scale bar: 200 um. Figure 4F shows quantification of the MyoD-positive cell ratio 14 days after infection with lentivirus expressing dC-T alone, lentivirus expressing gRNA targeting DMR-5 and dC-T, and lentivirus expressing dC-dT and gRNA targeting DMR-5. Figure 4G shows the distribution profile of MHC-positive cell clusters based on the number of nuclei per MHC+ cluster (classified as 2-5, 6-10, 11-20, and >20 nuclei per MHC+ cluster) 14 days after infection.When treated with 5-Aza, co-expression of dC-T and targeting gRNA, but not other combinations, significantly promotes the formation of more mature and larger MHC+ clusters compared to mock controls or dC-T alone. Figure 4H shows quantification of myotube density in MHC-positive clusters with more than 2 or more than 5 nuclei 14 days after infection. Addition of 5-Aza induces MHC+ myotube formation. Co-expression of dC-T and targeting gRNA significantly synergizes with 5-Aza to induce larger myotubes with higher nuclei (MHC+ clusters with more than 5 nuclei). Data in F-H are quantified from 3-5 representative images. Bars represent mean ± SD. [Figure 5-1]Figures 5A-I show targeted methylation of CTCF binding sites. Figure 5A shows a schematic of dCas9-Dnmt3a targeting of CTCF binding sites with specific gRNAs to induce de novo methylation, blocking CTCF recruitment, and opening the CTCF loop to alter gene expression in the adjacent loop. Figure 5B shows a schematic of CTCF target 1 (miR290 locus) with a super-enhancer and miR290 in the loop, the AU018091 gene in the left adjacent loop, and the Nlrp12 gene in the right adjacent loop (close to the target CTCF binding site). The Myadm gene is in the right adjacent loop to the loop containing Nlrp12. The super-enhancer domain is indicated by a red bar. The target CTCF site is highlighted by a box. ChIP-seq binding profiles (reads / million / base pairs) for CTCF (black) and H3K27Ac (super enhancer) (red) are also shown, as well as the methylation track (yellow) annotated with DMRs (blue). Figures 5C-5E show that doxycycline-inducible dCas9-Dnmt3a mESCs were infected with lentiviruses expressing scrambled gRNA or CTCF target 1 gRNA, and dC-dT and CTCF target 1 gRNA for 3 days, after which Cherry-positive cells were sorted by FACS. After 3 days of culture in the presence of doxycycline, the cells were placed on gelatin-coated plates for 1 h and harvested after removal of feeder cells for RT-qPCR analysis in Figure 5C and bisulfite sequencing in Figures 5D and 5E. Bars represent the mean ± SD of three experimental replicates. Figure 5F shows a schematic of CTCF target 2 with a super-enhancer and Pou5f1 gene in this loop, H2Q10 gene in the left adjacent loop (close to the target CTCF binding site), and Tcf19 in the right adjacent loop. The super-enhancer domain is indicated by a red bar. The target CTCF site is highlighted by a box. ChIP-seq binding profiles (reads / million / base pairs) for CTCF (black) and H3K27Ac (super-enhancer) (red) are also shown, as well as the methylation track (yellow) with DMRs (blue) annotated.Figures 5G-I show the same set of experiments as described in Figures 5C-E were performed for CTCF target 2, where cells were harvested for RT-qPCR analysis as in Figure 5C and bisulfite sequencing as in Figures 5D-E. Bars represent the mean ± SD of three experimental replicates. [Figure 5-2]Figures 5A-I show targeted methylation of CTCF binding sites. Figure 5A shows a schematic of dCas9-Dnmt3a targeting of CTCF binding sites with specific gRNAs to induce de novo methylation, blocking CTCF recruitment, and opening the CTCF loop to alter gene expression in the adjacent loop. Figure 5B shows a schematic of CTCF target 1 (miR290 locus) with a super-enhancer and miR290 in the loop, the AU018091 gene in the left adjacent loop, and the Nlrp12 gene in the right adjacent loop (close to the target CTCF binding site). The Myadm gene is in the right adjacent loop to the loop containing Nlrp12. The super-enhancer domain is indicated by a red bar. The target CTCF site is highlighted by a box. ChIP-seq binding profiles (reads / million / base pairs) for CTCF (black) and H3K27Ac (super enhancer) (red) are also shown, as well as the methylation track (yellow) annotated with DMRs (blue). Figures 5C-5E show that doxycycline-inducible dCas9-Dnmt3a mESCs were infected with lentiviruses expressing scrambled gRNA or CTCF target 1 gRNA, and dC-dT and CTCF target 1 gRNA for 3 days, after which Cherry-positive cells were sorted by FACS. After 3 days of culture in the presence of doxycycline, the cells were placed on gelatin-coated plates for 1 h and harvested after removal of feeder cells for RT-qPCR analysis in Figure 5C and bisulfite sequencing in Figures 5D and 5E. Bars represent the mean ± SD of three experimental replicates. Figure 5F shows a schematic of CTCF target 2 with a super-enhancer and Pou5f1 gene in this loop, H2Q10 gene in the left adjacent loop (close to the target CTCF binding site), and Tcf19 in the right adjacent loop. The super-enhancer domain is indicated by a red bar. The target CTCF site is highlighted by a box. ChIP-seq binding profiles (reads / million / base pairs) for CTCF (black) and H3K27Ac (super-enhancer) (red) are also shown, as well as the methylation track (yellow) with DMRs (blue) annotated.Figures 5G-I show the same set of experiments as described in Figures 5C-E were performed for CTCF target 2, where cells were harvested for RT-qPCR analysis as in Figure 5C and bisulfite sequencing as in Figures 5D-E. Bars represent the mean ± SD of three experimental replicates. [Figure 5-3]Figures 5A-I show targeted methylation of CTCF binding sites. Figure 5A shows a schematic of dCas9-Dnmt3a targeting of CTCF binding sites with specific gRNAs to induce de novo methylation, blocking CTCF recruitment, and opening the CTCF loop to alter gene expression in the adjacent loop. Figure 5B shows a schematic of CTCF target 1 (miR290 locus) with a super-enhancer and miR290 in the loop, the AU018091 gene in the left adjacent loop, and the Nlrp12 gene in the right adjacent loop (close to the target CTCF binding site). The Myadm gene is in the right adjacent loop to the loop containing Nlrp12. The super-enhancer domain is indicated by a red bar. The target CTCF site is highlighted by a box. ChIP-seq binding profiles (reads / million / base pairs) for CTCF (black) and H3K27Ac (super enhancer) (red) are also shown, as well as the methylation track (yellow) annotated with DMRs (blue). Figures 5C-5E show that doxycycline-inducible dCas9-Dnmt3a mESCs were infected with lentiviruses expressing scrambled gRNA or CTCF target 1 gRNA, and dC-dT and CTCF target 1 gRNA for 3 days, after which Cherry-positive cells were sorted by FACS. After 3 days of culture in the presence of doxycycline, the cells were placed on gelatin-coated plates for 1 h and harvested after removal of feeder cells for RT-qPCR analysis in Figure 5C and bisulfite sequencing in Figures 5D and 5E. Bars represent the mean ± SD of three experimental replicates. Figure 5F shows a schematic of CTCF target 2 with a super-enhancer and Pou5f1 gene in this loop, H2Q10 gene in the left adjacent loop (close to the target CTCF binding site), and Tcf19 in the right adjacent loop. The super-enhancer domain is indicated by a red bar. The target CTCF site is highlighted by a box. ChIP-seq binding profiles (reads / million / base pairs) for CTCF (black) and H3K27Ac (super-enhancer) (red) are also shown, as well as the methylation track (yellow) with DMRs (blue) annotated.Figures 5G-I show the same set of experiments as described in Figures 5C-E were performed for CTCF target 2, where cells were harvested for RT-qPCR analysis as in Figure 5C and bisulfite sequencing as in Figures 5D-E. Bars represent the mean ± SD of three experimental replicates. [Figure 6-1]Figures 6A-D show targeted methylation of CTCF binding sites to engineer CTCF loops. Figure 6A shows quantitative Chromosome Conformation Capture (3C) analysis at the miR290 locus in cells described in C. Super-enhancer domains are indicated by red bars. Targeted CTCF sites are highlighted by boxes. Arrows indicate chromosomal locations where interaction frequency between them was assayed. Asterisks indicate 3C anchor sites. ChIP-seq binding profiles (reads / million base pairs) for CTCF (black) and H3K27Ac (super-enhancer) (red) are also shown, as well as methylation tracks (yellow) annotated with DMRs (blue). Interaction frequencies between the indicated chromosomal locations and 3C anchor sites are represented in bar graphs (mean ± SD) in the lower panel. qPCR reactions were performed in duplicate and values are normalized to the average interaction frequency in cells with scrambled gRNA. (p<0.05 for all three regions; Student's t-test, ns represents no significance, NC represents negative control.) Figure 6B shows anti-CTCF ChIP experiments followed by quantitative PCR analysis using the cells from Figure 6A. Bars represent the mean ± SD of three experimental replicates. Figure 6C shows quantitative Chromosome Conformation Capture (3C) analysis at the Pou5f1 locus of the cells described in Figure 5G. Super-enhancer domains are indicated by red bars. Target CTCF sites are highlighted by boxes. Arrows indicate chromosomal locations where the interaction frequency between them was assayed. Asterisks indicate 3C anchor sites. ChIP-seq binding profiles (reads / million / base pairs) for CTCF (black) and H3K27Ac (super-enhancer) (red) are also shown, as well as methylation tracks (yellow) annotated with DMRs (blue). Interaction frequencies between the indicated chromosomal locations and 3C anchor sites are represented as bar graphs (mean ± SD) in the lower panel. qPCR reactions were performed in duplicate and values were normalized to the average interaction frequency in cells with scrambled gRNA (p<0.05; Student's t-test, ns indicates no significance).Figure 6D shows anti-CTCF ChIP experiments followed by quantitative PCR analysis using cells from C. Bars represent the mean ± SD of three experimental replicates. [Figure 6-2]Figures 6A-D show targeted methylation of CTCF binding sites to engineer CTCF loops. Figure 6A shows quantitative Chromosome Conformation Capture (3C) analysis at the miR290 locus in cells described in C. Super-enhancer domains are indicated by red bars. Targeted CTCF sites are highlighted by boxes. Arrows indicate chromosomal locations where interaction frequency between them was assayed. Asterisks indicate 3C anchor sites. ChIP-seq binding profiles (reads / million base pairs) for CTCF (black) and H3K27Ac (super-enhancer) (red) are also shown, as well as methylation tracks (yellow) annotated with DMRs (blue). Interaction frequencies between the indicated chromosomal locations and 3C anchor sites are represented in bar graphs (mean ± SD) in the lower panel. qPCR reactions were performed in duplicate and values are normalized to the average interaction frequency in cells with scrambled gRNA. (p<0.05 for all three regions; Student's t-test, ns represents no significance, NC represents negative control.) Figure 6B shows anti-CTCF ChIP experiments followed by quantitative PCR analysis using the cells from Figure 6A. Bars represent the mean ± SD of three experimental replicates. Figure 6C shows quantitative Chromosome Conformation Capture (3C) analysis at the Pou5f1 locus of the cells described in Figure 5G. Super-enhancer domains are indicated by red bars. Target CTCF sites are highlighted by boxes. Arrows indicate chromosomal locations where the interaction frequency between them was assayed. Asterisks indicate 3C anchor sites. ChIP-seq binding profiles (reads / million / base pairs) for CTCF (black) and H3K27Ac (super-enhancer) (red) are also shown, as well as methylation tracks (yellow) annotated with DMRs (blue). Interaction frequencies between the indicated chromosomal locations and 3C anchor sites are represented as bar graphs (mean ± SD) in the lower panel. qPCR reactions were performed in duplicate and values were normalized to the average interaction frequency in cells with scrambled gRNA (p<0.05; Student's t-test, ns indicates no significance).Figure 6D shows anti-CTCF ChIP experiments followed by quantitative PCR analysis using cells from C. Bars represent the mean ± SD of three experimental replicates. [Figure 7-1]Figure 7A-7H show targeted ex vivo and in vivo DNA methylation editing by dCas9-Tet1 to activate a silenced GFP reporter. Figure 7A shows a schematic diagram depicting the experimental procedure to activate a silenced GFP reporter ex vivo in mouse fibroblasts. Mouse tail fibroblasts were derived from a genetically modified mouse strain carrying a paternal IG-DMR-Snrpn-GFP allele (IG-DMRGFP / Pat) at the Dlk1-Dio3 locus. The IG-DMR-Snrpn promoter on the paternal allele is hypermethylated, so the GFP reporter is constitutively silenced. Cultured fibroblasts were infected with lentiviral vectors expressing dCas9-Tet1 and gRNA to demethylate the Snrpn promoter and activate the GFP reporter. Cells were subjected to imaging and FACS analysis. Figure 7B shows representative immunohistochemistry images of IG-DMRGFP / Pat fibroblasts infected with lentivirus expressing dCas9-Tet1(dC-T) and sc gRNA, lentivirus expressing an inactive form of dCas9-Tet1(dC-dT) and Snrpn-targeting gRNA, or lentivirus expressing dCas9-Tet1 and Snrpn-targeting gRNA. Cherry is stained red, GFP is stained green, and nuclei are stained with DAPI. Scale bar: 100um. Note that to turn on the Snrpn-GFP methylation reporter, both dCas9-Tet1 and targeting gRNA lentiviral vectors need to be transduced into the same cells. Therefore, in this experiment, the number of Cherry-positive cells (targeting gRNA) is expected to be higher than the number of GFP-positive cells (demethylation of the Snrpn promoter). Figure 7C shows quantification of the ratio of IG-DMRGFP / Pat mouse fibroblasts with GFP activation among Cherry (gRNA) positive cells. Approximately 80% of cells with expression of Snrpn-targeting gRNA turned on GFP expression. dC-T with sc gRNA and the inactive form of dC-T (dC-dT) with Snrpn-targeting gRNA cannot turn on GFP reporter expression. Bars represent the mean ± SD of three experimental replicates.Figure 7D shows a schematic diagram depicting the experimental procedure to activate the GFP reporter in vivo in IG-DMRGFP / Pat mouse brain. Lentiviral vectors expressing dC-T and sc gRNA, dC-dT and Snrpn-targeting gRNA, and dC-T and Snrpn-targeting gRNA were delivered by stereotaxic microinjection. Brains were sectioned and analyzed by immunohistochemistry. Figure 7E shows representative confocal micrographs of IG-DMRGFP / Pat mouse brain infected with dC-T and sc gRNA, dC-dT and Snrpn-targeting gRNA, and dC-T and Snrpn-targeting gRNA. Only dC-T with the targeting gRNA activated GFP expression. Scale bar: 100um. Figures 7G-7H show quantification of the ratio of IG-DMRGFP / Pat cells with GFP activation among Cherry (gRNA) positive cells in in vivo lentiviral delivery experiments in the brain (Figure 7G) and skin epidermis (Figure 7H). Approximately 70% of neurons and 85% of skin dermal cells expressing the Snrpn-targeting gRNA phenotype turned on GFP expression in vivo. In contrast, dC-T and scrambled gRNA, and the inactive form of Tet1 (dC-dT) and Snrpn-targeting gRNA did not turn on GFP reporter expression. Bars represent the mean ± SD of more than four representative images from two animals. [Figure 7-2]Figure 7A-7H show targeted ex vivo and in vivo DNA methylation editing by dCas9-Tet1 to activate a silenced GFP reporter. Figure 7A shows a schematic diagram depicting the experimental procedure to activate a silenced GFP reporter ex vivo in mouse fibroblasts. Mouse tail fibroblasts were derived from a genetically modified mouse strain carrying a paternal IG-DMR-Snrpn-GFP allele (IG-DMRGFP / Pat) at the Dlk1-Dio3 locus. The IG-DMR-Snrpn promoter on the paternal allele is hypermethylated, so the GFP reporter is constitutively silenced. Cultured fibroblasts were infected with lentiviral vectors expressing dCas9-Tet1 and gRNA to demethylate the Snrpn promoter and activate the GFP reporter. Cells were subjected to imaging and FACS analysis. Figure 7B shows representative immunohistochemistry images of IG-DMRGFP / Pat fibroblasts infected with lentivirus expressing dCas9-Tet1(dC-T) and sc gRNA, lentivirus expressing an inactive form of dCas9-Tet1(dC-dT) and Snrpn-targeting gRNA, or lentivirus expressing dCas9-Tet1 and Snrpn-targeting gRNA. Cherry is stained red, GFP is stained green, and nuclei are stained with DAPI. Scale bar: 100um. Note that to turn on the Snrpn-GFP methylation reporter, both dCas9-Tet1 and targeting gRNA lentiviral vectors need to be transduced into the same cells. Therefore, in this experiment, the number of Cherry-positive cells (targeting gRNA) is expected to be higher than the number of GFP-positive cells (demethylation of the Snrpn promoter). Figure 7C shows quantification of the ratio of IG-DMRGFP / Pat mouse fibroblasts with GFP activation among Cherry (gRNA) positive cells. Approximately 80% of cells with expression of Snrpn-targeting gRNA turned on GFP expression. dC-T with sc gRNA and the inactive form of dC-T (dC-dT) with Snrpn-targeting gRNA cannot turn on GFP reporter expression. Bars represent the mean ± SD of three experimental replicates.Figure 7D shows a schematic diagram depicting the experimental procedure to activate the GFP reporter in vivo in IG-DMRGFP / Pat mouse brain. Lentiviral vectors expressing dC-T and sc gRNA, dC-dT and Snrpn-targeting gRNA, and dC-T and Snrpn-targeting gRNA were delivered by stereotaxic microinjection. Brains were sectioned and analyzed by immunohistochemistry. Figure 7E shows representative confocal micrographs of IG-DMRGFP / Pat mouse brain infected with dC-T and sc gRNA, dC-dT and Snrpn-targeting gRNA, and dC-T and Snrpn-targeting gRNA. Only dC-T with the targeting gRNA activated GFP expression. Scale bar: 100um. Figures 7G-7H show quantification of the ratio of IG-DMRGFP / Pat cells with GFP activation among Cherry (gRNA) positive cells in in vivo lentiviral delivery experiments in the brain (Figure 7G) and skin epidermis (Figure 7H). Approximately 70% of neurons and 85% of skin dermal cells expressing the Snrpn-targeting gRNA phenotype turned on GFP expression in vivo. In contrast, dC-T and scrambled gRNA, and the inactive form of Tet1 (dC-dT) and Snrpn-targeting gRNA did not turn on GFP reporter expression. Bars represent the mean ± SD of more than four representative images from two animals. [Figure 7-3]Figure 7A-7H show targeted ex vivo and in vivo DNA methylation editing by dCas9-Tet1 to activate a silenced GFP reporter. Figure 7A shows a schematic diagram depicting the experimental procedure to activate a silenced GFP reporter ex vivo in mouse fibroblasts. Mouse tail fibroblasts were derived from a genetically modified mouse strain carrying a paternal IG-DMR-Snrpn-GFP allele (IG-DMRGFP / Pat) at the Dlk1-Dio3 locus. The IG-DMR-Snrpn promoter on the paternal allele is hypermethylated, so the GFP reporter is constitutively silenced. Cultured fibroblasts were infected with lentiviral vectors expressing dCas9-Tet1 and gRNA to demethylate the Snrpn promoter and activate the GFP reporter. Cells were subjected to imaging and FACS analysis. Figure 7B shows representative immunohistochemistry images of IG-DMRGFP / Pat fibroblasts infected with lentivirus expressing dCas9-Tet1(dC-T) and sc gRNA, lentivirus expressing an inactive form of dCas9-Tet1(dC-dT) and Snrpn-targeting gRNA, or lentivirus expressing dCas9-Tet1 and Snrpn-targeting gRNA. Cherry is stained red, GFP is stained green, and nuclei are stained with DAPI. Scale bar: 100um. Note that to turn on the Snrpn-GFP methylation reporter, both dCas9-Tet1 and targeting gRNA lentiviral vectors need to be transduced into the same cells. Therefore, in this experiment, the number of Cherry-positive cells (targeting gRNA) is expected to be higher than the number of GFP-positive cells (demethylation of the Snrpn promoter). Figure 7C shows quantification of the ratio of IG-DMRGFP / Pat mouse fibroblasts with GFP activation among Cherry (gRNA) positive cells. Approximately 80% of cells with expression of Snrpn-targeting gRNA turned on GFP expression. dC-T with sc gRNA and the inactive form of dC-T (dC-dT) with Snrpn-targeting gRNA cannot turn on GFP reporter expression. Bars represent the mean ± SD of three experimental replicates.Figure 7D shows a schematic diagram depicting the experimental procedure to activate the GFP reporter in vivo in IG-DMRGFP / Pat mouse brain. Lentiviral vectors expressing dC-T and sc gRNA, dC-dT and Snrpn-targeting gRNA, and dC-T and Snrpn-targeting gRNA were delivered by stereotaxic microinjection. Brains were sectioned and analyzed by immunohistochemistry. Figure 7E shows representative confocal micrographs of IG-DMRGFP / Pat mouse brain infected with dC-T and sc gRNA, dC-dT and Snrpn-targeting gRNA, and dC-T and Snrpn-targeting gRNA. Only dC-T with the targeting gRNA activated GFP expression. Scale bar: 100um. Figures 7G-7H show quantification of the ratio of IG-DMRGFP / Pat cells with GFP activation among Cherry (gRNA) positive cells in in vivo lentiviral delivery experiments in the brain (Figure 7G) and skin epidermis (Figure 7H). Approximately 70% of neurons and 85% of skin dermal cells expressing the Snrpn-targeting gRNA phenotype turned on GFP expression in vivo. In contrast, dC-T and scrambled gRNA, and the inactive form of Tet1 (dC-dT) and Snrpn-targeting gRNA did not turn on GFP reporter expression. Bars represent the mean ± SD of more than four representative images from two animals. [Figure 8-1]Figures 8A-E show the modified CRISPR system for editing 5-cytosine DNA methylation in mammalian genomes. Figure 8A shows the design of dCas9-effector constructs with differently positioned nuclear localization signals (NLSs) and guide RNAs (gRNAs) or extended guide RNAs (E-gRNAs) with CMV-driven puro-T2A-Cherry cassettes. Ub: human ubiquitin C promoter. Figure 8B shows the analysis of the expression of dCas-NLS-Tet1 and NLS-dCas9-NLS-Tet1 by immunoblotting with anti-Cas9 antibody after transfection of these constructs into HEK293T cells for 2 days. α-Tubulin was used as a loading control. Figure 8C shows a comparison of cellular translocation of dCas9-NLS-Tet1 and NLS-dCas9-NLS-Tet1 in HEK293T cells with or without co-expression of gRNA or E-gRNA targeting the same location of the MyoD locus. In the absence of sgRNA, dCas9-NLS-Tet1 is largely excluded from the nuclear compartment, and NLS-dCas9-NLS-Tet1 shows weak nuclear translocation in transfected HEK293T cells. Co-expression of either gRNA or E-gRNA induced translocation of these two proteins from the cytoplasm to the nucleus. In the merged images, dCas9 is stained green, Cherry is stained red, and DAPI is stained blue. The red dashed lines in the first two panels indicate image sections to quantify GFP intensity. Scale bar: 10um. Figure 8D shows box plots of quantification of the nuclear-cytoplasmic ratios of dCas9-NLS-Tet1 and NLS-dCas9-NLS-Tet1 in HEK293T cells in the absence or presence of gRNA or E-gRNA. Quantification used the average dCas9 intensity of the cytoplasmic and nuclear domains along the cross-sectional lines illustrated in C. "+" indicates the mean of 20 data points for each group; boxes indicate extreme data points (upper and lower bars), the 25-75% interval (box), and the median (middle line). Figure 8E shows quantification of induction index (defined as the nuclear-cytoplasmic ratio with sgRNA, normalized by the value without sgRNA) for dCas9-NLS-Tet1 and NLS-dCas9-NLS-Tet1.gRNA and E-gRNA induced 3.17-fold and 3.22-fold nuclear translocation for dCas9-NLS-Tet1, and 1.73-fold and 1.77-fold nuclear translocation for NLS-dCas9-NLS-Tet1, respectively. We speculated that the combination with the highest induction index would provide the best signal-to-noise ratio for targeted DNA methylation editing. [Figure 8-2]Figures 8A-E show the modified CRISPR system for editing 5-cytosine DNA methylation in mammalian genomes. Figure 8A shows the design of dCas9-effector constructs with differently positioned nuclear localization signals (NLSs) and guide RNAs (gRNAs) or extended guide RNAs (E-gRNAs) with CMV-driven puro-T2A-Cherry cassettes. Ub: human ubiquitin C promoter. Figure 8B shows the analysis of the expression of dCas-NLS-Tet1 and NLS-dCas9-NLS-Tet1 by immunoblotting with anti-Cas9 antibody after transfection of these constructs into HEK293T cells for 2 days. α-Tubulin was used as a loading control. Figure 8C shows a comparison of cellular translocation of dCas9-NLS-Tet1 and NLS-dCas9-NLS-Tet1 in HEK293T cells with or without co-expression of gRNA or E-gRNA targeting the same location of the MyoD locus. In the absence of sgRNA, dCas9-NLS-Tet1 is largely excluded from the nuclear compartment, and NLS-dCas9-NLS-Tet1 shows weak nuclear translocation in transfected HEK293T cells. Co-expression of either gRNA or E-gRNA induced translocation of these two proteins from the cytoplasm to the nucleus. In the merged images, dCas9 is stained green, Cherry is stained red, and DAPI is stained blue. The red dashed lines in the first two panels indicate image sections to quantify GFP intensity. Scale bar: 10um. Figure 8D shows box plots of quantification of the nuclear-cytoplasmic ratios of dCas9-NLS-Tet1 and NLS-dCas9-NLS-Tet1 in HEK293T cells in the absence or presence of gRNA or E-gRNA. Quantification used the average dCas9 intensity of the cytoplasmic and nuclear domains along the cross-sectional lines illustrated in C. "+" indicates the mean of 20 data points for each group; boxes indicate extreme data points (upper and lower bars), the 25-75% interval (box), and the median (middle line). Figure 8E shows quantification of induction index (defined as the nuclear-cytoplasmic ratio with sgRNA, normalized by the value without sgRNA) for dCas9-NLS-Tet1 and NLS-dCas9-NLS-Tet1.gRNA and E-gRNA induced 3.17-fold and 3.22-fold nuclear translocation for dCas9-NLS-Tet1, and 1.73-fold and 1.77-fold nuclear translocation for NLS-dCas9-NLS-Tet1, respectively. We speculated that the combination with the highest induction index would provide the best signal-to-noise ratio for targeted DNA methylation editing. [Figure 9-1]Figure 9A-9J show targeted promoter methylation editing activating the Dazle-Snrpn-GFP reporter by dCas9-Tet1 and repressing the Gapdh-Snrpn-GFP reporter by dCas9-Dnmt3a. Figure 9A shows the genomic sequence of the Dazl-Snrpn locus with gRNA sequences labeled in yellow and CpGs labeled in green. The PAM of each gRNA is highlighted in a red box. Dazl sequences are in lower case and Snrpn sequences are in upper case. Figure 9B shows fluorescent images of Dazl-Snrpn-GFP mESCs infected for 3 days with lentivirus expressing dCas9-Tet1 (dC-T) in the presence or absence of a targeted gRNA against the Snrpn promoter. Scale bar: 120um. Figure 9C shows flow cytometry analysis of Dazl-Snrpn-GFP mESCs after 3 days of infection with lentivirus expressing scrambled gRNA or four gRNAs targeting the Snrpn promoter region and dCas9-Tet1 (dC-T). Activation efficiency was calculated by the formula listed and shown as the mean ratio of Cherry and GFP double positive cells ± SD of two biological replicates. Figure 9D shows bisulfite sequencing of the Dazl-Snrpn region in Cherry+;GFP+ or Cherry+;GFP- cell populations after FACS sorting of Dazl-Snrpn mouse ES cells infected with lentivirus expressing dC-T and Snrpn gRNA. Figure 9E shows the genomic sequence of the Gapdh-Snrpn locus with gRNA sequences labeled in yellow and CpGs labeled in green. The PAM of each gRNA is highlighted in a red box. The Gapdh sequence is in lower case and the Snrpn sequence is in upper case. Figure 9F shows flow cytometry analysis of Gapdh-Snrpn-GFP mESCs 3 days after infection with lentivirus expressing dCas9-Dnmt3a (dC-D) and three gRNAs targeting the Snrpn promoter region. Inactivation efficiency was calculated by the formula listed and shown as the average ratio of Cherry-positive and GFP-negative cells ± SD of two biological replicates.Figure 9G shows bisulfite sequencing of the Gapdh-Snrpn region in Cherry+;GFP+ or Cherry+;GFP- cell populations after FACS sorting of Gapdh-Snrpn mouse ES cells infected with lentivirus expressing dC-D and Snrpn gRNAs. Figure 9H shows mESCs stably integrated with doxycycline-inducible dCas9-Dnmt3a cassette analyzed by RT-qPCR after 48 hours of doxycycline (2ug / ml) treatment. Bars represent the mean ± SD of three experimental replicates. Figure 9I shows flow cytometry analysis of Gapdh-Snrpn-GFP mESCs with doxycycline-inducible dCas9-Dnmt3a after 3 days of infection with lentivirus expressing three gRNAs as in F in the presence of doxycycline (2ug / ml). Inactivation efficiency was calculated as shown at the bottom and expressed as the average percentage of Cherry-positive and GFP-negative cells ± SD of two biological replicates. Figure 9J, left panel: Schematic diagram of dCas9-Dnmt3a-P2A-BFP and gRNA-Cherry constructs. Center panel: FACS analysis of Gapdh-Snrpn-GFP mESCs after infection with lentivirus expressing dCas9-Dnmt3a-P2A-BFP and Snrpn gRNA shows the percentage of BFP-only positive, Cherry-only positive, and double positive cell populations. Right panel: FACS analysis of the percentage of GFP- or GFP+ cells among the BFP+;Cherry+ cell population. [Figure 9-2]Figure 9A-9J show targeted promoter methylation editing activating the Dazle-Snrpn-GFP reporter by dCas9-Tet1 and repressing the Gapdh-Snrpn-GFP reporter by dCas9-Dnmt3a. Figure 9A shows the genomic sequence of the Dazl-Snrpn locus with gRNA sequences labeled in yellow and CpGs labeled in green. The PAM of each gRNA is highlighted in a red box. Dazl sequences are in lower case and Snrpn sequences are in upper case. Figure 9B shows fluorescent images of Dazl-Snrpn-GFP mESCs infected for 3 days with lentivirus expressing dCas9-Tet1 (dC-T) in the presence or absence of a targeted gRNA against the Snrpn promoter. Scale bar: 120um. Figure 9C shows flow cytometry analysis of Dazl-Snrpn-GFP mESCs after 3 days of infection with lentivirus expressing scrambled gRNA or four gRNAs targeting the Snrpn promoter region and dCas9-Tet1 (dC-T). Activation efficiency was calculated by the formula listed and shown as the mean ratio of Cherry and GFP double positive cells ± SD of two biological replicates. Figure 9D shows bisulfite sequencing of the Dazl-Snrpn region in Cherry+;GFP+ or Cherry+;GFP- cell populations after FACS sorting of Dazl-Snrpn mouse ES cells infected with lentivirus expressing dC-T and Snrpn gRNA. Figure 9E shows the genomic sequence of the Gapdh-Snrpn locus with gRNA sequences labeled in yellow and CpGs labeled in green. The PAM of each gRNA is highlighted in a red box. The Gapdh sequence is in lower case and the Snrpn sequence is in upper case. Figure 9F shows flow cytometry analysis of Gapdh-Snrpn-GFP mESCs 3 days after infection with lentivirus expressing dCas9-Dnmt3a (dC-D) and three gRNAs targeting the Snrpn promoter region. Inactivation efficiency was calculated by the formula listed and shown as the average ratio of Cherry-positive and GFP-negative cells ± SD of two biological replicates.Figure 9G shows bisulfite sequencing of the Gapdh-Snrpn region in Cherry+;GFP+ or Cherry+;GFP- cell populations after FACS sorting of Gapdh-Snrpn mouse ES cells infected with lentivirus expressing dC-D and Snrpn gRNAs. Figure 9H shows mESCs stably integrated with doxycycline-inducible dCas9-Dnmt3a cassette analyzed by RT-qPCR after 48 hours of doxycycline (2ug / ml) treatment. Bars represent the mean ± SD of three experimental replicates. Figure 9I shows flow cytometry analysis of Gapdh-Snrpn-GFP mESCs with doxycycline-inducible dCas9-Dnmt3a after 3 days of infection with lentivirus expressing three gRNAs as in F in the presence of doxycycline (2ug / ml). Inactivation efficiency was calculated as shown at the bottom and expressed as the average percentage of Cherry-positive and GFP-negative cells ± SD of two biological replicates. Figure 9J, left panel: Schematic diagram of dCas9-Dnmt3a-P2A-BFP and gRNA-Cherry constructs. Center panel: FACS analysis of Gapdh-Snrpn-GFP mESCs after infection with lentivirus expressing dCas9-Dnmt3a-P2A-BFP and Snrpn gRNA shows the percentage of BFP-only positive, Cherry-only positive, and double positive cell populations. Right panel: FACS analysis of the percentage of GFP- or GFP+ cells among the BFP+;Cherry+ cell population. [Figure 9-3]Figure 9A-9J show targeted promoter methylation editing activating the Dazle-Snrpn-GFP reporter by dCas9-Tet1 and repressing the Gapdh-Snrpn-GFP reporter by dCas9-Dnmt3a. Figure 9A shows the genomic sequence of the Dazl-Snrpn locus with gRNA sequences labeled in yellow and CpGs labeled in green. The PAM of each gRNA is highlighted in a red box. Dazl sequences are in lower case and Snrpn sequences are in upper case. Figure 9B shows fluorescent images of Dazl-Snrpn-GFP mESCs infected for 3 days with lentivirus expressing dCas9-Tet1 (dC-T) in the presence or absence of a targeted gRNA against the Snrpn promoter. Scale bar: 120um. Figure 9C shows flow cytometry analysis of Dazl-Snrpn-GFP mESCs after 3 days of infection with lentivirus expressing scrambled gRNA or four gRNAs targeting the Snrpn promoter region and dCas9-Tet1 (dC-T). Activation efficiency was calculated by the formula listed and shown as the mean ratio of Cherry and GFP double positive cells ± SD of two biological replicates. Figure 9D shows bisulfite sequencing of the Dazl-Snrpn region in Cherry+;GFP+ or Cherry+;GFP- cell populations after FACS sorting of Dazl-Snrpn mouse ES cells infected with lentivirus expressing dC-T and Snrpn gRNA. Figure 9E shows the genomic sequence of the Gapdh-Snrpn locus with gRNA sequences labeled in yellow and CpGs labeled in green. The PAM of each gRNA is highlighted in a red box. The Gapdh sequence is in lower case and the Snrpn sequence is in upper case. Figure 9F shows flow cytometry analysis of Gapdh-Snrpn-GFP mESCs 3 days after infection with lentivirus expressing dCas9-Dnmt3a (dC-D) and three gRNAs targeting the Snrpn promoter region. Inactivation efficiency was calculated by the formula listed and shown as the average ratio of Cherry-positive and GFP-negative cells ± SD of two biological replicates.Figure 9G shows bisulfite sequencing of the Gapdh-Snrpn region in Cherry+;GFP+ or Cherry+;GFP- cell populations after FACS sorting of Gapdh-Snrpn mouse ES cells infected with lentivirus expressing dC-D and Snrpn gRNAs. Figure 9H shows mESCs stably integrated with doxycycline-inducible dCas9-Dnmt3a cassette analyzed by RT-qPCR after 48 hours of doxycycline (2ug / ml) treatment. Bars represent the mean ± SD of three experimental replicates. Figure 9I shows flow cytometry analysis of Gapdh-Snrpn-GFP mESCs with doxycycline-inducible dCas9-Dnmt3a after 3 days of infection with lentivirus expressing three gRNAs as in F in the presence of doxycycline (2ug / ml). Inactivation efficiency was calculated as shown at the bottom and expressed as the average percentage of Cherry-positive and GFP-negative cells ± SD of two biological replicates. Figure 9J, left panel: Schematic diagram of dCas9-Dnmt3a-P2A-BFP and gRNA-Cherry constructs. Center panel: FACS analysis of Gapdh-Snrpn-GFP mESCs after infection with lentivirus expressing dCas9-Dnmt3a-P2A-BFP and Snrpn gRNA shows the percentage of BFP-only positive, Cherry-only positive, and double positive cell populations. Right panel: FACS analysis of the percentage of GFP- or GFP+ cells among the BFP+;Cherry+ cell population. [Figure 10-1]Figure 10A-G show a comparison of methylation editing between the TALE and dCas9 systems. Figure 10A shows HeLa cells transfected with dCas9-Dnmt3a and one p16-targeting gRNA (Cherry), or TALE-Dnmt3a-GFP. Transfection-positive cell populations (cherry+) or (GFP+) were sorted by FACS 48 hours after transfection. The methylation levels of each individual CpG in the p16 promoter region were analyzed by bisulfite sequencing. The average ratio ± SD of two biological replicates with a total of 34 single colonies sequenced for dCas9-Dnmt3a and 31 single colonies sequenced for TALE-Dnmt3a are shown. The red arrow indicates the position of the p16-targeting gRNA, and the purple arrow indicates the binding site for TALE-Dnmt3a. Figure 10B shows HEK293T cells co-transfected with dCas9-Tet1 and one RHOXF2 targeting gRNA (containing a puro cassette) or TALE-Tet1 containing a puro cassette expressing plasmid. Puromycin (2ug / ml) was added to the medium to select transfection-positive cells. Two days after sorting, cells were harvested and methylation levels were analyzed for individual CpGs in the RHOXF2 promoter region by bisulfite sequencing. The average percentage ± SD of two biological replicates with a total of 34 single colonies sequenced for dCas9-Tet1 and 38 single colonies sequenced for TALE-Tet1 is shown. The red arrow indicates the position of the RHOXF2 targeting gRNA, and the purple arrow indicates the binding site for TALE-Dnmt3a. Figure 10C shows a summary of the methylation level analysis in A and B. The effective range was determined by the distance from the gRNA target site of CpGs significantly edited by dCas9-Dnmt3a / Tet1 (>10% methylation change). Resolution was defined as the effective range of dCas9-Dnmt3a / Tet1 containing one single gRNA, and the higher the resolution, the narrower the effective range of dCas9-Dnmt3a / Tet1 that allows precise editing of DNA methylation.Figure 10D shows that Dox-inducible dCas9-Dnmt3a-expressing mouse ES cells described in Figure 9H were infected with scrambled gRNA or gRNA targeting miR290 locus or Dazl-Snrpn locus. FACS-sorted Cherry-positive cells were cultured with Dox (2ug / ml) for 3 days. The cells were then harvested for anti-dCas9 ChIP-seq analysis. Peaks were called using a pairwise peak calling procedure previously described (Wu et al., 2014) and displayed as a Manhattan plot representing genome-wide ChIP-seq peaks. All peaks with p<0.001 are shown. Each dot represents a peak, the X-axis indicates the genomic location, and the Y-axis indicates the peak apex height output by Model-based Analysis of ChIP-Seq (MACS) (Zhang et al., 2008). The size of each dot is proportional to the Y-axis value, and individual chromosomes are color-coded for visualization. FIG. 10E illustrates ChIP-seq peaks at the target locus with the highest signal (miR290 or Dazl-Snrpn) and the two off-target loci with the second and third highest signal (Vac14 and Tenm4 loci for miR290 gRNA; Vrk1 and Gm42619 loci for Dazl-Snrpn gRNA) with the adjacent genes listed below. Note that the four Dazl-Snrpn gRNAs recognize the promoter sequences of Dazl and Snrpn as shown in FIG. 9A, so the peaks of this group of gRNAs were mapped to both loci. FIG. 10F shows that genomic DNA from the cells used in FIG. 5C was subjected to bisulfite sequencing for off-target binding sites at the Vac14 and Tenm4 loci. Shown as the mean ratio ± SD of two biological replicates. Figure 10G shows that genomic DNA from the cells used in Figures 1D and 2C was subjected to bisulfite sequencing for off-target binding sites at the Vrk1 and Gm42619 loci, shown as the mean ratio of two biological replicates ± SD. [Figure 10-2]Figure 10A-G show a comparison of methylation editing between the TALE and dCas9 systems. Figure 10A shows HeLa cells transfected with dCas9-Dnmt3a and one p16-targeting gRNA (Cherry), or TALE-Dnmt3a-GFP. Transfection-positive cell populations (cherry+) or (GFP+) were sorted by FACS 48 hours after transfection. The methylation levels of each individual CpG in the p16 promoter region were analyzed by bisulfite sequencing. The average ratio ± SD of two biological replicates with a total of 34 single colonies sequenced for dCas9-Dnmt3a and 31 single colonies sequenced for TALE-Dnmt3a are shown. The red arrow indicates the position of the p16-targeting gRNA, and the purple arrow indicates the binding site for TALE-Dnmt3a. Figure 10B shows HEK293T cells co-transfected with dCas9-Tet1 and one RHOXF2 targeting gRNA (containing a puro cassette) or TALE-Tet1 containing a puro cassette expressing plasmid. Puromycin (2ug / ml) was added to the medium to select transfection-positive cells. Two days after sorting, cells were harvested and methylation levels were analyzed for individual CpGs in the RHOXF2 promoter region by bisulfite sequencing. The average percentage ± SD of two biological replicates with a total of 34 single colonies sequenced for dCas9-Tet1 and 38 single colonies sequenced for TALE-Tet1 is shown. The red arrow indicates the position of the RHOXF2 targeting gRNA, and the purple arrow indicates the binding site for TALE-Dnmt3a. Figure 10C shows a summary of the methylation level analysis in A and B. The effective range was determined by the distance from the gRNA target site of CpGs significantly edited by dCas9-Dnmt3a / Tet1 (>10% methylation change). Resolution was defined as the effective range of dCas9-Dnmt3a / Tet1 containing one single gRNA, and the higher the resolution, the narrower the effective range of dCas9-Dnmt3a / Tet1 that allows precise editing of DNA methylation.Figure 10D shows that Dox-inducible dCas9-Dnmt3a-expressing mouse ES cells described in Figure 9H were infected with scrambled gRNA or gRNA targeting miR290 locus or Dazl-Snrpn locus. FACS-sorted Cherry-positive cells were cultured with Dox (2ug / ml) for 3 days. The cells were then harvested for anti-dCas9 ChIP-seq analysis. Peaks were called using a pairwise peak calling procedure previously described (Wu et al., 2014) and displayed as a Manhattan plot representing genome-wide ChIP-seq peaks. All peaks with p<0.001 are shown. Each dot represents a peak, the X-axis indicates the genomic location, and the Y-axis indicates the peak apex height output by Model-based Analysis of ChIP-Seq (MACS) (Zhang et al., 2008). The size of each dot is proportional to the Y-axis value, and individual chromosomes are color-coded for visualization. FIG. 10E illustrates ChIP-seq peaks at the target locus with the highest signal (miR290 or Dazl-Snrpn) and the two off-target loci with the second and third highest signal (Vac14 and Tenm4 loci for miR290 gRNA; Vrk1 and Gm42619 loci for Dazl-Snrpn gRNA) with the adjacent genes listed below. Note that the four Dazl-Snrpn gRNAs recognize the promoter sequences of Dazl and Snrpn as shown in FIG. 9A, so the peaks of this group of gRNAs were mapped to both loci. FIG. 10F shows that genomic DNA from the cells used in FIG. 5C was subjected to bisulfite sequencing for off-target binding sites at the Vac14 and Tenm4 loci. Shown as the mean ratio ± SD of two biological replicates. Figure 10G shows that genomic DNA from the cells used in Figures 1D and 2C was subjected to bisulfite sequencing for off-target binding sites at the Vrk1 and Gm42619 loci, shown as the mean ratio of two biological replicates ± SD. [Figure 11-1]Figures 11A-11L show dCas9-Tet1 targeted demethylation of BDNF promoter IV in neurons. Figure 11A shows the genomic sequence of the BDNF promoter IV region with gRNA sequences labeled in yellow and CpGs labeled in green. The PAM of each gRNA is highlighted in a red box. Figure 11B, left panel: Schematic diagram of KCl treatment and lentiviral delivery experiments on E17.5 mouse primary cortical neurons to investigate BDNF expression. Cultured neurons were treated with AraC on DIV2 to arrest cell division in glial cells and neural progenitor cells. Right panel: DIV3 mouse cortical neurons were treated with 50 mM KCl and harvested at different time points for BDNF expression analysis by RT-qPCR. Figure 11C shows EDU labeling analysis of mouse primary neurons over the course of 24 h KCl treatment. It can be seen that only a very small number of EDU-positive cells were observed. EDU is stained in red, MAP2 in green, and nuclei with DAPI. Scale bar: 500 um. Figure 11D, top panel: Quantification of neuronal density over the course of KCl treatment. Postmitotic neuronal density remains steady over time at around 4.5x104 / cm2. Bars represent mean ± SD of three experimental replicates. Bottom panel: Quantification of EDU positive cells over the course of KCl treatment. Less than 2% of cells are EDU positive over 24 hours. Bars represent mean ± SD of three experimental replicates. Figure 11E shows confocal micrographs of ectopic expression of dCas9-Tet1 and BDNF induction by a set of four gRNAs targeting BDNF promoter IV. BDNF is stained in green, MAP2 in magenta, Cherry in red, and DAPI in blue. Note that lentiviral infection efficiency in these neurons is nearly 100%. Scale bar: 50 um. Figure 11F shows neurons from B and E subjected to RT-qPCR analysis for Npas4 expression. Bars represent the mean ± SD of three experimental replicates. Figure 11G shows DIV3 mouse cortical neurons were infected with dC-T alone or simultaneously with four gRNAs targeting BDNF promoter IV or individual BDNF gRNAs, followed by qPCR analysis of BDNF expression.Figures 11H-11I show Tet-assisted bisulfite sequencing (TAB-Seq) analysis of neurons. Figure 11H shows neurons infected with lentivirus expressing dC-T, or dC-dT and four BDNF gRNAs for 40 and 60 hours, and Figure 11I shows neurons after 6 hours of KCl treatment. Figure 11J shows DIV3 mouse cortical neurons treated with ABT (50 uM) for 6 hours, followed by KCl (50 mM) for 6 hours, harvested and subjected to RT-qPCR analysis. Bars represent the mean ± SD of three experimental replicates. Figure 11K shows DIV3 mouse cortical neurons treated with 2-hydroxyglutarate (10 mM) for 2 hours, followed by KCl (50 mM) for 6 hours, harvested and subjected to RT-qPCR analysis. Bars represent the mean ± SD of three experimental replicates. Figure 11L shows a time course of KCl treatment experiments (6, 9, and 12 hours) on DIV3 mouse cortical neurons derived from wild-type or Tet1 knockout E17.5 embryos. Bars represent the mean ± SD of three experimental replicates. [Figure 11-2]Figures 11A-11L show dCas9-Tet1 targeted demethylation of BDNF promoter IV in neurons. Figure 11A shows the genomic sequence of the BDNF promoter IV region with gRNA sequences labeled in yellow and CpGs labeled in green. The PAM of each gRNA is highlighted in a red box. Figure 11B, left panel: Schematic diagram of KCl treatment and lentiviral delivery experiments on E17.5 mouse primary cortical neurons to investigate BDNF expression. Cultured neurons were treated with AraC on DIV2 to arrest cell division in glial cells and neural progenitor cells. Right panel: DIV3 mouse cortical neurons were treated with 50 mM KCl and harvested at different time points for BDNF expression analysis by RT-qPCR. Figure 11C shows EDU labeling analysis of mouse primary neurons over the course of 24 h KCl treatment. It can be seen that only a very small number of EDU-positive cells were observed. EDU is stained in red, MAP2 in green, and nuclei with DAPI. Scale bar: 500 um. Figure 11D, top panel: Quantification of neuronal density over the course of KCl treatment. Postmitotic neuronal density remains steady over time at around 4.5x104 / cm2. Bars represent mean ± SD of three experimental replicates. Bottom panel: Quantification of EDU positive cells over the course of KCl treatment. Less than 2% of cells are EDU positive over 24 hours. Bars represent mean ± SD of three experimental replicates. Figure 11E shows confocal micrographs of ectopic expression of dCas9-Tet1 and BDNF induction by a set of four gRNAs targeting BDNF promoter IV. BDNF is stained in green, MAP2 in magenta, Cherry in red, and DAPI in blue. Note that lentiviral infection efficiency in these neurons is nearly 100%. Scale bar: 50 um. Figure 11F shows neurons from B and E subjected to RT-qPCR analysis for Npas4 expression. Bars represent the mean ± SD of three experimental replicates. Figure 11G shows DIV3 mouse cortical neurons were infected with dC-T alone or simultaneously with four gRNAs targeting BDNF promoter IV or individual BDNF gRNAs, followed by qPCR analysis of BDNF expression.Figures 11H-11I show Tet-assisted bisulfite sequencing (TAB-Seq) analysis of neurons. Figure 11H shows neurons infected with lentivirus expressing dC-T, or dC-dT and four BDNF gRNAs for 40 and 60 hours, and Figure 11I shows neurons after 6 hours of KCl treatment. Figure 11J shows DIV3 mouse cortical neurons treated with ABT (50 uM) for 6 hours, followed by KCl (50 mM) for 6 hours, harvested and subjected to RT-qPCR analysis. Bars represent the mean ± SD of three experimental replicates. Figure 11K shows DIV3 mouse cortical neurons treated with 2-hydroxyglutarate (10 mM) for 2 hours, followed by KCl (50 mM) for 6 hours, harvested and subjected to RT-qPCR analysis. Bars represent the mean ± SD of three experimental replicates. Figure 11L shows a time course of KCl treatment experiments (6, 9, and 12 hours) on DIV3 mouse cortical neurons derived from wild-type or Tet1 knockout E17.5 embryos. Bars represent the mean ± SD of three experimental replicates. [Figure 11-3]Figures 11A-11L show dCas9-Tet1 targeted demethylation of BDNF promoter IV in neurons. Figure 11A shows the genomic sequence of the BDNF promoter IV region with gRNA sequences labeled in yellow and CpGs labeled in green. The PAM of each gRNA is highlighted in a red box. Figure 11B, left panel: Schematic diagram of KCl treatment and lentiviral delivery experiments on E17.5 mouse primary cortical neurons to investigate BDNF expression. Cultured neurons were treated with AraC on DIV2 to arrest cell division in glial cells and neural progenitor cells. Right panel: DIV3 mouse cortical neurons were treated with 50 mM KCl and harvested at different time points for BDNF expression analysis by RT-qPCR. Figure 11C shows EDU labeling analysis of mouse primary neurons over the course of 24 h KCl treatment. It can be seen that only a very small number of EDU-positive cells were observed. EDU is stained in red, MAP2 in green, and nuclei with DAPI. Scale bar: 500 um. Figure 11D, top panel: Quantification of neuronal density over the course of KCl treatment. Postmitotic neuronal density remains steady over time at around 4.5x104 / cm2. Bars represent mean ± SD of three experimental replicates. Bottom panel: Quantification of EDU positive cells over the course of KCl treatment. Less than 2% of cells are EDU positive over 24 hours. Bars represent mean ± SD of three experimental replicates. Figure 11E shows confocal micrographs of ectopic expression of dCas9-Tet1 and BDNF induction by a set of four gRNAs targeting BDNF promoter IV. BDNF is stained in green, MAP2 in magenta, Cherry in red, and DAPI in blue. Note that lentiviral infection efficiency in these neurons is nearly 100%. Scale bar: 50 um. Figure 11F shows neurons from B and E subjected to RT-qPCR analysis for Npas4 expression. Bars represent the mean ± SD of three experimental replicates. Figure 11G shows DIV3 mouse cortical neurons were infected with dC-T alone or simultaneously with four gRNAs targeting BDNF promoter IV or individual BDNF gRNAs, followed by qPCR analysis of BDNF expression.Figures 11H-11I show Tet-assisted bisulfite sequencing (TAB-Seq) analysis of neurons. Figure 11H shows neurons infected with lentivirus expressing dC-T, or dC-dT and four BDNF gRNAs for 40 and 60 hours, and Figure 11I shows neurons after 6 hours of KCl treatment. Figure 11J shows DIV3 mouse cortical neurons treated with ABT (50 uM) for 6 hours, followed by KCl (50 mM) for 6 hours, harvested and subjected to RT-qPCR analysis. Bars represent the mean ± SD of three experimental replicates. Figure 11K shows DIV3 mouse cortical neurons treated with 2-hydroxyglutarate (10 mM) for 2 hours, followed by KCl (50 mM) for 6 hours, harvested and subjected to RT-qPCR analysis. Bars represent the mean ± SD of three experimental replicates. Figure 11L shows a time course of KCl treatment experiments (6, 9, and 12 hours) on DIV3 mouse cortical neurons derived from wild-type or Tet1 knockout E17.5 embryos. Bars represent the mean ± SD of three experimental replicates. [Figure 12-1]Figures 12A-12J show dCas9-Tet1-mediated demethylation of the MyoD distal enhancer and fibroblast-to-myoblast conversion. Figure 12A shows the genomic sequence of the MyoD distal enhancer region with gRNA sequences labeled in yellow and CpGs labeled in green. The PAM of each sgRNA is highlighted in a red box. Figure 12B shows the experimental scheme of the fibroblast-to-myoblast conversion assay. Briefly, C3H10T1 / 2 mouse embryonic fibroblasts were seeded in a 6-well plate at 1×104 cells per well and then infected with lentivirus expressing dCas9-Tet1 and the target gRNA. 24 hours after infection, cells were treated with 5-azacytidine (1 uM) for 24 hours as required (labeled in red) and harvested at different time points (14th, 16th, and 25th days, labeled in dark blue) with medium changes every other day for immunofluorescence staining. Scale bar: 100 um. Figure 12C shows representative confocal micrographs of myotube formation in C3H10T1 / 2 fibroblasts after 5-Aza treatment. Top panel: Clonal regions contain sparsely distributed small and medium sized myotubes. Middle panel: Clonal regions contain sparsely distributed large myotubes. Bottom panel: Clonal regions contain dense myotubes with heterogeneous sizes. MHC is stained green, MyoD is stained red, and DAPI is stained blue. Scale bar: 200 um. Figure 12D shows the percentage of mock C3H10T1 / 2 cells expressing MyoD at different time points after 5-Aza treatment. The percentage of cells expressing MyoD increased from about 6% at day 14 to about 13% at day 16 and reached about 20% at day 25. Bars represent mean ± SD. FIG. 12E shows the number of nuclei within MHC+ cell clusters (classified as 1-2 and >2 nuclei per MHC+ cluster). Larger myotube formation was observed at later time points of 5-Aza treatment. Bars represent mean ± SD. Data in FIG. 12D and FIG. 12E are quantified from 3-5 representative images per group. FIG. 12F shows C3H10T1 / 2 cells infected with lentivirus expressing dC-T and MyoD gRNA for 24 h, harvested with or without treatment with 5-Aza for 48 h, and subjected to qPCR analysis. Bars represent mean ± SD of three experimental replicates.FIG. 12G shows representative images of C3H10T1 / 2 cells 16 days after infection with lentivirus expressing dC-T and gRNA targeting DMR-5 (MyoD distal enhancer) in the fibroblast-to-myoblast conversion assay described in FIG. 12B. It can be seen that in cells with dC-T and the targeting gRNA, a moderate level of MyoD activation was observed (compared to cells treated with 5-Aza), but no myosin heavy chain (MHC) expression or myotube formation was observed. MHC is stained magenta, MyoD is stained green, and DAPI is stained blue. Scale bar: 200 um. FIG. 12H shows the percentage of MyoD positive cells 16 days after infection with lentivirus expressing dC-T alone or together with gRNA targeting DMR-5. Figure 12I shows the number of nuclei in MHC+ cell clusters 16 days after infection (classified as 2-5, 6-10, 11-20, and >20 nuclei per MHC+ cluster). When treated with 5-Aza, co-expression of gRNA with dC-T significantly promoted the formation of more mature and larger MHC+ clusters compared to mock control or dC-T alone. Figure 12J shows myotube density in MHC-positive clusters with >2 or >5 nuclei 16 days after infection. Addition of 5-Aza induces MHC+ myotube formation. Co-expression of dC-T with gRNA significantly induces larger myotubes with higher nuclei (MHC+ clusters with >5 nuclei). Data in Figures 12H-J are quantified from 3-5 representative images. Bars represent mean ± SD. [Figure 12-2]Figures 12A-12J show dCas9-Tet1-mediated demethylation of the MyoD distal enhancer and fibroblast-to-myoblast conversion. Figure 12A shows the genomic sequence of the MyoD distal enhancer region with gRNA sequences labeled in yellow and CpGs labeled in green. The PAM of each sgRNA is highlighted in a red box. Figure 12B shows the experimental scheme of the fibroblast-to-myoblast conversion assay. Briefly, C3H10T1 / 2 mouse embryonic fibroblasts were seeded in a 6-well plate at 1×104 cells per well and then infected with lentivirus expressing dCas9-Tet1 and the target gRNA. 24 hours after infection, cells were treated with 5-azacytidine (1 uM) for 24 hours as required (labeled in red) and harvested at different time points (14th, 16th, and 25th days, labeled in dark blue) with medium changes every other day for immunofluorescence staining. Scale bar: 100 um. Figure 12C shows representative confocal micrographs of myotube formation in C3H10T1 / 2 fibroblasts after 5-Aza treatment. Top panel: Clonal regions contain sparsely distributed small and medium sized myotubes. Middle panel: Clonal regions contain sparsely distributed large myotubes. Bottom panel: Clonal regions contain dense myotubes with heterogeneous sizes. MHC is stained green, MyoD is stained red, and DAPI is stained blue. Scale bar: 200 um. Figure 12D shows the percentage of mock C3H10T1 / 2 cells expressing MyoD at different time points after 5-Aza treatment. The percentage of cells expressing MyoD increased from about 6% at day 14 to about 13% at day 16 and reached about 20% at day 25. Bars represent mean ± SD. FIG. 12E shows the number of nuclei within MHC+ cell clusters (classified as 1-2 and >2 nuclei per MHC+ cluster). Larger myotube formation was observed at later time points of 5-Aza treatment. Bars represent mean ± SD. Data in FIG. 12D and FIG. 12E are quantified from 3-5 representative images per group. FIG. 12F shows C3H10T1 / 2 cells infected with lentivirus expressing dC-T and MyoD gRNA for 24 h, harvested with or without treatment with 5-Aza for 48 h, and subjected to qPCR analysis. Bars represent mean ± SD of three experimental replicates.FIG. 12G shows representative images of C3H10T1 / 2 cells 16 days after infection with lentivirus expressing dC-T and gRNA targeting DMR-5 (MyoD distal enhancer) in the fibroblast-to-myoblast conversion assay described in FIG. 12B. It can be seen that in cells with dC-T and the targeting gRNA, a moderate level of MyoD activation was observed (compared to cells treated with 5-Aza), but no myosin heavy chain (MHC) expression or myotube formation was observed. MHC is stained magenta, MyoD is stained green, and DAPI is stained blue. Scale bar: 200 um. FIG. 12H shows the percentage of MyoD positive cells 16 days after infection with lentivirus expressing dC-T alone or together with gRNA targeting DMR-5. Figure 12I shows the number of nuclei in MHC+ cell clusters 16 days after infection (classified as 2-5, 6-10, 11-20, and >20 nuclei per MHC+ cluster). When treated with 5-Aza, co-expression of gRNA with dC-T significantly promoted the formation of more mature and larger MHC+ clusters compared to mock control or dC-T alone. Figure 12J shows myotube density in MHC-positive clusters with >2 or >5 nuclei 16 days after infection. Addition of 5-Aza induces MHC+ myotube formation. Co-expression of dC-T with gRNA significantly induces larger myotubes with higher nuclei (MHC+ clusters with >5 nuclei). Data in Figures 12H-J are quantified from 3-5 representative images. Bars represent mean ± SD. [Figure 12-3]Figures 12A-12J show dCas9-Tet1-mediated demethylation of the MyoD distal enhancer and fibroblast-to-myoblast conversion. Figure 12A shows the genomic sequence of the MyoD distal enhancer region with gRNA sequences labeled in yellow and CpGs labeled in green. The PAM of each sgRNA is highlighted in a red box. Figure 12B shows the experimental scheme of the fibroblast-to-myoblast conversion assay. Briefly, C3H10T1 / 2 mouse embryonic fibroblasts were seeded in a 6-well plate at 1×104 cells per well and then infected with lentivirus expressing dCas9-Tet1 and the target gRNA. 24 hours after infection, cells were treated with 5-azacytidine (1 uM) for 24 hours as required (labeled in red) and harvested at different time points (14th, 16th, and 25th days, labeled in dark blue) with medium changes every other day for immunofluorescence staining. Scale bar: 100 um. Figure 12C shows representative confocal micrographs of myotube formation in C3H10T1 / 2 fibroblasts after 5-Aza treatment. Top panel: Clonal regions contain sparsely distributed small and medium sized myotubes. Middle panel: Clonal regions contain sparsely distributed large myotubes. Bottom panel: Clonal regions contain dense myotubes with heterogeneous sizes. MHC is stained green, MyoD is stained red, and DAPI is stained blue. Scale bar: 200 um. Figure 12D shows the percentage of mock C3H10T1 / 2 cells expressing MyoD at different time points after 5-Aza treatment. The percentage of cells expressing MyoD increased from about 6% at day 14 to about 13% at day 16 and reached about 20% at day 25. Bars represent mean ± SD. FIG. 12E shows the number of nuclei within MHC+ cell clusters (classified as 1-2 and >2 nuclei per MHC+ cluster). Larger myotube formation was observed at later time points of 5-Aza treatment. Bars represent mean ± SD. Data in FIG. 12D and FIG. 12E are quantified from 3-5 representative images per group. FIG. 12F shows C3H10T1 / 2 cells infected with lentivirus expressing dC-T and MyoD gRNA for 24 h, harvested with or without treatment with 5-Aza for 48 h, and subjected to qPCR analysis. Bars represent mean ± SD of three experimental replicates.FIG. 12G shows representative images of C3H10T1 / 2 cells 16 days after infection with lentivirus expressing dC-T and gRNA targeting DMR-5 (MyoD distal enhancer) in the fibroblast-to-myoblast conversion assay described in FIG. 12B. It can be seen that in cells with dC-T and the targeting gRNA, a moderate level of MyoD activation was observed (compared to cells treated with 5-Aza), but no myosin heavy chain (MHC) expression or myotube formation was observed. MHC is stained magenta, MyoD is stained green, and DAPI is stained blue. Scale bar: 200 um. FIG. 12H shows the percentage of MyoD positive cells 16 days after infection with lentivirus expressing dC-T alone or together with gRNA targeting DMR-5. Figure 12I shows the number of nuclei in MHC+ cell clusters 16 days after infection (classified as 2-5, 6-10, 11-20, and >20 nuclei per MHC+ cluster). When treated with 5-Aza, co-expression of gRNA with dC-T significantly promoted the formation of more mature and larger MHC+ clusters compared to mock control or dC-T alone. Figure 12J shows myotube density in MHC-positive clusters with >2 or >5 nuclei 16 days after infection. Addition of 5-Aza induces MHC+ myotube formation. Co-expression of dC-T with gRNA significantly induces larger myotubes with higher nuclei (MHC+ clusters with >5 nuclei). Data in Figures 12H-J are quantified from 3-5 representative images. Bars represent mean ± SD. [Figure 13A] Figures 13A-B show gRNA designs for methylation targeting CTCF binding sites at the miR290 and Pou5f1 loci. Figure 13A shows the genomic sequence of the CTCF target 1 region (miR290 locus) with the gRNA sequence labeled in yellow and the CpGs labeled in green. The PAM of each sgRNA is highlighted in red and the predicted CTCF binding motif is highlighted in blue. Figure 13B shows the genomic sequence of the CTCF target 2 region (H2Q10-Pou5f1 locus) with the gRNA sequence labeled in yellow and the CpGs labeled in green. The PAM of each sgRNA is highlighted in red and the predicted CTCF binding motif is highlighted in blue. [Figure 13B]Figures 13A-B show gRNA designs for methylation targeting CTCF binding sites at the miR290 and Pou5f1 loci. Figure 13A shows the genomic sequence of the CTCF target 1 region (miR290 locus) with the gRNA sequence labeled in yellow and the CpGs labeled in green. The PAM of each sgRNA is highlighted in red and the predicted CTCF binding motif is highlighted in blue. Figure 13B shows the genomic sequence of the CTCF target 2 region (H2Q10-Pou5f1 locus) with the gRNA sequence labeled in yellow and the CpGs labeled in green. The PAM of each sgRNA is highlighted in red and the predicted CTCF binding motif is highlighted in blue. [Figure 14-1] Figure 14A-F show activation of IG-DMRGFP / Pat reporter by dCas9-Tet1-mediated demethylation in mouse skin cells. Figure 14A shows a schematic diagram of the experimental procedure for ex vivo activation of silenced GFP reporter in IG-DMRGFP / Pat mouse fibroblasts. Cultured fibroblasts were infected with lentiviral vectors expressing dCas9-Tet1 and gRNA to demethylate the Snrpn promoter and activate the GFP reporter. Figure 14B shows FACS analysis of infected IG-DMRGFP / Pat mouse fibroblasts. Figure 14C shows quantification of the ratio of GFP+ cells among the Cherry-positive cell population in Figure 14B. Figure 14D shows a schematic diagram of lentiviral delivery to each site on the ventral side of IG-DMRGFP / Pat mice. Figure 14E shows representative confocal micrographs of IG-DMRGFP / Pat mouse skin infected with dCas9-Tet1 and sc gRNA, the inactive form of Tet1 (dC-dT) and Snrpn gRNA, and dCas9-Tet1 and Snrpn gRNA. The arrowhead indicates that only the combination of dC-T and Snrpn gRNA activated GFP expression. Note that red autofluorescence is visible at the left edge of the epidermis. Figure 14F shows two representative confocal micrographs of hair follicles lentivirally delivered with dC-T and Snrpn gRNA, which activate GFP expression. [Figure 14-2]Figure 14A-F show activation of IG-DMRGFP / Pat reporter by dCas9-Tet1-mediated demethylation in mouse skin cells. Figure 14A shows a schematic diagram of the experimental procedure for ex vivo activation of silenced GFP reporter in IG-DMRGFP / Pat mouse fibroblasts. Cultured fibroblasts were infected with lentiviral vectors expressing dCas9-Tet1 and gRNA to demethylate the Snrpn promoter and activate the GFP reporter. Figure 14B shows FACS analysis of infected IG-DMRGFP / Pat mouse fibroblasts. Figure 14C shows quantification of the ratio of GFP+ cells among the Cherry-positive cell population in Figure 14B. Figure 14D shows a schematic diagram of lentiviral delivery to each site on the ventral side of IG-DMRGFP / Pat mice. Figure 14E shows representative confocal micrographs of IG-DMRGFP / Pat mouse skin infected with dCas9-Tet1 and sc gRNA, the inactive form of Tet1 (dC-dT) and Snrpn gRNA, and dCas9-Tet1 and Snrpn gRNA. The arrowhead indicates that only the combination of dC-T and Snrpn gRNA activated GFP expression. Note that red autofluorescence is visible at the left edge of the epidermis. Figure 14F shows two representative confocal micrographs of hair follicles lentivirally delivered with dC-T and Snrpn gRNA, which activate GFP expression. [Figure 15] Various examples of cell types are shown. [Figure 16] Indicates DNA methylation. [Figure 17] 1 shows the DNA methylation cycle, which includes DNA methylation and reversal of DNA methylation. [Figure 18] Examples of DNA methylation maps of human tissues are shown. [Figure 19-1]Figure 19A-E show a summary of methylation and demethylation activities. Figure 19A shows demethylation of Dazl-Snrpn-GFP reporter and methylation of Gapdh-Snrpn-GFP reporter. Figure 19B shows targeted demethylation of BDNF promoter IV by dCas9-Tet1 to activate BDNF. Figure 19C shows targeted demethylation of MyoD distal enhancer by dCas9-Tet1 to promote muscle cell transdifferentiation. Figure 19D shows targeted methylation of CTCF binding site. Figure 19E shows targeted DNA methylation editing by dCas9-Tet1 in vivo to activate silenced GFP reporter. [Figure 19-2] Figure 19A-E show a summary of methylation and demethylation activities. Figure 19A shows demethylation of Dazl-Snrpn-GFP reporter and methylation of Gapdh-Snrpn-GFP reporter. Figure 19B shows targeted demethylation of BDNF promoter IV by dCas9-Tet1 to activate BDNF. Figure 19C shows targeted demethylation of MyoD distal enhancer by dCas9-Tet1 to promote muscle cell transdifferentiation. Figure 19D shows targeted methylation of CTCF binding site. Figure 19E shows targeted DNA methylation editing by dCas9-Tet1 in vivo to activate silenced GFP reporter. [Figure 20] 1 shows reversal of FMR-1 hypermethylation in fragile X syndrome. Cells expressing fragile X syndrome are contacted with dCas9-Tet1 fusion protein to specifically demethylate hypermethylated CCGs and reactivate FMR-1. [Figure 21] Figure 2 shows the proposed demethylation of BDNF acting on postmitotic neurons. [Figure 22] Quantification of the MyoD positive cell ratio after infection with lentivirus expressing dC-T alone, lentivirus expressing dC-T and a targeting gRNA, and lentivirus expressing dC-dT and a targeting gRNA is shown. [Figure 23-1]Figures 23A-C show targeted methylation of CTCF binding sites. Figure 23A shows the three-dimensional structure of the chromosome. Figure 23B shows gene expression levels of the indicated genes in wild-type and CTCF site deleted cells as measured by qRT-PCR. Figure 23C shows anti-CTCF ChIP experiments using cells from C, followed by quantitative PCR analysis. Bars represent the mean ± SD of three experimental replicates. [Figure 23-2] Figures 23A-C show targeted methylation of CTCF binding sites. Figure 23A shows the three-dimensional structure of the chromosome. Figure 23B shows gene expression levels of the indicated genes in wild-type and CTCF site deleted cells as measured by qRT-PCR. Figure 23C shows anti-CTCF ChIP experiments using cells from C, followed by quantitative PCR analysis. Bars represent the mean ± SD of three experimental replicates. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0033] The practice of the present invention will generally employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant nucleic acid (e.g., DNA) technology, immunology, and RNA interference (RNAi), which are within the skill of the art. Non-limiting descriptions of some of these techniques can be found in the following publications: Ausubel, F., et al., (eds.), Current Protocols in Molecular Biology, Current Protocols in Immunology, Current Protocols in Protein Science, and Current Protocols in Cell Biology, all published by John Wiley & Sons, NY, current editions as of December 2008; Sambrook, Russell, and Sambrook, Molecular Cloning: A Laboratory Manual, 3rd ed., Cold Spring Harbor Laboratory Press, 2006; Spring Harbor Laboratory Press, Cold Spring Harbor, 2001; Harlow, E. and Lane, D., Antibodies-A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1988; Freshney, RI, “Culture of Animals Non-limiting information regarding therapeutic agents and human diseases can be found in Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th Ed., McGraw Hill, 2005, Katzung, B. (ed.) Basic and Clinical Pharmacology, McGraw-Hill / Appleton & Lange; 10th ed. (2006) or 11th edition (July 2009). Non-limiting information regarding genes and genetic disorders can be found in McKusick, VA: Mendelian Inheritance in Man. A Catalog of Human Genes and Genetic Disorders. Baltimore: Johns Hopkins University Press, 1998 (12th edition), or the most recent online database: Online Mendelian Inheritance in Man, OMIM™, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD), as of May 1, 2010, at ncbi.nlm.nih.gov / omim / , and the database for genes, genetic disorders, and traits in animal species (other than human and mouse), Online Mendelian Inheritance in Animals (OMIA), at omia.angis.org.au / contact.shtml. All patents, patent applications, and other publications (e.g., scientific articles, books, websites, and databases) mentioned herein are incorporated herein by reference in their entirety. In the event of a discrepancy between this specification and any incorporated reference, this specification (including any amendments thereto that may be based on the incorporated reference) shall control. Unless otherwise indicated, this specification uses standard art-accepted meanings of terms. This specification uses standard abbreviations for various terms.
[0034] In one aspect, the present invention relates to a method for modifying or regulating one or more genomic sequences in a cell, comprising introducing into the cell a catalytically inactive site-specific nuclease fused to an effector domain having methylation or demethylation activity and one or more guide sequences, which can result in the modification of one or more genomic sequences in the cell. An isolated modified cell can be produced by the described method. The catalytically inactive site-specific nuclease can bind to each of one or more guide sequences, and the effector domain regulates the methylation or demethylation (e.g., DNA methylation or DNA demethylation) of the genomic sequence. The one or more guide sequences, the catalytically inactive site-specific nuclease, and the effector domain can be introduced into a cell, a zygote, an embryo, or a non-human mammal.
[0035] In another aspect, the present invention relates to a method of modulating the methylation of one or more genomic sequences in a cell. The method may include contacting the cell with a nucleic acid encoding a polypeptide comprising a catalytically inactive site-specific nuclease fused to an effector domain having methylation or demethylation activity. The cell is further contacted with a guide sequence or a nucleic acid encoding a guide sequence. In some aspects, the guide sequence targets the polypeptide to one or more genomic sequences. In some embodiments, the contacting of the cells may include direct introduction into the cell. In other aspects, the contacting of the cells includes expression in the cell or induction of expression in the cell. Genome methylation reporters are described in US Application No. 15 / 078,851, which is incorporated herein by reference in its entirety.
[0036] There are various ways in which a polypeptide comprising a catalytically inactive site-specific nuclease fused to an effector domain having methylation or demethylation activity can be delivered to a cell or subject, for example, by administration of a nucleic acid encoding the polypeptide, which may be, for example, a viral vector, or a translatable nucleic acid (e.g., a synthetic modified mRNA. Examples of modified mRNAs are described in Warren et al. (Cell 2002). Stem Cell 7(5):618-30, 2010, Mandal PK, Rossi DJ. Nat Protoc. 2013 8(3):568-82, US Patent Publication No. 20120046346 and / or PCT / US2011 / 032679 (WO / 2011 / 130624). Examples are further described in numerous PCT and US applications, as well as patents issued to Moderna Therapeutics, such as PCT / US2011 / 046861; PCT / US2011 / 054636, PCT / US2011 / 054617, USSN14 / 390,100 (and other patents and patent applications mentioned above). Guide sequences can also be delivered as nucleic acids encoding the guide sequences. For example, administration can be performed by direct administration to a tissue or organ (e.g., skin, heart, liver, lung, kidney, brain, eye, muscle, bone, nerve) or tumor. Administration can be by any route (e.g., oral, intravenous, intraperitoneal, gavage, topical, transdermal, intramuscular, enteral, subcutaneous), systemic or local, and can include any dosage (e.g., about 0.01 mg / kg to about 500 mg / kg), with single or multiple administrations. The nucleic acid can be encapsulated, for example, in liposomes, polymer particles (e.g., PLGA particles).
[0037] The methods described herein can be used to modify or regulate one or more genomic sequences of various cells, including somatic cells, stem cells, mitotic or postmitotic cells, neurons, fibroblasts, or zygotes. The cells, zygotes, embryos, or postnatal mammals can be of vertebrate (e.g., mammalian) origin. In some aspects, the vertebrates are mammals or birds. Particular examples include primate (e.g., human), rodent (e.g., mouse, rat), dog, cat, cow, horse, goat, pig, or avian (e.g., chicken, duck, goose, turkey) cells, zygotes, embryos, or postnatal mammals. In some embodiments, the cells, zygotes, embryos, or postnatal mammals are isolated (e.g., isolated cells; isolated zygotes; isolated embryos). In some embodiments, mouse cells, mouse zygotes, mouse embryos, or postnatal mouse mammals are used. In some embodiments, rat cells, rat zygotes, rat embryos, or postnatal rat mammals are used. In some embodiments, human cells, human zygotes, or human embryos are used. The methods described herein can be used to modify or regulate one or more genomic sequences in a mammal (e.g., a mouse) in vivo (e.g., methylate or demethylate a genomic sequence).
[0038] Stem cells can include totipotent stem cells, pluripotent stem cells, multipotent stem cells, oligopotent stem cells, and unipotent stem cells. Specific examples of stem cells include embryonic stem cells, fetal stem cells, adult stem cells, and induced pluripotent stem cells (iPSCs) (see, for example, U.S. Published Application Nos. 2010 / 0144031, 2011 / 0076678, 2011 / 0088107, and 2012 / 0028821, all of which are incorporated herein by reference).
[0039] Somatic cells may be primary cells (non-immortalized cells), such as freshly isolated from an animal, or derived from cell lines capable of sustained growth in culture (e.g., for more than three months) or cell lines capable of indefinite growth (immortalized cells). Adult somatic cells can be obtained from an individual, e.g., a human subject, and cultured according to standard cell culture protocols available to those skilled in the art. Somatic cells used in embodiments of the present invention include mammalian cells, e.g., human cells, non-human primate cells, or rodent (e.g., mouse, rat) cells. Somatic cells can be obtained by well-known methods from various organs, e.g., skin, lung, pancreas, liver, stomach, intestine, heart, breast, reproductive organs, muscle, blood, bladder, kidney, urethra, and other urinary organs, generally any organ or tissue that contains living somatic cells. Mammalian somatic cells that are useful in various embodiments include, for example, fibroblasts, Sertoli cells, granulosa cells, neurons, pancreatic cells, epidermal cells, epithelial cells, endothelial cells, hepatic cells, hair follicle cells, keratinocytes, hematopoietic cells, melanocytes, chondrocytes, lymphocytes (B lymphocytes and T lymphocytes), macrophages, monocytes, mononuclear cells, cardiac muscle cells, skeletal muscle cells, and the like.
[0040] In some embodiments, one or more guide sequences comprise a sequence that recognizes DNA in a site-specific manner. For example, the guide sequence can comprise a guide ribonucleic acid (RNA) sequence that is utilized by CRISPR system, or a sequence in TALEN or zinc finger system that recognizes DNA in a site-specific manner. The guide sequence comprises a portion that is complementary to a portion of each of one or more genomic sequences, and comprises a binding site for catalytically inactive site-specific nuclease. In some embodiments, this RNA sequence is referred to as guide RNA (gRNA) or single guide RNA (sgRNA).
[0041] In some embodiments, a single RNA sequence can be complementary to one or more (e.g., all) of the genomic sequences to be regulated or modified. In one embodiment, a single RNA is complementary to a single target genomic sequence. In certain embodiments intended to regulate or modify two or more target genomic sequences, multiple (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) RNA sequences are introduced. In that case, each RNA sequence is complementary (specific) to one target genomic sequence. In some embodiments, two or more, three or more, four or more, five or more, or six or more RNA sequences are complementary (specific) to different parts of the same target sequence. In one embodiment, two or more RNA sequences bind to different sequences of the same region of DNA. In some embodiments, a single RNA sequence is complementary to at least two or more targets (e.g., all) of a genomic sequence. It will also be apparent to one of skill in the art that the portion of the RNA sequence that is complementary to one or more genomic sequences and the portion of the RNA sequence that binds to a catalytically inactive site-specific nuclease can be introduced into a cell, zygote, embryo, or non-human animal as a single sequence or as two (or more) separate sequences. In some embodiments, the sequence that binds to a catalytically inactive site-specific nuclease comprises a stem loop.
[0042] In some embodiments, the RNA sequence used to modify gene expression in a non-human mammal is a natural RNA sequence, a modified RNA sequence (e.g., an RNA sequence containing one or more modified bases), a synthetic RNA sequence, or a combination thereof. As used herein, a "modified RNA" is an RNA that contains one or more modifications to the RNA sequence (e.g., modifications to the backbone and / or sugar) (e.g., an RNA that contains one or more non-standard and / or non-natural bases). Methods for modifying bases in RNA are well known in the art. Examples of such modified bases include those contained in nucleosides, namely, 5-methylcytidine (5mC), pseudouridine (Ψ), 5-methyluridine, 2'-O-methyluridine, 2-thiouridine, N-6 methyladenosine, hypoxanthine, dihydrouridine (D), inosine (I), and 7-methylguanosine (m7G). It should be noted that any number of bases in the RNA sequence may be substituted in various embodiments. Furthermore, it should be understood that combinations of different modifications may be used.
[0043] In some embodiments, the RNA sequence is morpholino.Morpholino is a synthetic molecule that is usually about 25 bases long and binds to the complementary sequence of RNA by standard nucleobase pairing.Morpholino has standard nucleobases, but the bases are linked to morpholine rings instead of deoxyribose rings, and are linked through phosphorodiamidate groups instead of phosphate groups.Morpholino does not degrade its target RNA molecule, unlike many antisense structural types (e.g., phosphorothioate, siRNA).Instead, morpholino acts by steric hindrance, binding to target sequences in RNA and blocking molecules that would otherwise be able to interact with RNA.
[0044] The length of each RNA sequence can vary from about 8 base pairs (bp) to about 200 bp. In some embodiments, the length of the RNA sequence can be about 9 to about 190 bp, about 10 to about 150 bp, about 15 to about 120 bp, about 20 to about 100 bp, about 30 to about 90 bp, about 40 to about 80 bp, or about 50 to about 70 bp.
[0045] The portion of each genomic sequence to which each RNA sequence is complementary can also vary in size. In certain embodiments, the portion of each genomic sequence to which the RNA is complementary is about 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, The RNA sequences may be 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 81, 92, 93, 94, 95, 96, 97, 98, or 100 nucleotides in length (consecutive nucleotides). In some embodiments, each RNA sequence may be at least about 70%, 75%, 80%, 85%, 90%, 95%, 100%, etc. identical or similar to a portion of each genomic sequence. In some embodiments, each RNA sequence is completely or partially identical or similar to each genomic sequence. For example, each RNA sequence may differ in perfect complementarity to a portion of the genomic sequence by about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, etc., nucleotides. In some embodiments, one or more RNA sequences are perfectly complementary (100%) over at least about 10 to about 25 (e.g., about 20) nucleotides of the genomic sequence.
[0046] The one or more guide sequences (e.g., RNA sequences) can be complementary to all or a portion of any of a variety of target genomic sequences to be modified. In some embodiments, the target genomic sequence comprises a methylation variable region, an enhancer (e.g., the MyoD distal enhancer), a promoter (e.g., the BDNF promoter), a reporter, or a CTCF binding site.
[0047] In some embodiments of the present invention, the method of modulating one or more genomic sequences comprises introducing into a cell one or more guide sequences that are complementary to all or a portion of a control region, open reading frame (ORF; splicing factor), intron sequence, chromosomal region (e.g., telomere, centromere) of one or more genomic sequences. In some embodiments, the genomic sequence is all or a portion of a plasmid or linear double-stranded DNA (dsDNA). In some embodiments, the control region targeted by one or more genomic sequences is a promoter, enhancer, and / or operator region. In some embodiments, all or a portion of the control region is targeted by one or more genomic sequences. All or a portion of the region targeted by one or more genomic sequences can be a methylation variable region. In some embodiments, the methylation variable region is located just about 25 bases, 50 bases, 100 bases, 200 bases, 300 bases, 400 bases, 500 bases, 600 bases, 700 bases, 800 bases, 900 bases, 1000 bases, 1500 bases, 2000 bases, 5000 bases, 10000 bases, 20000 bases, 50000 bases, or more upstream of one or more genes (e.g., endogenous genes; exogenous genes) or transcription start site (s) (TSS). In some embodiments, the methylation variable region is located downstream or within about 25 bases, 50 bases, 100 bases, 200 bases, 300 bases, 400 bases, 500 bases, 600 bases, 700 bases, 800 bases, 900 bases, 1000 bases, 1500 bases, 2000 bases, 5000 bases, 10000 bases, 20000 bases, 50000 bases, or more of one or more genes (e.g., endogenous genes; exogenous genes) or TSS. As will be understood by those skilled in the art, the regulatory region targeted by one or more genomic sequences may be located entirely or partially at or near the 5' end or TSS of a gene (e.g., endogenous or exogenous). The 5' end of the gene may include a non-transcribed (flanking) region (e.g., all or part of the promoter) and a portion of the transcribed region.
[0048] As will be apparent to one of skill in the art, one or more RNA sequences may further comprise one or more expression control elements. For example, in some embodiments, the RNA sequence comprises a promoter suitable for direct expression in a cell, and a portion of the RNA sequence is operably linked to the expression control element(s). The promoter may be a viral promoter (e.g., a CMV promoter) or a mammalian promoter (e.g., a PGK promoter). The RNA sequence may also comprise other genetic elements, such as those that enhance the expression or stability of the transcript. In some embodiments, the additional coding region encodes a selection marker (e.g., a reporter gene such as green fluorescent protein (GFP)).
[0049] As described herein, the one or more RNA sequences also comprise a binding site(s) for a catalytically inactive site-specific nuclease(s).The catalytically inactive site-specific nuclease can be a catalytically inactive CRISPR-associated (Cas) protein.In certain embodiments, upon hybridization of the one or more RNA sequences to one or more genomic sequences, the catalytically inactive site-specific nuclease binds to the one or more RNA sequences.
[0050] In some embodiments, the method of modulating one or more genomic sequences includes modulating the level of regulation of one or more genomic sequences by adjusting the amount (e.g., grams, milligrams, micrograms, nanograms, moles, millimoles, micromoles, nanomoles, stoichiometric amounts, molar ratios) of one or more guide sequences introduced into a cell or zygote. In some embodiments, the level of regulation of one genomic sequence is the same or different compared to the level of regulation of another genomic sequence in the same cell or zygote. In one embodiment, multiple genomic sequences are modulated (e.g., multiple activation).
[0051] In one aspect, the method further comprises introducing one or more catalytically inactive Cas (dCas) nucleic acids or variants thereof into the cell, embryo, zygote, or non-human mammal. In some aspects, the dCas protein or variants thereof is introduced into the cell, embryo, zygote, or non-human mammal. In some aspects, the cell, e.g., post-mitotic cell, neuron, fibroblast, stem cell (ES cell or iPS cell), zygote, embryo, or animal, may already incorporate a nucleic acid encoding dCas (which may be constitutive or inducible) and / or may already contain a dCas protein. For example, in some embodiments, the cell, zygote, embryo, or animal may be derived from a cell or organism into which a nucleic acid encoding a dCas protein has been introduced by a process involving artificial means.
[0052] Various CRISPR-associated (Cas) genes or proteins known in the art can be used in the methods of the invention, with the choice of Cas protein depending on the particular requirements of the method (e.g., ncbi.nlm.nih.gov / gene / ?term=cas9). Specific examples of Cas proteins include Cas1, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9, and Cas1O. In certain aspects, the Cas nucleic acid or protein used in the methods is Cas9. In some embodiments, the Cas protein, e.g., Cas9 protein, can be from any of a variety of prokaryotic species. In some embodiments, a particular Cas protein, e.g., a particular Cas9 protein, can be selected that recognizes a particular protospacer adjacent motif (PAM) sequence. In certain embodiments, the Cas protein, e.g., Cas9 protein, can be obtained from bacteria or archaea, or synthesized using known methods. In certain embodiments, the Cas protein can be from gram-positive or gram-negative bacteria. In certain embodiments, the Cas proteins may be derived from Streptococcus (e.g., S. pyogenes, S. thermophilus), Cryptococcus, Corynebacterium, Haemophilus, Eubacterium, Pasteurella, Prevotella, Veillonella, Marinobacter. In some embodiments, two or more different Cas proteins or nucleic acids encoding two or more Cas proteins can be introduced into a cell, zygote, embryo, or animal to allow, for example, recognition and modification of sites containing identical, similar, or different PAM motifs.
[0053] In some embodiments, the Cas protein is a Cpf1 protein or a functional part thereof. In some embodiments, the Cas protein is Cpf1 from any bacterial species or a functional part thereof. In certain embodiments, the Cpf1 protein is a Francisella novicida U112 protein or a functional part thereof, an Acidaminococcus sp. BV3L6 protein or a functional part thereof, or a Lachnospiraceae bacterium ND2006 protein or a functional part thereof. The Cpf1 protein is a member of the V-type CRISPR system. The Cpf1 protein is a polypeptide that comprises about 1300 amino acids. Cpf1 comprises a RuvC-like endonuclease domain.
[0054] In some embodiments, Cas9 nickases can be generated by inactivating one or more of the Cas9 nuclease domains. In some embodiments, an amino acid substitution at residue 10 of the RuvC I domain of Cas9 converts the nuclease into a DNA nickase. For example, an aspartic acid at amino acid residue 10 can be substituted with an alanine (Cong et al, Science, 339:819-823). Other amino acid mutations that generate catalytically inactive Cas9 proteins include mutations at residues 10 and / or 840. Mutations at both residues 10 and 840 can generate catalytically inactive Cas9 proteins, sometimes referred to herein as dCas9. For example, D10A and H840A Cas9 mutants are catalytically inactive.
[0055] Modulation of one or more genomic sequences may include the introduction of one or more effector domains. As used herein, an "effector domain" is a molecule (e.g., a protein) that modulates the expression and / or activation of a genomic sequence (e.g., a gene). An effector domain can have methylation or demethylation activity (e.g., DNA methylation or DNA demethylation activity). In some embodiments, an effector domain targets one or both alleles of a gene. An effector domain can be introduced as a nucleic acid sequence and / or as a protein. In some embodiments, an effector domain can be a constitutive or inducible effector domain. In some embodiments, a Cas (e.g., dCas) nucleic acid sequence or a variant thereof and an effector domain nucleic acid sequence are introduced into a cell as a chimeric sequence. In some embodiments, the effector domain is fused to a molecule that associates with (e.g., binds to) a Cas protein (e.g., an effector molecule is fused to an antibody or antigen-binding fragment thereof that binds to a Cas protein). In some embodiments, the Cas (e.g., dCas) protein or variants thereof and the effector domain are fused or tethered to generate a chimeric protein and introduced into a cell as the chimeric protein. In some embodiments, the Cas (e.g., dCas) protein and the effector domain are associated as a protein-protein interaction. In some embodiments, the Cas (e.g., dCas) protein and the effector domain are covalently linked. In some embodiments, the effector domain is non-covalently associated with the Cas (e.g., dCas) protein. In some embodiments, the Cas (e.g., dCas) nucleic acid sequence and the effector domain nucleic acid sequence are introduced as separate sequences and / or separate proteins. In some embodiments, the Cas (e.g., dCas) protein and the effector domain are not fused or tethered.
[0056] As provided herein, fusion of a catalytically inactive (D10A;H840A) Cas9 protein (dCas9) with all or a portion (e.g., biologically active portions thereof) of an effector domain(s) forms a chimeric protein that can be targeted to a specific DNA site by one or more RNA sequences (sgRNAs) to modulate the activity and / or expression of one or more genomic sequences (e.g., to exert an effect on transcription or chromatin organization, or to integrate a particular type of molecule at a specific DNA locus, or to act as a sensor of local histone or DNA status). In certain embodiments, fusion of a catalytically inactive (D10A;H840A) Cas9 protein with all or a portion (e.g., biologically active portions thereof) of an effector domain(s) forms a chimeric protein that can be targeted to a specific DNA site by one or more RNA sequences to modulate or modify the methylation or demethylation of one or more genomic sequences. As used herein, a "biologically active portion of an effector domain" is a portion (e.g., a "minimal" or "core" domain) that maintains (e.g., completely, partially, minimally) the function of the effector domain. Chimeric proteins are formed by fusion of Cas9 (e.g., dCas9) with all or part of one or more effector domains.
[0057] Examples of effector domains include transcription activation domains, coactivator domains, transcription factors, transcription pausing release factor domains, transcription elongation negative regulator domains, transcription repressor domains, chromatin integrator domains, remodeler domains, histone modifier domains, DNA modification domains, RNA binding domains, protein interaction input domains (Grunberg and Serrano, Nucleic Acids Research, 3 '8(8):'2663-267' 5(2010)), and protein interaction output domains (Grunberg and Serrano, Nucleic Acids Research, 3 '8(8):'2663-267' 5(2010)). As used herein, "protein interaction input" and "protein interaction output" refer to protein-protein interactions (PPIs). In some embodiments, PPIs can be controlled, for example, by small molecules or by light. In some aspects, inactive Cas proteins are used to target binding partners to different sites in the genome. The interaction of the binding partners brings the target locus into proximity. Protein interaction output devices are systems that detect / monitor the occurrence of PPI, typically by generating a detectable signal when PPI occurs (e.g., by reconstituting a fluorescent protein) or triggering a specific cellular response (e.g., by inducing apoptosis by reconstituting a caspase protein). In this context, it has been devised to target different sites in the genome using components of the "output device". Upon interaction, the "output device" generates a signal. This can be used to determine or monitor the proximity of the target locus. In some embodiments, the cells are treated with a drug to determine the effect of the drug on the cells. Other examples of effector domains include histone mark readers / interactors (cell.com / abstract / S0092-8674(10)00951-7) and DNA modification readers / interactors.
[0058] In some embodiments, the effector domain is a DNA modifier. Specific examples of DNA modifiers include those that convert 5mC to 5hmc, such as Tetl (TetlCD); DNA demethylation by Tetl, ACID A, MBD4, Apobecl, Apobec2, Apobec3, Tdg, Gadd45a, Gadd45b, and ROS1; Dnmtl, D Examples of DNA methylation include DNA methylation by nmt3a, Dnmt3b, CpG methyltransferase M.SssI, and / or M.EcoHK31I. In certain aspects, the effector domain is Tet1. In other certain aspects, the effector domain is Dmnt3a. In some embodiments, dCas9 is fused to Tet1. In other embodiments, dCas9 is fused to Dnmt3a.
[0059] DNA methylation is established by two de novo DNA methyltransferases (Dnmt3a / b) and maintained by Dnmt1 (Smith and Meissner, 2013). Developmental gene activation is associated with demethylation of promoter and enhancer sequences. In addition, demethylation can be achieved by oxidation of methyl groups by ten-eleven translocation (TET) dioxygenases to form 5-hydroxymethylcytosine (5-hmC), which is then repaired to unmodified cytosine by DNA replication-dependent dilution or by DNA glycosylase-initiated base excision repair (BER). BER is called active demethylation, a process proposed to operate at specific developmental stages, such as preimplantation embryos, or in postmitotic neurons (Wu and Zhang, 2014).
[0060] In one aspect of the invention, fusion of dCas9 to an effector domain may contemplate the fusion of a single copy or multiple / tandem copies of a full-length or partial-length effector. Other fusions may be with separate (functionally complementary) versions of the effector domain. Effector domains used in this method include any one of the following classes of proteins: proteins that mediate drug-induced DNA looping and / or genomic locus contact, proteins that aid in the three-dimensional proximity of the dCas9-bound genomic locus with another sgRNA.
[0061] Other examples of effector domains are described in PCT Application No. PCT / US2014 / 034387 and U.S. Application No. 14 / 785031, which are incorporated by reference in their entireties.
[0062] In some embodiments, the present invention relates to a nucleic acid sequence encoding (e.g., a composition comprising, consisting essentially of, or consisting of) a fusion protein (chimeric protein) comprising all or a portion of a Cas (e.g., dCas) protein fused to all or a portion of an effector domain. In some embodiments, the present invention relates to (e.g., a composition comprising, consisting essentially of, or consisting of) a fusion protein comprising all or a portion of a Cas (e.g., dCas) protein fused to all or a portion of an effector domain. In some embodiments, all or a portion of a Cas (e.g., dCas) protein targets but does not cleave a nucleic acid sequence. In some embodiments, a Cas (e.g., dCas) protein can be fused to the N-terminus or C-terminus of an effector domain. In some embodiments, a portion of an effector domain modulates methylation of a genomic sequence (e.g., demethylates or methylates a genomic sequence).
[0063] In some embodiments, the nucleic acid sequence encoding the fusion protein and / or the fusion protein is isolated. As used herein, an "isolated" nucleic acid sequence, a "substantially pure" nucleic acid sequence, or a "substantially pure and isolated" nucleic acid sequence is one that is separated from the nucleic acids that normally flank the gene or nucleotide sequence (as in a genomic sequence) and / or is completely or partially purified from other transcribed sequences (e.g., in an RNA or cDNA library). For example, an isolated nucleic acid of the invention may be substantially isolated relative to the complex cellular environment in which it occurs in nature, or the culture medium if produced by recombinant technology, or chemical precursors or other chemicals if chemically synthesized. As used herein, an "isolated" protein, a "substantially pure" protein, or a "substantially pure and isolated" protein (e.g., a chimeric protein; a fusion protein) is one that is substantially isolated relative to the complex cellular environment in which it occurs in nature, or the culture medium if produced by recombinant technology, or chemical precursors or other chemicals if chemically synthesized. In some cases, the isolated material will form part of a composition (e.g., a crude extract containing other substances), a buffer system, or a reagent mixture. In other situations, the material may be purified to essential homogeneity, for example as determined by agarose gel electrophoresis or column chromatography such as HPLC. Preferably, an isolated nucleic acid molecule comprises at least about 50%, 80%, 90%, 95%, 98%, or 99% (on a molar basis) of all macromolecular species present.
[0064] In one embodiment, the fusion of Cas9 to all or a portion of one or more effector domains includes one or more linkers. As used herein, a "linker" is something that connects or fuses two or more effector domains (see, e.g., Hermanson, Bioconjugate Techniques, 2003). nd(See, for example, the 1990 Edition, incorporated herein by reference in its entirety). As one of skill in the art would understand, a variety of linkers can be used. In one embodiment, the linker comprises one or more amino acids. In some embodiments, the linker comprises two or more amino acids. In one embodiment, the linker comprises the amino acid sequence GS. In some embodiments, a fusion of Cas9 (e.g., dCas9) with two or more effector domains comprises one or more linkers (e.g., GS linkers) interspersed between the domains. In some embodiments, one or more nuclear localization sequences may be located between the catalytically inactive nuclease (e.g., dCas9) and the effector domain. For example, the fusion protein can include dCas9-NLS-Tet1 or dCas9-NLS-Dnmt3a.
[0065] In some aspects of the invention, the method of modulating one or more genomic sequences in a cell may further include introducing an effector molecule. As used herein, an "effector molecule" is a molecule (e.g., a nucleic acid sequence; a protein; an organic molecule; an inorganic molecule, a small molecule) or a physical trigger (e.g., an inducer molecule; a trigger molecule) that associates with (e.g., binds to; specifically binds to) an effector domain to modulate the methylation or demethylation of a genomic sequence. The effector molecule can be contacted with a cell and / or introduced into the cell (e.g., as a nucleic acid sequence or as a protein sequence). In some embodiments, the effector molecule is endogenous. In other embodiments, the effector molecule is exogenous. For example, an exogenous effector molecule can be introduced into a cell. In some aspects, the effector molecule binds to the effector domain. In some aspects, the effector molecule is a nucleic acid, a protein, a drug, an organic small molecule, and derivatives / variants thereof. In some aspects of the invention, the effector molecule is an antibiotic or a derivative / variant thereof.
[0066] As will be apparent to those skilled in the art, the method may further include introducing other molecules or factors into the cell to facilitate methylation or demethylation of genomic sequences. The agent that inhibits or enhances DNA methylation may be an inhibitor of endogenous DNA methylase or DNA demethylase. For example, the inhibitor of DNA methylation may be a small molecule, e.g., a cytidine analogue, such as 5-azacytidine (azacitidine) and 5-azadeoxycytidine (decitabine). In another method, the agent that inhibits or enhances DNA methylation may be administered to the individual.
[0067] The methods described herein can be used to regulate or modify a variety of genomic sequences, which vary depending on the desired outcome.In one embodiment, the target genomic sequence is a gene sequence.In certain embodiments, the methods described herein can be used to genetically modify two or more different genes of the same gene family, two or more genes with redundant functions (e.g., redundancy may mean that at least two genes need to be inactivated to produce a particular phenotype, e.g., a detectable phenotype), two or more genes that are at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more identical, two or more copies of the same gene, two or more genes of the same biological pathway (e.g., signal transduction pathway, metabolic pathway), two or more genes that share at least one biological activity and / or act on at least one common substrate and / or are part of the same protein or protein-nucleic acid complex (e.g., hetero-oligomeric protein, spliceosome, proteasome, RISC, transcription complex, replication complex, centromere, channel, transporter). In some embodiments, two or more guide sequences can direct a polypeptide comprising a catalytically inactive site-specific nuclease fused to an effector domain to different sites located within a genomic sequence.
[0068] "Regulate" or "modify" is used consistent with the usage in the art. That is, it means to cause or promote a qualitative or quantitative change, alteration, or modification in a process, pathway, or phenomenon of interest. Without being limited thereto, such a change can be an increase, decrease, or change in the relative strength or activity of different components or branches of a process, pathway, or phenomenon. A "regulator" or "modifier" is an agent that causes or promotes a qualitative or quantitative change, alteration, or modification in a process, pathway, or phenomenon of interest.
[0069] In some embodiments, "regulating" or "modifying" the methylation of a genomic sequence refers to any of a variety of changes to the methylation state of one or more genomic sequences. For example, a method of modulating the methylation of one or more genomic sequences includes methylating or demethylating the genomic sequence (e.g., the genomic sequence may be methylated, or the genomic sequence may be demethylated).
[0070] The methods provided herein can also be used to modify or regulate one or more genomic sequences in cells present in cell compositions, such as embryos, zygotes, fetuses, and postnatal mammals. In some embodiments, the cells (e.g., postmitotic cells, neurons, fibroblasts, stem cells, etc.), zygotes, embryos, or postnatal mammals have already been genetically modified (already have one or more genetic modifications, e.g., epigenetic modifications) prior to subjecting the cells to the methods described herein. For example, the cells, zygotes, embryos, or postnatal animals may be ones into which exogenous nucleic acids have been introduced by a process involving human means (or may be lineages at least partially derived from cells or organisms into which exogenous nucleic acids have been introduced by a process involving human means). The nucleic acids may, for example, include sequences that are exogenous to the cells, such as sequences that are native sequences (i.e., sequences found in the cell in nature) but in an arrangement that does not exist in nature (e.g., a coding region linked to a promoter from a different gene), or modified versions of native sequences, etc. In some embodiments, the cell, zygote, embryo, or postnatal mammal has not been pre-genetically modified (does not pre-harbor one or more genetic modifications) prior to being subjected to the methods described herein.
[0071] In some embodiments, the present invention relates to a method for producing a non-human mammal with modifications in one or more genomic sequences, comprising introducing into a zygote or embryo a catalytically inactive site-specific nuclease fused to an effector domain having methylation or demethylation activity and one or more guide sequences. The zygote or embryo is maintained under conditions in which the guide sequences hybridize to a portion of each of the one or more genomic sequences and the catalytically inactive site-specific nuclease fused to the effector domain methylates or demethylates the genomic sequences, thereby producing an embryo with one or more modified genomic sequences. The embryo with one or more modified genomic sequences can be implanted into a foster non-human mammal. The foster non-human mammal is maintained under conditions to produce one or more offspring with the one or more modified genomic sequences, thereby producing a non-human mammal with modifications in one or more genomic sequences.
[0072] As will be apparent to one of skill in the art, non-human mammals can also be produced using the methods described herein and / or conventional methods (see, e.g., U.S. Published Application No. 2011 / 0302665). A method of producing a non-human mammalian embryo can include injecting a non-human mammalian ES cell (e.g., iPSC) into a non-human tetraploid blastocyst and maintaining the resulting tetraploid blastocyst under conditions that result in the formation of an embryo, thereby producing a non-human mammalian embryo. In some embodiments, the non-human mammalian cell is a mouse cell and the non-human mammalian embryo is a mouse. In some embodiments, the mouse cell is a mutant mouse cell and is injected into the non-human tetraploid blastocyst by microinjection. In some embodiments, laser-assisted micromanipulation or piezo injection is used. In some embodiments, the non-human mammalian embryo comprises a mouse embryo.
[0073] Another example of such a conventional technique is two-step cloning, which involves introducing an embryonic stem (ES) cell and / or induced pluripotent stem (iPS) cell containing one or more mutations into a blastocyst (e.g., a tetraploid blastocyst) and maintaining the blastocyst under conditions that result in the development of an embryo. The embryo is then implanted (fertilized) into a suitable foster mother, such as a pseudopregnant female (e.g., of the same species as the embryo). The foster mother is then maintained under conditions that result in the development of live offspring carrying the one or more mutations.
[0074] Another example is the use of tetraploid complementation assays, where cells from two mammalian embryos are combined to form a new embryo (Tarn and Rossant, Develop, 750:6156-6163 (2003)). This assay involves creating tetraploid cells, in which every chromosome is present four times. This is done by taking an embryo at the two-cell stage and passing an electric current to fuse the two cells. The resulting tetraploid cell continues to divide, and all daughter cells are also tetraploid. Such tetraploid embryos typically develop to the blastocyst stage and implant in the uterine wall. In tetraploid complementation assays, a tetraploid embryo (either at the morula or blastocyst stage) is combined with normal diploid embryonic stem cells (ES) from a different organism. The embryo develops normally. The fetus is derived exclusively from ES cells, whereas the extraembryonic tissues are derived exclusively from tetraploid cells.
[0075] Another conventional method used to generate non-human mammals is pronuclear microinjection. DNA is directly introduced into the male pronucleus of a non-human mammalian egg immediately after fertilization. The fertilized egg is implanted into a pseudopregnant female, similar to the two-step cloning described above. The offspring are screened for the integrated transgene. Heterozygous offspring can then be mated to generate homozygous animals.
[0076] A variety of non-human mammals can be used in the methods described herein. For example, the non-human mammal can be a rodent (e.g., mouse, rat, guinea pig, hamster), a non-human primate, a dog, a cat, a cow, a horse, a pig, or a goat.
[0077] In some embodiments, various mouse strains and mouse models of human disease are used in connection with the methods of generating non-human mammals with mutations in one or more target nucleic acid sequences described herein. Those skilled in the art will recognize numerous commercially available and non-commercially available laboratory mouse strains that model human disease. Mouse models exist for diseases such as cancer, cardiovascular disease, autoimmune diseases and disorders, inflammatory diseases, diabetes (types 1 and 2), neurological diseases, and other diseases. Examples of commercially available research strains include 11BHSD2 mice, GSK3B mice, 129-E mice, HSD1 1B1 mice, AK mice, Immortomouse®, athymic nude mice, LCAT mice, B6 albino mice, Lox-1 mice, B6C3F1 mice, Ly5 mice, B6D2F1 (BDF1) mice, MMP9 mice, BALB / c mice, NIH-III nude mice, BALB / c nude mice, NOD mice, NOD SCID mice, Black mice, and the like. Swiss mice, NSE-p25 mice, C3H mice, NU / NU nude mice, C57BL / 6-E mice, PCSK9 mice, C57BL / 6N mice, PGP mice (P-glycoprotein deficient), CB6F1 mice, repTOP™ ERE-Luc mice, CD-I® mice, repTOP™ mitoIRE mice, CD-I® nude mice, repTOP™ PPRE-Luc mice, CD1-E mice, Rip-HAT mice, CD2F1 (CDF1) mice, SCID Hairless Congenic (SHC™) mice, CF-1™ mice, SCID Hairless Outbred (SHO™) mice, DBA / 2 mice, SJL-E mice, Fox Chase CB 17™ mice, SKH1-E mice, Fox Chase SCID™ Beige mice, Swiss Webster (CFW™) mice, Fox Chase These include, but are not limited to, SCID® mice, TARGATT™ mice, FVB mice, THE POUND mice™, and GLUT 4 mice.Other mouse strains include BALB / c, C57BL / 6, C57BL / 10, C3H, ICR, CBA, A / J, NOD, DBA / 1, DBA / 2, MOLD, 129, HRS, MRL, NZB, NIH, AKR, SJL, NZW, CAST, KK, SENCAR, C57L, SAMR1, SAMP1, C57BR, and NZO.
[0078] In some embodiments, the methods of producing a non-human mammal having one or more modifications in its genomic sequence further comprise mating one or more commercially available and / or non-commercially available non-human mammals with a non-human mammal having one or more modifications in its genomic sequence produced by the methods described herein. The present invention also relates to a non-human mammal produced by the methods described herein.
[0079] In some embodiments, the genomic sequence is associated with a disease or condition (see, e.g., van der Weyden et al, Genome Biol, 12:224 (2011)). Specific examples of genetic modifications of interest include modifying the sequence(s) (e.g., gene(s)) to match a sequence from a different species (e.g., changing a mouse sequence to a human sequence for any gene(s) of interest), altering potential or known sites of post-translational modification (e.g., phosphorylation, glycosylation, lipidation, acylation, acetylation) of a protein, altering potential or known sites of epigenetic modification, altering potential or known sites of protein-protein or protein-nucleic acid interactions, inserting tags (e.g., epitope tags), and / or inserting or deleting splice sites.
[0080] In some embodiments, one copy of one or more genomic sequences is modified. In some embodiments, one or more of the genomic sequences in the cell are modified in both copies. In some embodiments, the modified one or more genomic sequences are endogenous to the cell.
[0081] In certain embodiments, at least two of the genomic sequences are endogenous genomic sequences. In some embodiments, at least two of the genomic sequences are exogenous genomic sequences. In some embodiments where there are at least two genomic sequences, at least one of the genomic sequences is an endogenous genomic sequence and at least one of the genomic sequences is an exogenous genomic sequence. In some embodiments, at least two of the genomic sequences are endogenous genes. In some embodiments, at least two of the genomic sequences are exogenous genes. In some embodiments where there are at least two genomic sequences, at least one of the genomic sequences is an endogenous gene and at least one of the genomic sequences is an exogenous gene. In some embodiments, at least two of the genomic sequences are at least 1 kB apart. In some embodiments, at least two of the genomic sequences are on different chromosomes. The genomic sequences may include tags (e.g., epitope tags or fluorescent tags) or transgenes (e.g., reporter genes).
[0082] Methods provided herein provide for multiplex genome editing in cells, embryos, zygotes, and non-human mammals. As shown herein, cells, embryos, zygotes, and non-human mammals with modifications in multiple genes can be produced in one step. In some embodiments, the methods described herein allow for the modification of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, etc. genomic sequences (e.g., genes) in a (single) cell, zygote, embryo, or non-human mammal using the methods described herein. In certain embodiments, one genomic sequence is modified in a (single) cell, zygote, embryo, or non-human mammal. In some embodiments, two genomic sequences are modified in a (single) cell, zygote, embryo, or non-human mammal. In some embodiments, three genomic sequences are modified in a (single) cell, zygote, embryo, or non-human mammal. In some embodiments, four genomic sequences are modified in a (single) cell, zygote, embryo, or non-human mammal. In some embodiments, five genomic sequences are modified in a (single) cell, zygote, embryo, or non-human mammal, etc.
[0083] As will be apparent to one of skill in the art, a variety of methods can be used to introduce the nucleic acid and / or protein into a cell, zygote, embryo, and / or mammal. Suitable methods include calcium phosphate or lipid-mediated transfection, electroporation, injection, and transduction or infection with a vector (e.g., a viral vector such as an adenoviral vector). In some embodiments, the nucleic acid and / or protein is complexed with a vehicle, e.g., a cationic vehicle, that facilitates uptake of the nucleic acid and / or protein, e.g., by endocytosis.
[0084] The methods described herein may further include isolating the cells or zygotes produced by the methods. Thus, in some aspects, the invention relates to cells or zygotes (isolated cells or zygotes) produced by the methods described herein. In some aspects, the disclosure provides clonal populations of cells bearing the modification(s), replicate cultures comprising cells bearing the modification(s), and cells isolated from the produced animals.
[0085] The methods described herein may further include breeding the generated animals with other animals (optionally of the same background) that have the genetic modification and / or other animals that have one or more phenotypes of interest (e.g., disease susceptibility, such as NOD mice). Additionally, the methods may include modifying cells, zygotes, and / or animals from the strain that have one or more genetic modifications and / or have one or more phenotypes of interest (e.g., disease susceptibility). In some embodiments, the genetic modification is an epigenetic modification.
[0086] The methods described herein can further include assessing whether one or more target nucleic acids are modified and / or regulated using a variety of known methods.
[0087] In some embodiments, the methods described herein are used to produce multiple genetic modifications in a cell, zygote, embryo, or animal, where at least one of the genetic modifications methylates or demethylates a gene, and where at least one of the genetic modifications is at a different gene or genomic location. In some embodiments, the genetic modifications further comprise an epigenetic modification. The resulting cell, zygote, embryo, or animal, or a cell, zygote, embryo, or animal produced therefrom, is analyzed. In some embodiments, at least one of the genetic modifications may be conditional (e.g., the effect of the modification, such as methylation or demethylation of a gene, is only manifested under certain conditions, typically under the control of a person skilled in the art). In some embodiments, the animal is developed at least to a postnatal stage, e.g., adulthood. After imposing conditions (sometimes referred to as "induction conditions") appropriate for the modification to produce an effect, the phenotype of the animal is analyzed. The phenotype can be compared to the phenotype of the unmodified animal, or to the phenotype before imposing the induction conditions.
[0088] Analysis may include any type of phenotypic analysis known in the art, such as examination of the structure, size, development, weight, or function of any tissue, organ, or organ system (or entire organism), behavior, activity of any biological pathway or process, levels of any particular substance or gene product, etc. In some embodiments, analysis includes gene expression analysis, for example, at the mRNA or protein level. In some embodiments, such analysis may include, for example, the use of microarrays (e.g., oligonucleotide microarrays, sometimes referred to as "chips"), high throughput sequencing (e.g., RNASeq), ChIP on Chip analysis, ChIPSeq analysis, etc. In some embodiments, high content screening may be used, in which methods may utilize elements of high throughput screening for analysis of individual cells through the use of automated microscopy and image analysis (see, e.g., Zanella et al, (2010). High content screening: seeing is believing. Trends Biotechnol. 28:237-245). In some embodiments, the analysis includes quantitative analysis of cellular components such as, for example, the spatiotemporal distribution of individual proteins, cytoskeletal structures, vesicles, and organelles upon contact with a test agent (e.g., a compound). In some embodiments, activation or inhibition of individual proteins and protein-protein interactions, and / or changes in biological processes and cellular functions can be evaluated. A variety of fluorescent probes are available depending on the biological processes, functions, and cellular components, which can be used, for example, with a fluorescent microscope. In some embodiments, cells or animals generated according to the methods herein can include reporters, for example, fluorescent reporters or enzymes (e.g., luciferases such as Gaussia luciferase, Renilla luciferase, or firefly luciferase), which report on the expression or activity of a particular gene.Fusing such reporters to a protein can make the protein or its activity detectable, optionally using non-invasive detection means, e.g., imaging or detection means such as PET imaging, MRI, fluorescence detection, etc. Multiplex genome editing according to the present invention can allow for the introduction of reporters for detecting multiple proteins, e.g., 2-20 different proteins, e.g., in a cell, tissue, organ, or animal, e.g., a living animal.
[0089] Multiplex genome editing according to the present invention can be useful to determine or test the biological role(s) and / or disease role(s) of genes of unknown function, for example to discover the composite effect produced by modification of a first and second gene, and pinpoint the genetic or biochemical pathway(s) in which such gene(s) or encoded gene product(s) are involved.
[0090] In some embodiments, it is contemplated that the methods described herein use cells or zygotes derived from animals produced or produced in projects such as the International Knockout Mouse Consortium (IKMC) (website at knockoutmouse.org). In some embodiments, it is contemplated that animals produced as described herein are bred with animals produced by or available through the IKMC. For example, in some embodiments, the mouse gene modified according to the methods described herein is any gene from the Mouse Genome Informatics (MGI) database, from which sequence and genomic coordinates are available. Any gene may be predicted, for example, by NCBI, Ensembl, and Vega (Vertebrate Genome Annotation) pipelines against the Mouse Genome Build 37 (NCBI) or Genome Reference Consortium GRCm38.
[0091] In some embodiments, the gene or genomic location to be modified is contained in the genome of a species for which a fully sequenced genome exists. Genomic sequences can be found, for example, at UCSC Genome Browser (genome.ucsc.edu / index.html). For example, in some embodiments, the human genes or sequences modified according to the methods described herein can be found in the Human Genome Build hgl9 (Genome Reference Consortium). In some embodiments, the gene is any gene that has been assigned a gene ID in the NCBI gene database (ncbi.nlm.nih.gov / gene). In some embodiments, the gene is any gene whose genomic, cDNA, mRNA, or encoded gene product (e.g., protein) sequence has been published by the National Center for Any gene publicly available in a database such as any of those available at Biotechnology Information (ncbi.nih.gov) or Universal Protein Resource (uniprot.org). Databases include, for example, GenBank, RefSeq, Gene, UniProtKB / SwissProt, UniProtKB / Trembl, etc.
[0092] In some embodiments, the subject is genetically modifying known or suspected methylation variable regions (DMRs). There are various examples of methylation variable regions. Methylation variable regions can be differentially methylated between cells of different cell types (e.g., muscle cells and neurons or skin cells and liver cells). Methylation variable regions can also be differentially methylated between diseased and non-diseased cells (e.g., cancer cells and non-cancer cells). Methylation variable regions can also be differentially methylated between differentiation states (e.g., progenitor cells and terminally differentiated cells). The effect on expression of one or more genes (e.g., within up to about .5, 1, 2, 5, 10, 20, 50, 100, 500 kb, or within about 1, 2, 5, or 10 MB of the modification) can be evaluated. Genetic modifications can be made to sequences to determine whether such genetic modifications change the phenotype of a cell or animal, or affect RNA or protein products, or alter susceptibility to disease. Genetic modifications can include epigenetic modifications. In some aspects, the methylation variable region can be hypermethylated or unmethylated.
[0093] In some embodiments, the method is directed to demethylating genomic sequences that are abnormally hypermethylated or methylating genomic sequences that are abnormally unmethylated. In some embodiments, abnormally hypermethylated or abnormally unmethylated sequences can occur in diseases or disorders. In other embodiments, the method is directed to methylating CTCF sites that are abnormally unmethylated (e.g., CTCF binding sites) or demethylating CTCF sites that are abnormally methylated. The methylation or demethylation of CTCF sites can be altered to treat or prevent diseases or disorders that express abnormally unmethylated or abnormally hypermethylated sequences or regions. For example, if one wishes to increase expression of a gene outside the loop (e.g., if expression of the gene is abnormally low and / or increased expression is desired for therapeutic or other purposes), one can methylate the CTCF binding site to open the CTCF loop, thereby placing the outside gene under the control of an enhancer inside the loop.
[0094] In some embodiments, the methods described herein can be used to generate cells with modifications in promoter sequences.Targeting dCas9-Tet1 fusion protein to methylated promoter sequences or targeting dCas9-Dnmt3a fusion protein to unmethylated promoter sequences results in the activation or silencing of endogenous reporters, respectively.For example, dCas9-Tet1 fusion protein targets BDNF promoter IV and induces BDNF expression in postmitotic neurons by demethylating the promoter.
[0095] In some embodiments, the methods described herein can be used to generate cells with modifications in enhancer sequences.Targeting dCas9-Tet1 fusion protein to methylated enhancer sequences or targeting dCas9-Dnmt3a fusion protein to unmethylated enhancer sequences results in activation or silencing of endogenous enhancers, respectively.For example, dCas9-Tet1 fusion protein targets the MyoD distal enhancer of fibroblasts and demethylates the enhancer, thereby promoting the reprogramming of fibroblasts into myoblasts.
[0096] In other embodiments, the methods described herein can be used to generate cells with modifications at CTCF binding sites.DCas9-Tet1 or dCas9-Dnmt3a fusion protein can be targeted to CTCF binding sites to affect CTCF binding and disrupt DNA looping.For example, dCas9-Dnmt3a fusion protein can perform de novo methylation targeting the anchor site of CTCF loop, blocking CTCF binding and disrupting DNA looping, thereby changing gene expression in adjacent loops.
[0097] In some embodiments, any of the methods described herein may include isolating one or more cells, samples, or materials from an animal produced according to the methods described herein, such as any genetically modified animal produced as described herein. In some embodiments, the method may further include analyzing one or more cells, samples, or materials. Such analysis may, for example, evaluate the effect of the genetic modification(s) introduced according to the method. The genetic modification may include methylation or demethylation of genomic sequences and / or may include epigenetic modifications.
[0098] In some embodiments, animals generated according to the methods described herein may be useful for identifying candidate drugs for treating disease and / or testing for potential toxicity or side effects of drugs. In some embodiments, any method described herein may include contacting an animal generated according to the methods described herein, such as any genetically modified animal generated as described herein, with a test agent (e.g., a small molecule, a nucleic acid, a polypeptide, a lipid, etc.). In some embodiments, the contacting includes administering the test agent. The test agent may be administered by any route (e.g., oral, intravenous, intraperitoneal, gavage, topical, transdermal, intramuscular, enteral, subcutaneous), systemically or locally, may include any dose (e.g., about 0.01 mg / kg to about 500 mg / kg), and may involve a single dose or multiple doses. In some embodiments, the method may further include analyzing the animal. Such analysis may, for example, evaluate the effect of the test agent in an animal having a genetic modification(s) introduced according to the methods. In some embodiments, test agents that reduce or enhance the effect of one or more genetic modification(s) may be identified. In some embodiments, if the test agent reduces or suppresses the onset of a disease associated with or caused by the genetic modification(s) (or alleviates or suppresses one or more symptoms or signs of such a disease), the test agent can be identified as a candidate drug for treating a disease associated with or caused by the genetic modification(s), or a disease associated with or caused by a naturally occurring mutation in a gene or genomic location that has the genetic modification.
[0099] In some embodiments, the cells may be diseased cells or may be derived from a subject suffering from a disease, e.g., a disease that affects the cell or the organ from which the cell was obtained. In some embodiments, a mutation is introduced into a genomic region of the cell that is associated with the disease (e.g., any disease of interest, such as those mentioned herein). For example, some embodiments are directed to methylating or demethylating genes or genomic locations known or suspected to be involved in the pathogenesis of the disease and / or known or suspected to be involved in increasing or decreasing the risk of developing the disease or a particular symptom(s) of the disease. Some embodiments are directed to methylating or demethylating genes or genomic locations to determine whether such modifications alter the risk of developing the disease or one or more symptoms of the disease, alter the progression of the disease, or alter the subject's response to a therapy or candidate therapy for the disease. In some embodiments, they are directed to changing an abnormal or disease-associated nucleotide or sequence to one that is normal or not associated with the disease. In some embodiments, this can allow for the creation of genetically matched cells or cell lines (e.g., iPS cells or cell lines) that differ in genetic modifications only at one or more selected sites. Multiplex genome editing as described herein can enable the creation of cells or cell lines that are isogenic except for genetic modifications at, for example, 2-20 selected sites, which can enable the study of the combined effects of multiple modifications suspected or known to be involved in disease risk, development, or progression.
[0100] The terms "disease", "disorder", or "pathology" are used interchangeably and may refer to any alteration from the health and / or normal function of an organism, such as a physical or mental abnormality that causes pain, discomfort, dysfunction, suffering, degeneration, or death to an afflicted individual. Disease includes any disease known to those of skill in the art. In some embodiments, the disease is a chronic disease, e.g., it is one that typically persists or has persisted for at least 3-6 months, e.g., 1, 2, 3, 5, 10 years, or more, or indefinitely. A disease may have a characteristic set of symptoms and / or signs that typically occur in individuals suffering from the disease. Diseases and methods of diagnosis and treatment thereof are described in standard medical textbooks, such as Longo, D., et al. (eds.), Harrison's Principles of Internal Medicine, 18th Edition; McGraw-Hill Professional, 2011 and / or Goldman's Cecil Medicine, Saunders; 24 edition (August 5, 2011). In certain embodiments, the disease is a polygenic disease (also called a complex disease, a multifactorial disease, or a polygenic disease). Such diseases may be associated with the influence of multiple genes, sometimes in conjunction with environmental factors (e.g., exposure to certain physical or chemical agents, or biological agents such as viruses, lifestyle factors such as diet, smoking, etc.). A polygenic disease may be any disease in which it is known or suspected that multiple genes (e.g., specific alleles of such genes, specific polymorphisms in such genes) may contribute to the risk of developing the disease and / or to the way the disease manifests (e.g., severity of the disease, age of onset, rate of progression, etc.). In some embodiments, a polygenic disease is a disease that has a genetic component such that familial clustering (occurring more frequently in certain families than in the general population) is observed, but does not follow Mendelian laws of inheritance, e.g., the disease does not clearly follow dominant, recessive, X-linked, or Y-linked inheritance patterns.In some embodiments, polygenic diseases are not usually controlled by a high-impact variant in a single gene (as in Mendelian disorders). In some embodiments, polygenic diseases may occur in familial forms and sporadically. Examples include, for example, Parkinson's disease, Alzheimer's disease, and various types of cancer. Examples of polygenic diseases include many common diseases such as hypertension, diabetes mellitus (e.g., type II diabetes mellitus), cardiovascular disease, cancer, and stroke (ischemic, hemorrhagic). In some embodiments, the disease, e.g., polygenic disease, is a psychiatric disease, a neurological disease, a neurodevelopmental disease, a neurodegenerative disease, a cardiovascular disease, an autoimmune disease, a cancer, a metabolic disease, or a respiratory disease. In some embodiments, at least one gene is involved in familial forms of polygenic diseases.
[0101] In some embodiments, the disease is cancer, a term that is generally used interchangeably to refer to a disease characterized by one or more tumors, e.g., one or more malignant or potentially malignant tumors. As used herein, the term "tumor" encompasses abnormal growth, including abnormal proliferation of cells. As known in the art, tumors are typically characterized by excessive cell proliferation that is not properly controlled (e.g., does not respond normally to physiological influences and signals that would normally limit proliferation) and may exhibit one or more of the following characteristics: dysplasia (e.g., lack of normal cell differentiation, thereby resulting in an increase in the number or proportion of immature cells); aplasia (e.g., greater lack of differentiation, greater loss of structural organization, abnormalities such as cellular pleomorphism, large hyperchromatic nuclei, high nuclear-cytoplasmic ratios, atypical mitoses); invasion of adjacent tissues (e.g., rupture of basement membrane); and / or metastasis. Malignant tumors tend to grow continuously and have the capacity to spread, e.g., to invade locally and / or metastasize locally and / or distantly, whereas benign tumors often remain localized to the site of origin and are often self-limited in terms of growth. The term "tumor" includes malignant solid tumors, e.g., carcinomas (cancers arising from epithelial cells), sarcomas (cancers arising from cells of mesenchymal origin), and malignant growths (e.g., certain hematological tumors) where there may be no detectable solid tumor mass.Cancers include, but are not limited to: breast cancer; biliary tract cancer; bladder cancer; brain tumors (e.g., glioblastoma, medulloblastoma); cervical cancer; choriocarcinoma; colon cancer; uterine cancer; esophageal cancer; gastric cancer; blood tumors including acute lymphocytic leukemia and acute myeloid leukemia; T-cell acute lymphocytic leukemia / lymphoma; hairy cell leukemia; chronic lymphocytic leukemia, chronic myelogenous leukemia, multiple myeloma; adult T-cell leukemia / lymphoma; intraepithelial neoplasia including Bowen's disease and Paget's disease; liver cancer; lung cancer; lymphomas including Hodgkin's disease and lymphocytic lymphoma; neuroblastoma oral cancer, including melanoma, squamous cell carcinoma; ovarian cancer, including ovarian cancer arising from epithelial, stromal, germ cells, and mesenchymal cells; neuroblastoma, pancreatic cancer; prostate cancer; rectal cancer; sarcomas, including angiosarcoma, gastrointestinal stromal tumors, leiomyosarcoma, rhabdomyosarcoma, liposarcoma, fibrosarcoma, and osteosarcoma; kidney cancer, including renal cell carcinoma and Wilms' tumor; skin cancer, including basal cell carcinoma and squamous cell carcinoma; testicular cancer, including germ cell tumors, such as seminoma, non-seminoma (teratomas, choriocarcinoma), stromal tumors, and germ cell tumors; thyroid cancer, including thyroid adenocarcinoma and medullary carcinoma. It will be appreciated that a variety of different types of tumors may occur in a particular organ, which may differ, for example, with respect to clinical and / or pathological features and / or molecular markers. Tumors occurring in a variety of different organs are described, for example, in the WHO Classification of Tumours series, 4, by the International Agency for Research on Cancer (IARC). th ed or 3 rded (Pathology and Genetics of Tumours series), WHO Press, Geneva, Switzerland, the entire volume of which is incorporated herein by reference. In some embodiments, the cancer is one in which mutation or overexpression of a particular gene is known or suspected to be involved in the development, progression, recurrence, etc. of the cancer. In some embodiments, such genes are targets for genetic modification by the methods described herein. In some embodiments, the gene is an oncogene, a proto-oncogene, or a tumor suppressor gene. The term "oncogene" encompasses nucleic acids whose expression may increase the likelihood or contribute to the onset or progression of cancer. A normal cellular sequence ("proto-oncogene") may be activated by mutation and / or aberrant expression to become an oncogene (sometimes referred to as an "activated oncogene"). In various embodiments, an oncogene may include the complete coding sequence for a gene product, or a portion of the complete sequence or a sequence encoding a fusion protein that at least partially maintains oncogenic potential. Oncogenic mutations may result, for example, in altered (e.g., increased) protein activity, lack of proper regulation, or altered (e.g., increased) RA or protein levels. Aberrant expression may occur, for example, due to chromosomal rearrangements resulting in juxtaposition to regulatory elements such as enhancers, epigenetic mechanisms, or amplification, which may result in increased amounts of the proto-oncogene product or its production in the wrong cell type. Proto-oncogenes often encode proteins that control or are involved in cell proliferation, differentiation, and / or apoptosis. Such proteins include, for example, various transcription factors, chromatin remodeling factors, growth factors, growth factor receptors, signal transducers, and apoptosis regulators. A TSG may be any gene whose loss or reduced function of the expression product of that gene may increase the likelihood of or contribute to the initiation or progression of cancer. Loss or reduced function may occur, for example, by mutation or epigenetic mechanisms.Many TSGs encode proteins that normally function to inhibit or negatively regulate cell proliferation and / or promote apoptosis. Exemplary oncogenes include, for example, MYC, SRC, FOS, JUN, MYB, RAS, RAF, ABL, ALK, AKT, TRK, BCL2, WNT, HER2 / NEU, EGFR, MAPK, ERK, MDM2, CDK4, GLI1, GLI2, IGF2, TP53, and the like. Exemplary TSGs include, for example, RB, TP53, APC, NF1, BRCA1, BRCA2, PTEN, CDK inhibitor proteins (e.g., p16, p21), PTCH, WT1, and the like. It will be understood that some of these oncogene and TSG names encompass multiple family members and many other TSGs are known.
[0102] In some embodiments, the disease is a cardiovascular disease, such as arteriosclerotic heart or vascular disease, congestive heart failure, myocardial infarction, cerebrovascular disease, peripheral arterial disease, cardiomyopathy.
[0103] In some embodiments, the disease is a psychiatric, neurological, or neurodevelopmental disease, such as schizophrenia, depression, bipolar disorder, epilepsy, autism, or addiction. Neurodegenerative diseases include, for example, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and frontotemporal dementia. In some embodiments, the disease is an autoimmune disease, such as acute disseminated encephalomyelitis, alopecia areata, antiphospholipid syndrome, autoimmune hepatitis, autoimmune myocarditis, autoimmune pancreatitis, autoimmune polyendocrine syndrome uveitis, inflammatory bowel disease (Crohn's disease, ulcerative colitis), type I diabetes (e.g., juvenile-onset diabetes), multiple sclerosis, scleroderma, and ankylosing spondylitis. , sarcoid, pemphigus vulgaris, pemphigoid, psoriasis, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, Behçet's syndrome, Reiter's disease, Berger's disease, dermatomyositis, polymyositis, antineutrophil cytoplasmic antibody-associated vasculitis (e.g., granulomatosis with polyangiitis (also known as Wegener's granulomatosis), microscopic polyangiitis, and Churg-Strauss syndrome), scleroderma, Sjogren's syndrome, anti-glomerular basement membrane disease (including Goodpasture's syndrome), dilated cardiomyopathy, primary biliary cirrhosis, thyroiditis (e.g., Hashimoto's thyroiditis, Graves' disease), transverse myelitis, and Guillain-Barré syndrome.
[0104] In some embodiments, the disease is a respiratory disease, such as allergies, asthma, chronic obstructive pulmonary disease, pulmonary hypertension, pulmonary fibrosis, and sarcoidosis, which affect the respiratory system.
[0105] In some embodiments, the disease is a kidney disease, such as polycystic kidney disease, lupus, nephropathy (nephrotic or nephritic), or glomerulonephritis of any type.
[0106] In some embodiments, the disease is, for example, age-related blindness or hearing loss.
[0107] In some embodiments, the disease is an infectious disease, such as any disease caused by a virus, bacteria, fungus, or parasite.
[0108] In some embodiments, the disease expresses hypermethylation (e.g., aberrant hypermethylation) or demethylation (e.g., aberrant demethylation) in genomic sequences. For example, fragile X syndrome expresses hypermethylation of FMR-1. dCas9-Tet1 fusion protein can be used to specifically demethylate hypermethylated CCGs to reactivate FMG-1, thereby treating fragile X syndrome. The methods described herein can be used to treat or prevent diseases or disorders that express aberrant methylation (e.g., hypermethylation or demethylation).
[0109] It will be understood that the classification of diseases herein is not intended to be limiting, and those of skill in the art will understand that various diseases can be appropriately classified into several different groups.
[0110] In some embodiments, the disease is one for which at least one genome-wide association (GWA) study (GWAS) has been performed. In some embodiments, the GWAS classifies a plurality of "cases" (subjects with the disease of interest or a particular symptom thereof) and "controls" (subjects without the disease or condition) for thousands to millions, e.g., 1 million or more, e.g., 1 million to 5 million or more alleles (e.g., single nucleotide polymorphisms) located across the entire genome or a substantial portion thereof (e.g., at least 80%, 90%, 95%, or more of the genome). It will be understood that data for the controls can be obtained from historical data. Genotyping can be performed using microarrays or other methods. Alleles that are associated (e.g., statistically significantly) with an increased (or decreased) risk of the disease (or particular condition) can thereby be identified. It will be understood that statistical results can be corrected according to multiple hypothesis testing, for example, using methods known in the art. In some embodiments, the GWAS classifies a plurality of "cases" (subjects with the disease of interest or a particular symptom thereof) for thousands to millions, e.g., 1 million or more, e.g., 1 million to 5 million or more alleles (e.g., single nucleotide polymorphisms) located across the entire genome or a substantial portion thereof (e.g., at least 80%, 90%, 95%, or more of the genome). It will be understood that data for the controls can be obtained from historical data. Genotyping can be performed using microarrays or other methods. Alleles that are associated (e.g., statistically significantly) with an increased (or decreased) risk of the disease (or particular condition) can thereby be identified. It will be understood that statistical results can be corrected according to multiple hypothesis testing, for example, using methods known in the art. In some embodiments, the GWAS classifies a plurality of "cases" (subjects with the disease of interest or a particular symptom) for thousands to millions, e.g., -7 , 10 -8 , or 10 -9A p-value of less than 0.01 is considered evidence of association. In some embodiments, the gene or allele or polymorphism has been identified in at least one GWAS as contributing to the risk or severity of the disease. For example, see genome.gov / gwastudies for examples of GWAS studies and genetic variations (alleles, polymorphisms) associated with various diseases. In some embodiments, the gene (or any sequence) is one in which the allele or polymorphism is associated with at least 1.1, 1.2, 1.5, 2, 3, 4, 5, 7.5, 10, or more of an increased or decreased risk of developing the disease compared to individuals who do not have that allele or polymorphism. In some embodiments, the allele or polymorphism is associated with at least 1.1, 1.2, 1.5, 2, 3, 4, 5, 7.5, 10, or more of an increased or decreased risk of developing the disease compared to individuals who do not have that allele or polymorphism. The present invention is directed to genes, alleles, polymorphisms, or loci that may contribute to any phenotypic trait of interest, such as life span, body weight, resistance to infection, response or lack thereof to various therapeutic agents, resistance or susceptibility to potentially harmful substances such as toxins or infectious agents (e.g., viruses, bacteria, fungi, parasites). The phenotypic trait may be a physical sign (such as blood pressure), a biochemical marker, which in some embodiments may be detectable in bodily fluids such as blood, saliva, urine, tears, e.g., metabolite levels, LDL, etc. An abnormally low or high level of the marker may then be correlated with disease or not, or susceptibility to or protection from disease.
[0111] In some embodiments, the sequence inserted into the genome encodes a tag. The sequence can be inserted into the gene at an appropriate location to produce a fusion protein containing the tag. The term "tag" is used broadly to encompass any of a wide variety of polypeptides. In some embodiments, the tag comprises a sequence useful for purifying, expressing, solubilizing, and / or detecting the polypeptide. In some embodiments, the tag can serve multiple functions. In some embodiments, the tag is a relatively small polypeptide, for example ranging from a few amino acids in length up to about 100 amino acids in length. In some embodiments, the tag is more than 100 amino acids in length, for example up to about 500 amino acids in length or more. In some embodiments, the tag comprises an HA, TAP, Myc, 6XHis, Flag, V5, or GST tag, to name a few. A tag (e.g., any of the aforementioned tags) that comprises an epitope for an antibody, e.g., a monoclonal antibody, that is available (e.g., commercially available) or known in the art may be referred to as an "epitope tag." In some embodiments, the tag comprises a solubility enhancing tag (e.g., a SUMO tag, a NUS A tag, a SNUT tag, a Strep tag, or a monomeric variant of the Ocr protein of bacteriophage T7). See, e.g., Esposito D and Chatterjee DK.Curr Opin BiotechnoL;17(4):353-8(2006). In some embodiments, the tag is cleavable such that at least a portion of the tag can be removed, e.g., by a protease. In some embodiments, this is accomplished by including in the tag a protease cleavage site adjacent to or linked to a functional portion of the tag. Exemplary proteases include, e.g., thrombin, TEV protease, Factor Xa, PreScission protease, and the like. In some embodiments, a "self-cleaving" tag is used. See, e.g., PCT / US05 / 05763.In some embodiments, the tag comprises a fluorescent polypeptide (e.g., GFP or its derivatives such as enhanced GFP (EGFP)) or an enzyme that can act on a substrate to generate a detectable signal, e.g., a fluorescent signal or a colorimetric signal. Luciferase (e.g., firefly luciferase, Renilla luciferase, or Gaussia luciferase) is an example of such an enzyme. Examples of fluorescent proteins include GFP and its derivatives, proteins that contain chromophores that emit different colors of light, e.g., red, yellow, and cyan fluorescent proteins. Tags, e.g., fluorescent proteins, can be monomeric. In certain embodiments, the fluorescent protein is, for example, Sirius, Azurite, EBFP2, TagBFP, mTurquoise, ECFP, Cerulean, TagCFP, mTFP1, mUkG1, mAG1, AcGFP1, TagGFP2, EGFP, mWasabi, EmGFP, TagYPF, EYFP, Topaz, SYFP2, Venus, Citrine, mKO, mK02, mOrange, mOrange2, TagRFP, TagRFP-T, mStrawberry, mRuby, mCherry, mRaspberry, mKate2, mPlum, niNeptune, mTomato, T-Sapphire, mAmetrine, mKeima. For GFP and many other fluorescent or luminescent proteins, see, e.g., Chalfie, M. and Kain, SR (eds.) Green fluorescent protein: properties, applications, and protocols (Methods of biochemical analysis, v. 47). Wiley-Interscience, Hoboken, NJ, 2006 and / or Chudakov, DM, et al, Physiol Rev. 90(3):1103-63, 2010. In some embodiments, the tag may comprise a domain that binds to and / or acts on a sensor of a small molecule (e.g., a metabolite) or an ion (e.g., calcium ion, chloride ion), or a sensor of intracellular potential, pH, or other condition.Any genetically encodable sensor may be used, and several such sensors are known in the art. In some embodiments, FRET-based sensors may be used. In some embodiments, the proteins encoded by the genes are distinguishably labeled by modifying various genes to incorporate different tags. For example, 2-20 different tags may be introduced. In some embodiments, the tags have different emission and / or absorption spectra. In some embodiments, the tags can absorb and / or emit light in the infrared or near infrared range. It will be understood that any nucleic acid sequence encoding a tag can be codon-optimized for expression in the cell, zygote, embryo, or animal into which it is to be introduced.
[0112] In some embodiments, one may be interested in expressing a fragment or domain of a protein that can act in a dominant negative manner, e.g., a fragment or domain of a protein that can inhibit the normal function or interaction of a protein.
[0113] In some embodiments, the gene of interest encodes a protein whose accumulation is associated with one or more diseases sometimes referred to as protein misfolding diseases, such as alpha-synuclein (Parkinson's disease and related disorders), amyloid beta or tau (Alzheimer's disease), and TDP-43 (frontotemporal dementia, ALS).
[0114] In some embodiments, the gene of interest encodes a transcription factor, a transcriptional coactivator or corepressor, an enzyme, a chaperone, a heat shock factor, a heat shock protein, a receptor, a secreted protein, a transmembrane protein, a histone (e.g., H1, H2A, H2B, H3, H4), a peripheral membrane protein, a soluble protein, a nuclear protein, a mitochondrial protein, a growth factor, a cytokine (e.g., an interleukin, such as any of IL-1 through IL-33), an interferon (e.g., alpha, beta, or gamma), a chemokine (e.g., a CXC, CX3C, C (or XC), or a CX3C chemokine). The chemokine can be CCL1 through CCL28, CXCL1 through CXCL17, XCL1 or XCL2, or CXC3L1. In some embodiments, the gene encodes a colony stimulating factor, a hormone (e.g., insulin, thyroid hormone, growth hormone, estrogen, progesterone, testosterone), an extracellular matrix protein (e.g., collagen, fibronectin), a motor protein (e.g., dynein, myosin), a cell adhesion molecule, a major or minor histocompatibility (MHC) gene, a transporter, a channel (e.g., an ion channel), an immunoglobulin (Ig) superfamily (IgSF) gene (e.g., a gene encoding an antibody, a T cell receptor, a B cell receptor), a tumor necrosis factor, an NF-kappa B protein, an integrin, a cadherin superfamily member (e.g., a cadherin), a selectin, a coagulation factor, a complement factor, plasminogen, a plasminogen activator. Growth factors include, for example, members of the vascular endothelial growth factor (VEGF, e.g., VEGF-A, VEGF-B, VEGF-C, VEGF-D), epidermal growth factor (EGF), insulin-like growth factor (IGF; IGF-1, IGF-2), fibroblast growth factor (FGF, e.g., FGF1-FGF22), platelet-derived growth factor (PDGF), or nerve growth factor (NGF) family. It will be understood that the aforementioned protein families include multiple members. In various embodiments, any such member may be used. In some embodiments, the growth factor promotes proliferation and / or differentiation of one or more hematopoietic cell types.For example, the growth factor can be CSF1 (macrophage colony stimulating factor), CSF2 (granulocyte macrophage colony stimulating factor, GM-CSF), or CSF3 (granulocyte colony stimulating factor, G-CSF). In some embodiments, the gene encodes erythropoietin (EPO). In some embodiments, the gene encodes a neurotrophic factor, i.e., a factor that promotes the survival, development, and / or function of neural lineage cells (a term used herein that includes neural progenitor cells, neurons, and glial cells, e.g., astrocytes, oligodendrocytes, microglia). For example, in some embodiments, the protein is a factor that promotes neurite outgrowth. In some embodiments, the protein is ciliary neurotrophic factor (CNTF) or brain-derived neurotrophic factor (BDNF).
[0115] In some embodiments, the gene of interest encodes a polypeptide that is a subunit of any protein that is composed of multiple subunits.
[0116] An enzyme can be any protein that catalyzes a reaction species that has been assigned an Enzyme Code (EC number) by the Commission on Nomenclature of the International Union of Biochemistry and Molecular Biology (NC-IUBMB). Enzymes include, for example, oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases. Examples include, for example, kinases (protein kinases, e.g., Ser / Thr kinases, Tyr kinases), lipid kinases (e.g., phosphatidylinositide 3-kinases (PI3-kinases or PI3K)), phosphatases, acetyltransferases, methyltransferases, deacetylases, demethylases, lipases, cytochrome P450, glucuronidases, and recombinases (e.g., Rag-1, Rag-2). Enzymes can be involved in the biosynthesis, modification, or degradation of nucleotides, nucleic acids, amino acids, proteins, neurotransmitters, xenobiotics (e.g., drugs), or other macromolecules.
[0117] Mammalian genomes encode at least about 500 different kinases. Kinases can be classified based on the nature of their common substrates, including protein kinases (i.e., kinases that transfer phosphate to one or more protein(s)), lipid kinases (i.e., kinases that transfer phosphate groups to one or more lipid(s)), nucleotide kinases, etc. Protein kinases (PKs) are of particular interest in certain aspects of the invention. PKs are often referred to as serine / threonine kinases (S / TKs) or tyrosine kinases (TKs) based on their substrate preferences. Serine / threonine kinases (EC 2.7.11.1) phosphorylate serine and / or threonine residues, whereas TKs (EC 2.7.10.1 and EC 2.7.10.2) phosphorylate tyrosine residues. Several "dual specificity" kinases (EC 2.7.12.1) are known that can phosphorylate both serine / threonine and tyrosine residues. The human protein kinase family can be further divided into the following groups based on sequence / structural similarity: (1) AGC kinases-include PKA, PKC, and PKG; (2) CaM kinases-include calcium / calmodulin-dependent protein kinases; (3) CK1-include casein kinase 1 group; (4) CMGC-include CDK, MAPK, GSK3, and CLK kinases; (5) STE-include homologues of yeast Sterile 7, Sterile 11, and Sterile 20 kinases; (6) TK-include tyrosine kinases; (7) TKL-include tyrosine-kinase-like group kinases. A further group called "atypical protein kinases" includes proteins that have no sequence homology with other groups but are known or predicted to have kinase activity and, in some cases, are predicted to have a structural fold similar to typical kinases.
[0118] Receptors include, for example, G protein-coupled receptors, tyrosine kinase receptors, serine / threonine kinase receptors, Toll-like receptors, nuclear receptors, immune cell surface receptors. In some embodiments, the receptor is a receptor for any of the hormones, cytokines, growth factors, or secreted proteins mentioned herein. Numerous G protein-coupled receptors (GPCRs) are known in the art. See, for example, Vroling B, GPCRDB: information system for G protein-coupled receptors. Nucleic Acids Res. 2011 Jan;39(Database issue):D309-19. Epub 2010 Nov 2. GPCRDB can be viewed online at gpcr.org / 7tm / . G protein-coupled receptors include, for example, adrenergic receptors, cannabinoid receptors, purinergic receptors, neuropeptide receptors, and olfactory receptors. Transcription factors (TFs), sometimes called sequence-specific DNA binding factors, bind to specific DNA sequences and (alone or in complexes with other proteins) regulate, e.g., activate or repress, transcription. Exemplary TFs are listed, for example, in the TRANSFAC® database, Gene Ontology (geneonlology.org / ), or DBD (transcriptionfactor.org) (Wilson, et al, DBD-taxonomically broad transcription factor predictions: new content and functionality Nucleic Acids Research 2008 doi:10.1093 / nar / gkm964). TFs can be classified based on the structure of their DNA-binding domain (DBD). For example, in certain embodiments, TFs are β-scaffolding factors with helix-loop-helix, helix-turn-helix, winged helix, leucine zipper, bZIP, zinc finger, homeodomain, or minor groove contact protein.Examples of transcription factors include p53, STAT3, PAS family transcription factors (eg, HIF family: HIF1A, HIF2A, HIF3A), and aryl hydrocarbon receptor.
[0119] Other methods of modifying or regulating the nucleic acid of a cell or a non-human mammal are described in PCT Application No. PCT / US2014 / 034387 and U.S. Application No. 14 / 785031, which are incorporated by reference in their entireties.
[0120] Those skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The details of the description and examples herein are representative and illustrative of certain embodiments and are not intended to limit the scope of the invention. Modifications and other uses of the invention will occur to those skilled in the art. Such modifications are encompassed within the spirit of the invention. It will be readily apparent to those skilled in the art that various substitutions and modifications can be made to the invention disclosed herein without departing from the scope and spirit of the invention.
[0121] As used herein and in the claims, the articles "a" and "an" should be understood to include plural referents unless specifically stated to the contrary. A claim or description containing "or" between one or more elements of a group is deemed to be satisfied when one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process, unless specifically stated to the contrary or otherwise clear from the context. The invention includes embodiments in which exactly one element of the group is present in, employed in, or otherwise relevant to a given product or process. The invention also includes embodiments in which more than one, or all elements of the group are present in, employed in, or otherwise relevant to a given product or process. Furthermore, the present invention should be understood to be capable of all variations, combinations, and substitutions of one or more limitations, elements, clauses, descriptive terms, etc. from one or more of the enumerated claims as presented in another claim that is dependent on the same base claim (or any other claim, if relevant), unless otherwise stated or unless it is obvious to one skilled in the art that an inconsistency or contradiction would result. All embodiments described herein are contemplated as applicable to all different aspects of the present invention, where appropriate. It is also contemplated that any of the embodiments or aspects can be freely combined with one or more other such embodiments or aspects, where appropriate. Where elements are presented as enumerations, such as in a Markush group or similar format, it should be understood that each subgroup of elements is also disclosed and that any element(s) can be excluded from the group. In general, when the invention or aspects of the invention are referred to as including certain elements, features, etc., it should be understood that the particular embodiment or aspect of the invention consists of, or consists essentially of, such elements, features, etc. For the sake of brevity, these embodiments are not specifically described in any significant number of words herein.It should also be understood that any embodiment or aspect of the invention may be explicitly excluded from the claims, regardless of whether a specific exclusion is recited herein. For example, any one or more of a nucleic acid, polypeptide, cell, species or type of organism, disorder, subject, or combination thereof may be excluded.
[0122] Where a claim or description is directed to a composition, e.g., a nucleic acid, a polypeptide, a cell, or a non-human transgenic animal, it should be understood that aspects of the invention include methods of making or using the composition according to any of the methods disclosed herein, and methods of using the composition for any of the purposes disclosed herein, unless otherwise indicated or it is clear to one of ordinary skill in the art that an inconsistency or contradiction would arise. Where a claim or description is directed to a method, it should be understood that aspects of the invention include, for example, methods of making compositions useful for carrying out the method, and products made according to the method, unless otherwise indicated or it is clear to one of ordinary skill in the art that an inconsistency or contradiction would arise.
[0123] When ranges are specified herein, the invention includes embodiments that include the endpoints, exclude both endpoints, and include one endpoint and exclude the other. Both endpoints should be assumed to be inclusive unless otherwise stated. Furthermore, unless otherwise stated or apparent from the context and the knowledge of one of ordinary skill in the art, values expressed as ranges should be understood to assume any particular value or subrange within the range specified in another embodiment of the invention, to the tenth of the unit of the lower limit of that range, unless otherwise clearly indicated from the context. Also, when a series of numerical values is specified herein, it is understood that the invention includes embodiments that are approximately related to the range defined by any intermediate value or any two values in the series, and embodiments in which the lower limit may be the minimum and the upper limit may be the maximum. As used herein, numerical values include values expressed as percentages. For any embodiment of the invention in which a numerical value is preceded by "about" or "approximately", the invention includes embodiments in which the exact value is recited. For any embodiment of the invention in which a numerical value is not preceded by "about" or "approximately", the invention includes embodiments in which the numerical value is preceded by "about" or "approximately". "Approximately" or "about" generally includes numbers that fall within 1% in either direction (greater or less than) a number, or in some embodiments, within 5% of a number, or in some embodiments, within 10% of a number, unless otherwise stated or clear from the context (unless such number unacceptably exceeds 100% of the acceptable value). Unless expressly stated to the contrary, in any method including multiple acts claimed herein, the order of the acts of the method is not necessarily limited to the order in which the acts of the method are recited, but it should be understood that the invention includes embodiments in which the order is so limited. It should also be understood that any product or composition described herein may be considered "isolated" unless otherwise stated or clear from the context.
[0124] Specific examples of these methods are described in the Examples. EXAMPLES
[0125] In this study, we demonstrate that fusion of dCas9 with Tet1 or Dnmt3a enzymatic domains allows targeted erasure or establishment of DNA methylation, respectively. As proof of principle, we first integrated two synthetic methylation reporters into mouse embryonic stem cells (mESCs) to induce modifications to DNA methylation. Utilizing dCas9-Tet1, we revisited long-standing questions in the field of DNA methylation. Our results show that targeted demethylation of BDNF promoter IV is sufficient to activate its expression in mouse cortical neurons, and targeted demethylation of the MyoD distal enhancer promotes the reprogramming of fibroblasts into myoblasts and promotes myotube formation. With dCas9-Dnmt3a, targeted methylation of CTCF binding sites can alter the expression of genes in proximal loops by blocking CTCF recruitment and increasing the frequency of interaction with sequestered super-enhancers in the target loop. Furthermore, lentiviral delivery of dCas9-Tet1 loaded with a targeting gRNA into mice enabled in vivo activation of a methylation reporter by demethylation of its promoter. Thus, dCas9-Tet1 and dCas9-Dnmt3a provide powerful tools for investigating the functional significance of DNA methylation in a locus-specific manner.
[0126] A modified CRISPR system for editing DNA methylation To achieve targeted editing of DNA methylation, dCas9 was fused with enzymes of the methylation / demethylation pathway (Figure 1A). Based on previous studies using a TALE system targeting specific CpGs (Bernstein et al., 2015; Maeder et al., 2013), we selected Tet1 and Dnmt3a as effectors in our system. Co-expression of sequence-specific guide RNA (gRNA) is expected to target dCas9-Tet1 or dCas9-Dnmt3a to specific loci and mediate modification of DNA methylation status without changing the DNA sequence. To optimize this chimeric CRISPR / dCas9-effector system, two types of dCas9-Tet1 lentiviral constructs with nuclear localization signals (NLS) at different positions were tested: dCas9-NLS-Tet1 and NLS-dCas9-NLS-Tet1 (Figures 8A and 8B). We also tested two gRNA lentiviral constructs: a widely used chimeric single guide RNA, called gRNA (Jinek et al., 2012), and a modified guide RNA, called E-gRNA, with enhanced ability to guide Cas9 to the intended genomic locus (Chen et al., 2013). Both gRNA constructs contain a puro selection cassette and a Cherry fluorescent protein cassette driven by an independent CMV promoter, allowing fluorescence-activated cell sorting (FACS) of gRNA-expressing cells after lentiviral transduction (Figure 8A). We characterized these constructs and showed robust gRNA-induced nuclear translocation in the dCas9-NLS-Tet1 construct (Figure 8C-8E). Therefore, we chose this construct for all studies to minimize nonspecific modifications of DNA. The two gRNAs behaved similarly (Figure 8C-8E) and were used interchangeably.
[0127] dCas9-Tet1 and dCas9-Dnmt3a enable targeted alteration of CpG methylation status To assess whether the dCas9-Tet1 and dCas9-Dnmt3a fusion constructs induce demethylation or de novo methylation of specific sequences, respectively, we utilized a methylation reporter system previously developed in our laboratory (Stelzer et al., 2015). This reporter system consists of a synthetic methylation-sensing promoter (a conserved sequence element derived from the promoter of an imprinted gene, Snrpn) that controls the expression of green fluorescent protein (GFP). Insertion of this reporter construct into a genomic locus was shown to accurately report the methylation status of adjacent sequences (Stelzer et al., 2015).
[0128] Demethylation of specific CpGs: To test whether a defined sequence can be demethylated, we introduced a dCas9-Tet1 construct combined with a gRNA targeting the Snrpn-GFP reporter inserted into the Dazl promoter (Figure 1B and Figure 9A). Dazl is a germ cell-specific gene that is hypermethylated and not active in ES cells, so it does not express the GFP reporter. To activate GFP expression by dCas9-Tet1, we designed four gRNAs targeting all 14 CpGs in the Snrpn promoter region. After 3 days of infection with a lentiviral vector co-expressing dCas9-Tet1 and four gRNAs, some infected positive cells that showed Cherry positive signals expressed from the gRNA constructs began to show GFP on (Figure 9B). To evaluate the activation efficiency by dCas9-Tet1 with the target gRNA added, we analyzed cells infected with both viruses using FACS. Of the Cherry-positive population, approximately 26% of cells activated GFP with the targeted gRNA, whereas only 1% of cells were GFP-positive with the scrambled gRNA (Figure 1C and Figure 9C). These Cherry-positive single cells were further cultured to form ES cell colonies. Cells using the targeted gRNA expressed GFP, but not with the scrambled gRNA (Figure 1D). To confirm that GFP activation in these cells was caused by demethylation of the Snrpn promoter, bisulfite sequencing of genomic DNA obtained from these samples was performed. As shown in Figure 1E-F, samples from cells using the targeted gRNA showed robust demethylation only at the Snrpn promoter region, but not at the adjacent Dazl locus. Moreover, samples from cells using the scrambled gRNA showed a methylation status similar to that of the uninfected (mock) control. The GFP-positive and GFP-negative populations among the infected Cherry-positive cells were further analyzed. As shown in Figure 9D, more robust demethylation was observed in the Snrpn promoter region in double-positive cells (Cherry+;GFP+). These results support that dCas9-Tet1 with gRNA can target DNA methylation deletion in proliferating cells.
[0129] De novo methylation of specific CpGs: To evaluate whether the dCas9-Dnmt3a fusion protein allows de novo methylation of promoter sequences and silencing of gene expression, we used cells carrying the Snrpn-GFP reporter in the Gapdh promoter. These cells are GFP positive because Gapdh is not methylated and is expressed in ES cells (Stelzer et al., 2015). Gapdh-Snrpn-GFP ESCs were infected with lentivirus expressing dCas9-Dnmt3a and gRNA targeting the Snrpn promoter or scrambled gRNA (Figure 2A and Figure 9E), followed by FACS analysis. Of the infected (Cherry positive) population, approximately 12% of cells in the targeted gRNA inactivated GFP, whereas only 2% of cells were GFP negative with the scrambled gRNA (Figure 2B and Figure 9F). When Cherry-positive cells were grown in culture, GFP expression in cells with targeted gRNA remained off, whereas cells with scrambled gRNA and mock controls remained GFP positive (Figure 2C). Furthermore, bisulfite sequencing showed that transduction of dCas9-Dnmt3a / gRNA led to a significant increase in DNA methylation in the Snrpn promoter region, but not in the adjacent Gapdh region (Figures 2D-2E). Further analysis of GFP-positive and GFP-negative populations of infected Cherry-positive cells showed more robust methylation of the Snrpn promoter region in Cherry+;GFP- cells (Figure 9G). To overcome the potential limitations caused by the low co-transduction efficiency of both dCas9-Dnmt3a and gRNA lentiviruses, a doxycycline-inducible dCas9-Dnmt3a expression cassette was integrated into the Gapdh-Snrpn-GFP mES cell line by using the PiggyBac transposon system (Figure 9H). FACS analysis after delivery of the same group's targeting gRNA showed that the GFP inactivation efficiency increased to 25% (Figure 2F and Figure 9I). Sorted Cherry-positive cells showed loss of GFP expression upon doxycycline treatment (Figure 2G), and methylation at the Snrpn promoter region was robust (Figure 2H).We also generated a new construct, dCas9-Dnmt3a-P2A-BFP, that allows the isolation of dCas9-Dnmt3a-expressing cells by FACS. After lentiviral delivery of this construct together with gRNA, a GFP inactivation efficiency of approximately 70% was achieved in FACS-sorted double-positive cells (BFP+; Cherry+) (Figure 9J).
[0130] In summary, our results show that when targeted by specific guide RNAs, the above dCas9 fusion constructs efficiently demethylate methylated sequences (dCas9-Tet1) or de novo methylate unmethylated sequences (dCas9-Dnmt3a) in dividing cells.
[0131] Comparison of dCas9-based and TALE-based methylation editing To compare the efficacy and scope of methylation editing by dCas9-Tet1 / Dnmt3a with the TALE-based method, we selected two loci previously reported to be edited by the TALE-based method (Bernstein et al., 2015; Maeder et al., 2013) and designed a single gRNA to target dCas9-Tet1 / Dnmt3 to the same site as the binding site of TALE-Tet1 / Dnmt3a. As shown in Figure 10A and Figure 10C, dCas9-Dnmt3a with one single gRNA targeting the p16 locus induced an average 25% increase in methylation within a 320 bp region of the p16 promoter, whereas TALE-Dnmt3a induced only a 13% increase within a 650 bp region. Similarly, dCas9-Tet1 with one single gRNA targeting the RHOXF2 locus induced an average 28% reduction in methylation within a 150 bp region of the RHOXF2 promoter, whereas TALE-Tet1 induced only a 14% reduction within a 200 bp region (Figure 10B-C). These results suggest that the dCas9-Tet1 / Dnmt3a system has higher efficacy and resolution for methylation editing than the TALE-based method.
[0132] To assess the specificity of dCas9-Tet1 / Dnmt3a-mediated methylation editing, we performed ChIP-seq assays of dCas9 and identified 9 binding sites in the presence of gRNAs targeting the Dazl-Snrpn region described in Figure 9A and 18 binding sites in the presence of gRNAs targeting the CTCF binding site adjacent to the miR290 locus (see Figure 13A below). Figure 10D shows that among the binding sites identified for each group of gRNAs, the target locus (Dazl-Snrpn or miR290) showed the highest level of binding to dCas9-Dnmt3a (Table S1). The second and third strongest binding sites for each target locus are shown in Figure 10E. Moreover, bisulfite sequencing analysis of these loci showed only slight changes in methylation levels (Figure 10F-10G), likely due to the significantly lower binding affinity of dCas9-Dnmt3a / Tet1 at these off-target loci compared to the target loci. These results indicate that dCas9-based epigenetic editing can be highly specific.
[0133] Targeted demethylation of BDNF promoter IV activates BDNF in neurons It has been proposed that DNA replication-independent active demethylation acts in postmitotic neurons (Guo et al., 2011; Martinowich et al., 2003). To test whether active demethylation can be induced in postmitotic neurons, the dCas9-Tet1 system was applied to test the regulation of BDNF gene. BDNF expression can be induced by neural activity accompanied by demethylation of its promoter IV (Chen et al., 2003; Martinowich et al., 2003). We designed four gRNAs targeting 11 CpGs of BDNF promoter IV (Figure 11A) and determined whether dCas9-Tet1 can activate BDNF by inducing demethylation of this promoter (Figure 3A). Following well-established experimental procedures for generating primary neuronal cultures (Ebert et al., 2013), mouse cortical neurons were isolated from E17.5 embryos and cultured in vitro for 2 days (DIV2). As shown in Figure 11B and Figure 11D, KCl treatment induced BDNF expression in these neurons without detectable cell proliferation. Neurons at day 3 of culture (DIV3) were infected with lentiviral vectors expressing dCas9-Tet1 (with or without the four gRNAs) with nearly 100% transduction efficiency (Figure 11E). 48 hours after infection, a portion of the culture was treated with KCl to induce neuronal activity. As shown in Figure 3B-C, dCas9-Tet1 / gRNA induced BDNF expression approximately 6-fold, whereas in the absence of gRNA, dCas9-Tet1 showed only a slight induction (less than 2-fold) and the catalytically-quiescent form of Tet1 (dC-dT) showed no induction. Importantly, the same group of dCas9-Tet1 / gRNA did not induce expression of Npas4, another neuronal activity-inducible gene (Lin et al., 2008) (Figure S11F). Co-transduction of dCas9-Tet1 with each individual gRNA targeting the BDNF promoter IV showed a 2- to 3-fold induction of BDNF (Figure S11G). Bisulfite sequencing was performed to examine the methylation status of the BDNF promoter IV.As shown in Figures 3D-E, dCas9-Tet1 / gRNA significantly reduced methylation in this region in contrast to the gRNA negative control, whereas KCl treatment also induced demethylation of CpGs at positions -148, -66, and 19 (relative to the transcription start site).
[0134] Our results demonstrate that demethylation of BDNF promoter IV can be induced by dCas9-Tet1 / gRNA and is sufficient to activate BDNF expression. Because postmitotic neurons were used for these experiments, the loss of methylation was likely due to active demethylation. To further support this conclusion, we examined the 5-hmC levels of BDNF promoter IV over the time course of the dCas9-Tet1-induced demethylation process by Tet-assisted bisulfite sequencing (TAB-seq) analysis. As shown in Figure 11H, 5-hmC was detected 40 hours after infection with dCas9-Tet1 and gRNA lentivirus and decreased 60 hours later. Similarly, 5-hmC was also detected after KCl treatment (Figure 11I). Because bisulfite sequencing does not distinguish between unmethylated 5-cytosine (5-C) and 5-formylcytosine / 5-carboxylcytosine (5-fC / 5-caC) generated from 5-hmC, some CpGs may have been modified with 5-fC / 5-caC after targeting with dCas9-Tet1 / gRNA. However, inhibition of the base excision repair pathway by treatment with ABT-888 (an inhibitor of PARP) reduced BDNF activation by KCl treatment (Figure S11J), suggesting that demethylation of BDNF promoter IV contributes to BDNF activation.
[0135] To test whether endogenous Tet activity is required to control BDNF expression upon neuronal activity stimulation, we treated DIV3 neurons with 2-hydroxyglutarate, a competitive inhibitor of α-ketoglutarate-dependent dioxygenases including the Tet enzyme (Xu et al., 2011). As shown in Figure S11K, pharmacological inhibition of Tet enzyme activity completely abolished the induction of BDNF expression by KCl treatment. Furthermore, mouse primary cortical neurons carrying a Tet1 null mutant showed a significant attenuation of the activation kinetics of BDNF (Figure S11L), supporting the role of endogenous Tet in the induction of neuronal activity.
[0136] Targeted demethylation of the MyoD distal enhancer promotes myogenic reprogramming of fibroblasts The role of MyoD as a master regulator in muscle development was first revealed by the observation that demethylation of DNA in fibroblasts by 5-aza (5-aza-2'-deoxycytidine) treatment leads to activation of MyoD and subsequent myoblast conversion and myotube formation (Constantinides et al., 1977; Davis et al., 1987; Lassar et al., 1986). As shown in Figure 4A, six muscle-specific DMRs have been described within the 50 kb upstream region of the MyoD gene (Schultz et al., 2015), with DMR-5 overlapping with a known distal enhancer of MyoD (Brunk et al., 1996). To test whether demethylation of DMR-5 activates MyoD in fibroblasts, we designed four gRNAs targeting this DMR (Figure S12A). Co-expression of dCas9-Tet1 with these gRNAs in C3H10T1 / 2 cells, a subclone from mouse embryonic fibroblasts previously used for 5-Aza-mediated activation of MyoD (Constantinides et al., 1977), resulted in a moderate (3-fold) induction of MyoD expression as shown in Figure 4B. Combination of dCas9-Tet1 / MyoD DMR-5 gRNA with 5-Aza treatment resulted in a high induction of MyoD as shown in Figure S12F. Bisulfite sequencing showed a substantial reduction in methylation in the DMR-5 region of sorted infection-positive cells transduced with dCas9-Tet1 and target gRNA lentiviruses, but not with catalytically-quiescent Tet1 (dC-dT) or scrambled gRNA (Figure 4C-D). To examine whether demethylation of the MyoD distal enhancer region could reprogram fibroblasts into muscle cells, C3H10T1 / 2 cells were infected with lentivirus expressing dCas9-Tet1 and gRNA. Cells were cultured for 14 days and analyzed for expression of MyoD and MHC (myosin heavy chain, a myotube-specific marker). As shown in Figure 4E-F, co-expression of dCas9-Tet1 with gRNA targeting DMR-5 induced moderate expression levels of MyoD, but was insufficient to induce myotube formation without 5-aza treatment.
[0137] We next investigated whether DMR-5-targeted demethylation synergized with 5-Aza treatment for inducing myotube formation (Figure 12B). To follow the course of myotube formation after 5-Aza treatment, a time-course experiment was performed. Heterogeneous-sized multinucleated myotubes (MHC positive) began to form 14 days after treatment, and both the MyoD positive cell ratio and myotube density and size increased thereafter until day 25 (Figure 12C-E). Co-expression of dCas9-Tet1 with gRNA targeting MyoD DMR-5 promoted myotube formation 14 days after treatment compared to cells expressing dCas9-Tet1 alone or dC-dT with MyoD DMR-5 gRNA, as evidenced by significantly more mature multinucleated MHC+ clusters (>2 nuclei per MHC+ cluster) (Figure 4E, Figure 4G-H). Similar observations were made when cells were analyzed at later time points (16 days) after treatment (Figures 12G-12J). Our results suggest that demethylation of the MyoD distal enhancer by dCas9-Tet1 / gRNA synergizes with 5-Aza to substantially promote myoblast conversion and myotube formation in C3H10T1 / 2 cells.
[0138] Targeted de novo methylation of CTCF binding sites alters CTCF-mediated chromatin loops CTCF is a highly conserved zinc finger protein that plays a major role in the overall organization of chromatin structure (Phillips and Corces, 2009). Transcriptional enhancers usually interact with their target genes through the formation of DNA loops (Gibcus and Dekker, 2013; Gorkin et al., 2014; Kagey et al., 2010). DNA loops are usually constrained within larger CTCF-mediated loops called insulated neighborhoods (Dowen et al., 2014; Ji et al., 2016; Phillips-Cremins et al., 2013), which can form clusters of loops that contribute to topologically associating domains (TADs) (Dixon et al., 2012; Nora et al., 2012). Loss of the CTCF loop anchor site in the isolation region may allow the enhancer to inappropriately interact with genes located outside the loop, resulting in increased expression of the external genes (Dowen et al. ( et al., 2014). Interestingly, methylation of the DNA recognition site of CTCF has been reported to block CTCF binding (Bell and Felsenfeld, 2000; Wang et al., 2012). To test whether methylation of specific CTCF sites can alter CTCF-mediated chromatin looping, the dCas9-Dnmt3a system was applied to the target CTCF anchor site (Figure 5A). We designed specific gRNAs (Figure 13) to target dCas9-Dnmt3a to two CTCF sites and examined whether de novo methylation interferes with the looping function of CTCF (Figure 5B and Figure 5F). Doxycycline-inducible dCas9-Dnmt3a mES cells (Figure 9H) were infected with lentivirus expressing gRNA, and transduced cells were sorted by FACS for further analysis.
[0139] Targeting dCas9-Dnmt3a to a CTCF binding site adjacent to the miR290 loop harboring the super-enhancer (Figure 5B) induced de novo methylation of CpGs at this site (Figure 5D-E). Gene expression analysis of transduced cells showed a significant increase in the Nlrp12 gene, which is outside the quarantine zone containing this super-enhancer and next to the targeted CTCF site, but did not affect expression of genes located inside the miR290 loop or in other adjacent loops, including AU01801 and Myadm (Figure 5C). Similarly, targeting of dCas9-Dnmt3a to CTCF binding sites adjacent to another super-enhancer-harboring Pou5f1 gene loop (Figure 5F) induced methylation of CpGs at the CTCF binding sequence (Figure 5H-I) and increased expression of H2Q10 located in the adjacent loop and next to the targeted CTCF site, but did not affect expression of the Pou5f1 gene itself or the Tcf19 gene in the other adjacent loop (Figure 5G). For both targeted CTCF sites, catalytically inactive Dnmt3a forms (dC-dD) did not induce changes in methylation levels or gene expression, as did dC-D (Figure 5C-E and Figure 5G-I). These observations are consistent with results obtained when these CTCF sites are deleted (Dowen et al., 2014) and support the notion that methylation of CTCF binding sites disrupts their insulator function.
[0140] To test whether methylation targeting CTCF binding sites increases the interaction frequency between isolated super-enhancers and activated genes, we performed Chromosome Conformation Capture (3C) assays at these loci. As shown in Figure 6A, the interaction frequency between the super-enhancer in the miR290 loop and the newly activated gene (Nlrp12) in the neighboring loop was significantly increased, whereas the interaction between Nlrp12 and the Myadm gene remained the same, indicating that the conformation of this target CTCF loop is open. To confirm that the increase in interaction frequency was due to blocking of the anchor of CTCF, we performed CTCF ChIP assays. Binding of CTCF to the target genomic site was significantly reduced in samples with miR290-targeting gRNA compared to samples with scrambled gRNA, gRNA targeting other CTCF binding sites, or catalytically inactive dC-dD appended with miR290-targeting gRNA (Figure 6B), supporting the view that DNA methylation blocks the anchor of CTCF, thereby altering the conformation of the CTCF loop. We performed a similar set of experiments for a second CTCF loop (the Pou5f1 loop) and demonstrated an increase in the frequency of interactions between the isolated super-enhancer and the newly activated gene (H2Q10) and a decrease in CTCF binding following targeted methylation of the CTCF binding site (Figure 6C-D).
[0141] In summary, our results demonstrate that the dCas9-Dnmt3a system can be used to alter the methylation status of specific CTCF anchor sites, thereby disrupting CTCF looping function.
[0142] In vivo demethylation of endogenous loci for gene activation by dCas9-Tet1 To test whether dCas9-mediated DNA methylation editing tools could be used to alter methylation in vivo, we took advantage of previously generated methylation-sensitive reporter mice (Figure 7A; ref: Stelzer et al., Parent-of-origin DNA methylation dynamics during mouse development, Developmental Cell, under review by the editors). In these transgenic mice, we inserted a methylation-sensitive Snrpn-GFP cassette into the Dlk1-Dio3 locus to report the methylation status of its intergenic methylation variable region (IG-DMR). The IG-DMR of this locus acquires paternal methylation during spermatogenesis, and thus the GFP reporter (IG-DMR GF / Pat ) is constitutively repressed in mice heterozygous for the paternal Snrpn-GFP allele (see reference Stelzer et al., Parent-of-origin DNA methylation dynamics during mouse development, Developmental Cell, under review by the editors). As shown above, the GFP reporter at the Dazl locus was activated in mES cells by demethylation of the targeted promoter (Figure 1). To assess whether the Dlk1-Dio3 locus GFP reporter could be activated by dCas9-Tet1 in differentiated cells, we used the IG-DMR GFP / Pat Adult mouse skin fibroblasts were obtained from the tails of transgenic mice and further transduced with lentiviruses expressing dCas9-Tet1 and Snrpn-targeting gRNA or scrambled gRNA, or with lentiviruses expressing catalytically-quiescent forms of Tet1 (dC-dT) and Snrpn-targeting gRNA (Figure 7A). Results in Figures 7B-C show that approximately 80% of Cherry (gRNA)-positive fibroblasts show GFP reporter activation only when transduced with both dCas9-Tet1 and Snrpn gRNA lentiviruses. Further FACS analysis of the cells supported this view (Figures 14A-C).
[0143] To investigate whether DNA methylation status could be modified in vivo, we used IG-DMR GFP / Pat Three ventral epidermal sites of transgenic mice were infected with dCas9-Tet1 and Snrpn gRNA (Figure S14D). Cells were infected at low density, and Cherry expression was observed only in some hair follicles. dCas9-Tet1 and Snrpn gRNA were able to activate GFP reporter expression in vivo in approximately 85% of infected skin dermal cells, whereas dCas9-Tet1 and scrambled gRNA or dC-dT and Snrpn gRNA could not (Figure S7H, Figure S14E-F). In addition, using a stereotaxic apparatus, we were able to detect IG-DMR GFP / Pat The brains of transgenic mice were infected with lentiviral vectors, and the effects on targeted DNA methylation in brain sections were analyzed by confocal microscopy. To exclude possible inter-individual variability, lentiviral vectors expressing dCas9-Tet1 and Snrpn gRNAs, as well as a combination of two negative control vectors, were injected into different regions of the same brain (Figure 7D). As shown in Figure 7E-F, after infection with all three lentiviral combinations, as indicated by Cherry expression, only the lentiviral vector expressing dCas9-Tet1 and Snrpn gRNAs activated the GFP reporter with an activation efficiency of approximately 70%, but not the vectors expressing dCas9-Tet1 and sc gRNAs or dC-dT and Snrpn gRNAs (Figure 7G).
[0144] Consideration In this study, we repurposed the CRISPR / Cas9 system to edit the methylation status of genomic sequences. We fused a catalytically inactive Cas9 protein (dCas9) to either the catalytic domain of Tet1 (dCas9-Tet1) or the catalytic domain of Dnmt3a (dCas9-Dnmt3a) and predictably altered the epigenetic status of the target sequence. Targeting with dCas9-Tet1 demethylated and activated a GFP reporter inserted into the promoter region of the methylated and silenced Dazl gene, whereas targeting with dCas9-Dnmt3a de novo methylated and silenced a GFP reporter inserted into the promoter region of the active, unmethylated Gapdh gene. When dCas9-Tet1 targeted the inactive BDNF promoter IV in postmitotic neurons, the promoter was demethylated and activated. Importantly, this tool predictably altered the methylation status and activity of the control region. Targeted demethylation of the inactive distal enhancer of MyoD activated the MyoD gene and promoted muscle differentiation, and targeted methylation of the CTCF anchor site inhibited CTCF binding and prevented its function as an insulator between chromatin loops. Finally, this editing tool could alter the methylation status of regulatory sequences in vivo, as injection of lentiviral vectors of dCas9-Tet1 and a target gRNA into the dermis or brain of transgenic mice demethylated the methylated Snrpn promoter of the Dlk1-Dio3 imprinted locus and activated a methylation-sensitive GFP reporter.
[0145] Dynamic DNA methylation has been proposed to decode neural activity (Sweatt, 2013). For example, treatment of neurons with KCl has been shown to desilence promoter IV of BDNF and induce BDNF expression associated with demethylation of some of the methylated CpGs in the promoter region (Chen et al., 2003; Martinowich et al., 2003). When BDNF promoter IV was targeted by dCas9-Tet1, extensive demethylation of methylated CpGs was observed, activating BDNF to the same extent as when cultures were treated with KCl. Because neurons are postmitotic, dCas9-Tet1-mediated demethylation of promoter sequences is likely the result of active demethylation as previously proposed (Wu and Zhang, 2014). After targeting with dCas9-Tet1 / gRNA, some CpGs in the BDNF promoter can be modified with 5-fC / 5-caC, but inhibiting the BER pathway to prevent the repair of 5-fC / 5-caC to unmethylated cytosines reduced BDNF expression. This suggested that demethylation of BDNF promoter IV contributes to BDNF activation. Importantly, our results establish a causal relationship between demethylation of BDNF promoter IV and gene activation.
[0146] The role of DNA methylation as a barrier between cell lineages is consistent with previous observations that demethylation of DNA in fibroblasts by treatment with 5-Aza can activate MyoD and mediate myotube formation (Constantinides et al., 1977; Davis et al., 1987; Lassar et al., 1986). Targeting dCas9-Tet1 to the methylation distal enhancer of MyoD in fibroblasts induced CpG demethylation and resulted in moderate activation of MyoD but failed to form myoblasts. However, when dCas9-Tet1 / gRNA lentiviral transduction was combined with 5-Aza treatment, a significant enhancement of myoblast and myotube formation was observed compared to 5-Aza treatment alone. Additionally, additional DMRs upstream of MyoD have been identified ( Schultz et al., 2015 ), and it is conceivable that demethylation of these sites, in combination with the distal enhancer, may be required for efficient induction of fibroblast-to-myoblast conversion.
[0147] Recent studies of mammalian chromosome structure have revealed that chromatin is composed of topologically associated domains and gene loops mediated by chromatin structural proteins such as cohesin and CTCF (Ji et al., 2016; Seitan et al. al., 2013; Sofueva et al., 2013; Tang et al., 2015; Zuin et al., 2014). Emerging data suggest that higher-order chromatin structure provides epigenetic information during development and is frequently altered in cancer (Flavahan et al., 2016; Ji et al., 2016; Narendra et al., 2015). It has been reported that methylation of the recognition sequence of CTCF inhibits CTCF binding (Bell and Felsenfeld, 2000; Kang et al., 2015; Wang et al., 2012). Targeting dCas9-Dnmt3a to two CTCF binding sites induced de novo methylation of CpGs at the CTCF binding sites, disrupting the insulator function of the protein as evidenced by increased interaction frequency between isolated super-enhancers in the targeted loop and genes in the adjacent loop, leading to upregulation of genes in the adjacent loop, suggesting that the dCas9-Dnmt3a system is a useful tool to manipulate chromatin structure and assess its functional significance in developmental and disease contexts.
[0148] Our results show that dCas9 fused with the epigenetic effectors Tet1 and Dnmt3a is a powerful toolbox for editing DNA methylation at specific genomic sequences. These tools have higher efficacy and resolution for methylation editing compared to TALE-based methods, and ChIP-seq of dCas9 followed by bisulfite sequencing of potential off-target binding loci revealed subtle changes in methylation levels, suggesting that a high degree of specificity can be achieved with appropriately designed gRNAs. These dCas9-Dnmt3a / Tet1 tools will be useful to gain insight into the functional significance of DNA methylation in diverse biological processes such as gene expression, cell fate determination, and organization of higher-order chromatin structure.
[0149] Experimental procedure Plasmid design and construction PCR amplified Tet1 catalytic domain from pJFA344C7 (Addgene plasmid: 49236), Tet1 inactive catalytic domain from MLM3739 (Addgene plasmid: 49959), or Dnmt3a from pcDNA3-hDNMT3A (Addgene plasmid: 35521) were cloned into modified pdCas9 plasmid (Addgene plasmid: 44246) with BamHI and EcoRI sites. dCas9-NLS-Tet1 or dCas9-NLS-Dnmt3a were then PCR amplified and cloned into FUW vector (Addgene plasmid: 14882) with AscI and EcoRI to package lentivirus. NLS-dCas9-NLS-Tet1 was cloned by inserting the annealed oligo (NLS) into FUW-dCas9-NLS-Tet1 with XbaI and AscI. The gRNA expression plasmids were cloned by inserting the annealed oligos into pgRNA plasmid (Addgene plasmid: 44248) with AarI site. PiggyBac-dCas9-Tet1 and PiggyBac-dCas9-Dnmt3a were cloned by ligating dCas9-NLS-Tet1 or dCas9-NLS-Dnmt3a PCR amplified from the FUW construct with modified PiggyBac transposon vector (Wilson et al., 2007) with NheI and EcoRI. All constructs were sequenced before transfection. Primer information for gRNA design and construction is listed in Supplementary Table S2. The related plasmids have been deposited in the Addgene plasmid database. The TALE-Dnmt3a construct targeting the p16 locus was a gift from Dr. Klaus Kaestner, and the TALE-Tet1 targeting the RHOXF2 locus was from Addgene (plasmid #49943). The full-length protein sequences of dCas9-Dnmt3a and dCas9-Tet1CD and their mutants are listed in Supplementary Table S6.
[0150] Cell culture, lentivirus production, and generation of stable cell lines Mouse embryonic stem cells (mESCs) were cultured on irradiated mouse embryonic fibroblasts (MEFs) using standard ESC medium. Standard medium was DMEM (500 ml) supplemented with 10% FBS (Hyclone), 10ug recombinant leukemia inhibitory factor (LIF), 0.1 mM β-mercaptoethanol (Sigma-Aldrich), penicillin / streptomycin, 1 mM L-glutamine, and 1% non-essential amino acids (all from Invitrogen). C3H10T1 / 2 cells were cultured in standard DEME medium with 10% FBS. Lentiviruses expressing dCas9-Tet1, dCas9-Dnmt3a, and gRNA were generated by transfecting HEK293T cells with FUW or pgRNA constructs together with standard packaging vectors (pCMV-dR8.74 and pCMV-VSVG) followed by concentration by ultracentrifugation. Viral titers (T) were calculated based on the infection efficiency in 293T cells as T = (P*N) / (V), where T = titer (TU / ul), P = % of cells infected positive by fluorescent marker, N = number of cells at transduction, and V = total amount of virus used. TU is an abbreviation for transduction unit. To generate stable cell lines with doxycycline-inducible dCas9-Tet1 or dCas9-Dnmt3a transgenes, PiggyBac-dCas9-Tet1 or PiggyBac-dCas9-Dnmt3a constructs, together with a helper plasmid expressing the transposase, were transfected into C3H10T1 / 2 cells using X-tremeGENE 9 transfection reagent (Roche) or into mESC cells using Xfect transfection reagent (Clontech) according to the supplier's protocol. Stably transfected cells were selected by treatment with G418 (400ug / ml) for 10 days. GFP / PATThe IG-DMR-Snrpn-GFP methylation reporter was obtained from the tail of a reporter mouse. Briefly, mouse tails of approximately 2 cm length were obtained from 3-month-old mice carrying a paternally inherited IG-DMR-Snrpn-GFP methylation reporter and sterilized with 70% EtOH. Tail pieces cut into approximately 2 mm x 2 mm pieces were digested with 5 ml of 1 mg / ml collagenase IV in a 15 ml Falcon tube at 37°C for 90 minutes. Digestion was stopped by adding 5 ml of MEF medium to the tube. Dissociated cells were pushed through a 40 um cell strainer while gently triturating using a syringe plug. Cells were then harvested, cultured, and infected with viruses. Cells were analyzed in this study on day 3 post-infection.
[0151] Mouse strains and reproductive strategies Tet1 mutant mice were previously generated in our laboratory (Dawlaty et al. (E. et al., 2011). The Tet1 KO mice in this study were a continuation of the mixed 129 and C57BL / 6 background mice. To obtain Tet1 KO mice, male and female mice heterozygous for Tet1 were crossed. To obtain primary cortical neurons of wild-type mice, male and female C57BL / 6 mice were crossed. GFP / Pat Methylation reporter mouse lines were generated as described (reference: Stelzer et al., Parent-of-origin DNA methylation dynamics during mouse development, Developmental Cell, under editorial review). GFP / Pat Male mice carrying the reporter allele were bred with C57BL / 6 females to generate adult offspring carrying the paternally inherited allele and to analyze DNA methylation editing in vivo. Mice were handled according to institutional guidelines and maintained at the Massachusetts Institute of Technology (MIT). It has been approved by the Committee on Animal Care (CAC) and the Department of Comparative Medicine (DCM) of the United Nations.
[0152] Virus infection of mice and preparation of tissue samples Mice were infected with the appropriate lentivirus cocktail according to institutional guidelines and approved by the Committee on Animal Care (CAC) and Department of Comparative Medicine (DCM) of the Massachusetts Institute of Technology. Specifically, lentiviruses expressing dCas9-Tet1 and sc gRNA, lentiviruses expressing an inactive mutant of dC-dT and a target gRNA, and lentiviruses expressing dCas9-Tet1 and a target gRNA were injected into the paternal IG-DMR chromosome by Hamilton syringe to infect the skin of mice. GFP Deeply anesthetized mice carrying the reporter allele were delivered to multiple dermal sites on the ventral side (Figure 14D). To infect the mouse brain, the various lentivirus mixtures were delivered to the paternal IG-DMR foci using a stereotaxic instrument (Leica BIOSYSTEMS, BenchMark Digital Stereotaxic with Manual Fine Drive). GFP / PatDeeply anesthetized mice were delivered to the following locations (relative to the Franklin and Paxinos mouse brain atlas) carrying reporter alleles (Figure 7D): dCas9-Tet1 with sc gRNA (AP 0.70mm, ML 1.50mm, DV 1.50mm), inactive mutant of dC-dT with Snrpn gRNA (AP -1.90mm, ML -1.50mm, DV 1.50mm), and dCas9-Tet1 with Snrpn gRNA (AP -1.90mm, ML 1.50mm, DV 1.50mm). The titers of dC-T / dC-dT and gRNA lentiviruses are 1.2×104 TU / ul and 1.2×105 TU / ul, respectively. Mice were sacrificed 3 days after infection. Animals were fixed by transcardial perfusion with 4% paraformaldehyde (PFA) / PBS. Fixed skin pads and brain samples were dissected and post-fixed in 4% paraformaldehyde (PFA) / PBS overnight at 4°C. Brain samples were sectioned at 150um thickness on a vibratome (Leica VT1100) and skin samples were sectioned at 10um thickness on a cryostat (Leica) prior to immunohistochemistry analysis. For vibratome sectioning, tissues were embedded in 3% agarose gel. For frozen sectioning, tissues were equilibrated in 30% sucrose / PBS before embedding in optimal cutting temperature (OCT) compound.
[0153] Immunohistochemistry, microscopy, and image analysis Neurons, HEK293T cells, mouse ES cells, and C3H10T1 / 2 cells were fixed with 4% paraformaldehyde (PFA) for 10 min at room temperature. Cells were permeabilized with PBST (1x PBS solution with 0.1% Triton X-100) and then blocked with 10% normal donkey serum (NDS) in PBST. Cells were then incubated with primary antibodies appropriately diluted in PBST with 5% NDS for 1 h at room temperature or 12 h at 4°C, washed three times with PBST at room temperature, and then incubated with the desired secondary antibodies in TBST with 5% NDS and DAPI to counterstain nuclei. Cells were washed three times with PBST and then mounted on slides with Fluoromount G (SouthernBiotech). The immunostaining procedure for tissue sections was previously described (Wu et al., 2014a). Briefly, sections were permeabilized with PBST (1x PBS solution with 0.5% Triton X-100) for 1 hour at room temperature, then blocked with 10% normal donkey serum (NDS) in PBST. Sections were then incubated with the desired primary antibody in PBST with 5% NDS for 24 hours at 4°C, washed three times with PBST at room temperature, and then incubated with secondary antibody in TBST with 5% NDS and DAPI to counterstain nuclei. Sections were washed three times with PBST before being mounted on slides. The following antibodies were used in this study: chicken anti-GFP (1:1000, Aves Labs), mouse anti-Cas9 (7A9, 1:1000, EMD Millipore), rabbit anti-BDNF (1:1000, Thermo Fisher), chicken anti-MAP2 (1:1000, Sigma Aldrich), mouse anti-Tuj1 (1:1000, R&D system), rabbit anti-MyoD (C-20, 1:1000, Santa Cruz Biotechnology), mouse anti-MHC (MF20, 1:1000, Fisher Scientific), and mouse anti-MyoG (F5G, 1:1000, Life Technologies). Images were acquired with a Zeiss LSM710 confocal microscope and processed with Zen software, ImageJ / Fiji, and Adobe Photoshop.For imaging-based quantification, 3–5 representative images were quantified unless otherwise specified, and data were plotted as mean ± SD using Excel or Graphpad.
[0154] FACS analysis To assess the percentage of GFP- and / or Cherry-positive cells after treatment, treated cells were dissociated with trypsin, single-cell suspensions were prepared in growth medium, and run on a BD FACSAria cell sorter at the Whitehead Institute Flow Cytometry Core according to the manufacturer's protocol. Data were analyzed with FlowJo software.
[0155] Mouse primary cortical neuron cultures, EdU labeling, and neural induction Dissociated E17.5 cortical neuronal cultures were generated from wild-type or Tet1 KO mouse embryos as previously described (Ebert et al., 2013). Briefly, E17.5 cortices were dissociated in ice-cold 1x HBSS (Gibco 14185-052) containing 1x pen / strep (Gibco: 15140122), 1x pyruvate (Gibco: 11360070) and 30 mM glucose. Tissues were sectioned to approximately 1 mm3 and dissociated with a papain neural tissue dissociation system (Worthington Biochemicals) according to the manufacturer's instructions. Cells were resuspended in NM5 medium (5% FBS (Hyclone), 2% B27 supplement (Gibco 17504044), 1x pen / strep, and 1x glutamax I (Gibco 35050-061)). 1 × 10 cells per well of a 6-well plate coated with poly-D-lysine (PDL, Sigma) 6Cells were seeded on 100 wells. At DIV2, cells were treated with 2.5uM AraC (Sigma C-6645) overnight to eliminate excessive cell division of mitotic astrocytes and neural progenitors. At DIV3, cultures were fed with fresh NM5 medium followed by membrane depolarization with 50mM KCl or infection with the preferred lentivirus. As treatments were started from the very beginning of in vitro culture, the AP5 and TTX (tetrodotoxin) treatment steps, which silence basal activity in cultures, were omitted before KCl treatment. For EDU labeling, primary neuronal cultures were treated with EDU at a final concentration of 10uM for 24 hours, followed by the Click-it EDU labeling procedure according to the manufacturer's instructions (Thermo Fisher Scientific). Cells were fixed for immunohistochemistry analysis, lysed with Trizol to extract total RNA and perform RT-qPCR, or lysed to extract DNA and perform bisulfite sequencing analysis.
[0156] Fibroblast-to-myoblast conversion assay The myoblast conversion assay has been described previously (Constantinides et al. Briefly, C3H10T1 / 2 mouse embryonic fibroblast cells were plated in 6-well plates at 1 × 10 cells per well. 4 After seeding, cells were infected with lentivirus expressing dCas9-Tet1 and target gRNA. 24 hours after infection, cells were treated with vehicle control (HEPES buffer) or 5-azacytidine (1 uM) for 24 hours, harvested at different time points, and then analyzed. The DMR upstream of the mouse MyoD gene was defined based on human / mouse genome homology (Schultz et al., 2015).
[0157] Western blot The various constructs were transfected into HEK293T cells using X-tremeGENE 9 reagent according to the manufacturer's protocol. Two days after transfection, cells were lysed with RIPA buffer containing proteinase inhibitors (Invitrogen) and standard immunoblot analysis was performed. Mouse anti-Cas9 (1:1000, Active Motif) and mouse α-tubulin (1:1000, Sigma) antibodies were used.
[0158] RT-qPCR Cells were harvested using Trizol followed by Direct-zol (Zymo Research) according to the manufacturer's instructions. RNA was converted to cDNA using first strand cDNA synthesis (Invitrogen Superscript III). Quantitative PCR reactions were prepared using SYBR Green (Invitrogen) and reactions were performed on a 7900HT Fast ABI instrument. Primer information for RT-qPCR is listed in Supplementary Table S3.
[0159] ChIP assay ChIP experiments were performed as described previously (Dowen et al., 2014). Briefly, cells were crosslinked with 1% formaldehyde in medium for 10 min at room temperature, and the reaction was stopped by adding 0.125 M glycine for 5 min. Harvested cells were washed twice with PBS and then resuspended in 3.5 ml sonication buffer. Sonication was performed in an ice-water mixture at 24 watts for 10 cycles of 0.5 min pulse on and 1 min rest. Cell lysates were then centrifuged at 14,000x rpm for 10 min at 4°C. 50 ul of the supernatant was saved as gDNA input. 10 ul of anti-CTCF antibody (EMD Millipore:07729) or anti-Cas9 antibody (Active Motif) was added and incubated overnight at 4°C. 50ul of Protein G Dynabeads was added to the antibody-cell lysate mixture and incubated overnight at 4°C. The beads were then washed with sonication buffer, high salt (500mM NaCl) sonication buffer, LiCl wash buffer, and TE buffer. Bound protein-DNA complexes were eluted from the beads by incubation in a 65°C oven for 15 minutes and then reverse cross-linked overnight at 65°C. Bound DNA was purified with Qiagen QIAquick PCR Purification Kit before qPCR analysis or sequencing.
[0160] ChIP-seq data analysis Sequencing data were analyzed as previously reported (Wu et al., 2014b). Reads were demultiplexed and the first 25 bases were mapped to the mouse genome (mm10) using STAR (Dobin et al., 2013) to find unique mappings, allowing one mismatch. Mapped reads were collapsed and an equal number of reads (~15 million) were randomly sampled from each sample to match the sequencing depth. Peaks were detected using MACS (Zhang et al., 2008) with default settings. For each sample, the other five samples were used as controls, respectively, and only peaks detected above all five controls were defined as candidate peaks. Candidate peaks were filtered by fold enrichment over background and a threshold was selected to ensure that none of the four control samples (input, mock IP, dCas9 alone, and scrambled gRNA) had peaks above this threshold. Of note, for inputs that mapped to 45S rRNA and mitochondrial DNA, six candidate peaks were excluded from the analysis. The raw data are available at the following link: ncbi.nlm.nih.gov / geo / query / acc.cgi?token=ktohskmgnhudhud&acc=GSE83890.
[0161] Bisulfite conversion, PCR, and sequencing Bisulfite conversion of DNA was established using the EpiTect Bisulfite Kit (Qiagen) according to the manufacturer's instructions. The resulting modified DNA was amplified by a first round of nested PCR followed by a second round with locus-specific PCR primers (Supplementary Table S3). The first round of nested PCR was performed as follows: 94 °C for 4 min; 55 °C for 2 min; 72 °C for 2 min; repeat steps 1-3 once; 94 °C for 1 min; 55 °C for 2 min; 72 °C for 2 min; repeat steps 5-7 35 times; 72 °C for 5 min; hold at 12 °C. The second round of PCR was as follows: 95 °C for 4 min; 94 °C for 1 min; 55 °C for 2 min; 72 °C for 2 min; repeat steps 2-4 35 times; 72 °C for 5 min; hold at 12 °C. The resulting amplification products were gel purified, subcloned into pCR2.1-TOPO-TA cloning vector (Life technologies) and sequenced. Primer information for bisulfite sequencing is listed in Supplementary Table S4.
[0162] Locus-specific TAB-seq TAB-Seq was performed as previously described (Yu et al., 2012). Briefly, 1 ug of genomic DNA from treated mouse cortical neurons was glucosylated for 1 h at 37°C in a solution containing 50 mM HEPES buffer (pH 8.0), 25 mM MgCl2, 100 ng / ml model DNA, 200 mM UDP-Glc, and 1 mM bGT. After the reaction, the DNA was column purified. The oxidation reaction was carried out in a solution containing 50 mM HEPES buffer (pH 8.0), 100 mM ammonium iron(II) sulfate, 1 mM α-ketoglutarate, 2 mM ascorbic acid, 2.5 mM DTT, 100 mM NaCl, 1.2 mM ATP, 15 ng / ml glucosylated DNA, and 3 mM recombinant mTet1. The reaction was incubated at 37°C for 1 h. After treatment with proteinase K, DNA was column purified and then purified using EpiTect according to the supplier's instructions. Bisulfite Kit (QIAGEN). The resulting modified DNA was amplified by a first round of nested PCR, followed by a second round using locus-specific PCR primers (Supplementary Table S3). The resulting amplification products were gel purified, subcloned into pJET cloning vector (Life technologies), and sequenced. Primer information for bisulfite sequencing is listed in Supplementary Table S4.
[0163] Chromosome Conformation Capture (3C) Assay 5×10 6 mESCs were fixed with 1% formaldehyde for 20 min at room temperature, and the reaction was quenched with 0.125 M glycine for 5 min at room temperature. Crosslinked cells were harvested and washed with 1 ml of ice-cold PBS. The cell pellet was resuspended in 550 μl of lysis buffer (10 mM Tris-HCl with pH 8.0, 10 mM NaCl, and 0.2% IGEPAL CA630 with proteinase inhibitors) and incubated on ice for 20 min. The cell pellet was then washed twice with 1x NEB buffer 2 (NEB, B7002S) and then incubated with 50 μl of 0.5% SDS at 62 °C for 10 min. After heating, 145 μl of H2O and 25 μl of 10% Triton X-100 were added to the mixture and incubated at 37 °C for 15 min. Chromatin was digested overnight at 37° C. by adding 25 μl of 10x NEB buffer 2 and 100 U of BglII (NEB, R0144S). The digestion reaction was inactivated by incubating at 62° C. for 20 min. Then, 713 μl of HO, 120 μl of 10x T4 DNA ligase buffer (NEB, B0202), 100 μl of 10% Triton X-100, 12 μl of 10 mg / ml BSA, and 5 μl of T4 DNA ligase (NEB, M0202) was added and incubated at 16°C for 22 hours. Chromatin was reverse cross-linked and DNA was purified by phenol:chloroform:isoamyl alcohol (Sigma, P3803) extraction. 3C interactions at the miR290 and Pou5f1 loci (Figure 6A and Figure 6C) were analyzed by quantitative real-time PCR using custom Taqman probes. The amount of DNA in the qPCR reaction was normalized across the 3C library using a custom Taqman probe targeting the Actb locus. Primer and probe sequences are listed in Supplementary Table S5.
[0164] Supplementary table Supplementary Table S1: dCas9 ChIP-Seq (SEQ ID NOs: 1-35) [Table 1]
[0165] Supplementary Table S2: Primer sequences for constructing guide RNAs [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4]
[0166] Supplementary Table S3: qPCR primers [Table 3-1] [Table 3-2]
[0167] Supplementary Table S4: Primers for bisulfite sequencing [Table 4-1] [Table 4-2]
[0168] Supplementary Table S5: Primers for 3C assay [Table 5-1] [Table 5-2]
[0169] Supplementary Table S6: Full-length protein sequences of dCas9-Dnmt3a / Tet and mutants. dCas9-Dnmt3a (dC-D) (SEQ ID NO: 157) [ka]
[0170] dCas9-Dnmt3a_IM (dC-dD, an inactive mutant form of Dnmt3a) (SEQ ID NO: 158) [ka]
[0171] dCas9-Tet1CD(dC-T) (SEQ ID NO: 159) [ka]
[0172] dCas9-Tet1CD_IM (dC-dT, an inactive mutant form of Tet1) (SEQ ID NO: 160) [ka] [ka]
[0173] dCas9-Dnmt3a-P2A-BFP (SEQ ID NO: 161) [ka] [ka] References (the contents of which are incorporated herein by reference in their entirety): Bell, AC, and Felsenfeld, G. (2000).Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene.Nature 405,482-485. Bernstein, DL, Le Lay, JE, Ruano, EG, and Kaestner, KH (2015). TALE-mediated epigenetic suppression of CDKN2A increases replication in human fibroblasts. J Clin Invest 125, 1998-2006. Bird, A. (2002).DNA methylation patterns and epigenetic memory.Genes Dev 16,6-21. Boch, J., and Bonas, U. (2010). Xanthomonas AvrBs3 family-type III effectors: discovery and function. Annual review of phytopathology 48, 419-436. Brunk, BP, Goldhamer, DJ, and Emerson, CP, Jr. (1996).Regulated demethylation of the myoD distal enhancer during skeletal myogenesis.Dev Biol 177,490-503. Carroll,D.(2008).Progress and prospects:zinc-finger nucleases as gene therapy agents.Gene Ther 15,1463-1468. Cedar,H.,and Bergman,Y.(2012).Programming of DNA methylation patterns.Annu Rev Biochem 81,97-117. Chen,B.,Gilbert,L.A.,Cimini,B.A.,Schnitzbauer,J.,Zhang,W.,Li,G.W.,Park,J.,Blackburn,E.H.,Weissman,J.S.,Qi,L.S.,et al.(2013).Dynamic imaging of genomic loci in living human cells by an optimized CRISPR / Cas system.Cell 155,1479-1491. Chen,W.G.,Chang,Q.,Lin,Y.,Meissner,A.,West,A.E.,Griffith,E.C.,Jaenisch,R.,and Greenberg,M.E.(2003).Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2.Science 302,885-889. Choudhury,S.R.,Cui,Y.,Lubecka,K.,Stefanska,B.,and Irudayaraj,J.(2016).CRISPR-dCas9 mediated TET1 targeting for selective DNA demethylation at BRCA1 promoter.Oncotarget. Cong,L.,Ran,F.A.,Cox,D.,Lin,S.L.,Barretto,R.,Habib,N.,Hsu,P.D.,Wu,X.B.,Jiang,W.Y.,Marraffini,L.A.,et al.(2013).Multiplex Genome Engineering Using CRISPR / Cas Systems.Science 339,819-823. Constantinides,P.G.,Jones,P.A.,and Gevers,W.(1977).Functional striated muscle cells from non- myoblast precursors following 5-azacytidine treatment.Nature 267,364-366. Davis,R.L.,Weintraub,H.,and Lassar,A.B.(1987).Expression of a single transfected cDNA converts fibroblasts to myoblasts.Cell 51,987-1000. Dawlaty,M.M.,Breiling,A.,Le,T.,Barrasa,M.I.,Raddatz,G.,Gao,Q.,Powell,B.E.,Cheng,A.W.,Faull,K.F.,Lyko,F.,et al.(2014).Loss of Tet enzymes compromises proper differentiation of embryonic stem cells.Dev Cell 29,102-111. Dawlaty,M.M.,Ganz,K.,Powell,B.E.,Hu,Y.C.,Markoulaki,S.,Cheng,A.W.,Gao,Q.,Kim,J.,Choi,S.W.,Page,D.C.,et al.(2011).Tet1 is dispensable for maintaining pluripotency and its loss is compatible with embryonic and postnatal development.Cell Stem Cell 9,166-175. De Jager,P.L.,Srivastava,G.,Lunnon,K.,Burgess,J.,Schalkwyk,L.C.,Yu,L.,Eaton,M.L.,Keenan,B.T.,Ernst,J.,McCabe,C.,et al.(2014).Alzheimer’s disease:early alterations in brain DNA methylation at ANK1,BIN1,RHBDF2 and other loci.Nat Neurosci 17,1156-1163. Dixon,J.R.,Selvaraj,S.,Yue,F.,Kim,A.,Li,Y.,Shen,Y.,Hu,M.,Liu,J.S.,and Ren,B.(2012).Topological domains in mammalian genomes identified by analysis of chromatin interactions.Nature 485,376-380. Dobin,A.,Davis,C.A.,Schlesinger,F.,Drenkow,J.,Zaleski,C.,Jha,S.,Batut,P.,Chaisson,M.,and Gingeras,T.R.(2013).STAR:ultrafast universal RNA-seq aligner.Bioinformatics 29,15-21. Doi,A.,Park,I.H.,Wen,B.,Murakami,P.,Aryee,M.J.,Irizarry,R.,Herb,B.,Ladd-Acosta,C.,Rho,J.,Loewer,S.,et al.(2009).Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells,embryonic stem cells and fibroblasts.Nat Genet 41,1350-1353. Dowen,J.M.,Fan,Z.P.,Hnisz,D.,Ren,G.,Abraham,B.J.,Zhang,L.N.,Weintraub,A.S.,Schuijers,J.,Lee,T.I.,Zhao,K.,et al.(2014).Control of cell identity genes occurs in insulated neighborhoods in mammalian chromosomes.Cell 159,374-387. Ebert,D.H.,Gabel,H.W.,Robinson,N.D.,Kastan,N.R.,Hu,L.S.,Cohen,S.,Navarro,A.J.,Lyst,M.J.,Ekiert,R.,Bird,A.P.,et al.(2013).Activity-dependent phosphorylation of MeCP2 threonine 308 regulates interaction with NCoR.Nature 499,341-345. Flavahan,W.A.,Drier,Y.,Liau,B.B.,Gillespie,S.M.,Venteicher,A.S.,Stemmer-Rachamimov,A.O.,Suva,M.L.,and Bernstein,B.E.(2016).Insulator dysfunction and oncogene activation in IDH mutant gliomas.Nature 529,110-114. Gibcus,J.H.,and Dekker,J.(2013).The hierarchy of the 3D genome.Mol Cell 49,773-782. Gilbert,L.A.,Larson,M.H.,Morsut,L.,Liu,Z.,Brar,G.A.,Torres,S.E.,Stern-Ginossar,N.,Brandman,O.,Whitehead,E.H.,Doudna,J.A.,et al.(2013).CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes.Cell 154,442-451. Gorkin,D.U.,Leung,D.,and Ren,B.(2014).The 3D genome in transcriptional regulation and pluripotency.Cell Stem Cell 14,762-775. Guo,J.U.,Su,Y.,Zhong,C.,Ming,G.L.,and Song,H.(2011).Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain.Cell 145,423-434. Hilton,I.B.,D’Ippolito,A.M.,Vockley,C.M.,Thakore,P.I.,Crawford,G.E.,Reddy,T.E.,and Gersbach,C.A.(2015).Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers.Nat Biotechnol 33,510-517. Hockemeyer,D.,Soldner,F.,Beard,C.,Gao,Q.,Mitalipova,M.,DeKelver,R.C.,Katibah,G.E.,Amora,R.,Boydston,E.A.,Zeitler,B.,et al.(2009).Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases.Nat Biotechnol 27,851-857. Hockemeyer,D.,Wang,H.,Kiani,S.,Lai,C.S.,Gao,Q.,Cassady,J.P.,Cost,G.J.,Zhang,L.,Santiago,Y.,Miller,J.C.,et al.(2011).Genetic engineering of human pluripotent cells using TALE nucleases.Nat Biotechnol 29,731-734. Jaenisch,R.,and Bird,A.(2003).Epigenetic regulation of gene expression:how the genome integrates intrinsic and environmental signals.Nat Genet 33 Suppl,245-254.Ji,X.,Dadon,D.B.,Powell,B.E.,Fan,Z.P.,Borges-Rivera,D.,Shachar,S.,Weintraub,A.S.,Hnisz,D.,Pegoraro,G.,Lee,T.I.,et al.(2016).3D Chromosome Regulatory Landscape of Human Pluripotent Cells.Cell Stem Cell 18,262-275. Jinek,M.,Chylinski,K.,Fonfara,I.,Hauer,M.,Doudna,J.A.,and Charpentier,E.(2012).A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.Science 337,816-821. Kagey,M.H.,Newman,J.J.,Bilodeau,S.,Zhan,Y.,Orlando,D.A.,van Berkum,N.L.,Ebmeier,C.C.,Goossens,J.,Rahl,P.B.,Levine,S.S.,et al.(2010).Mediator and cohesin connect gene expression and chromatin architecture.Nature 467,430-435. Kang,J.Y.,Song,S.H.,Yun,J.,Jeon,M.S.,Kim,H.P.,Han,S.W.,and Kim,T.Y.(2015).Disruption of CTCF / cohesin-mediated high-order chromatin structures by DNA methylation downregulates PTGS2 expression.Oncogene 34,5677-5684. Konermann,S.,Brigham,M.D.,Trevino,A.E.,Joung,J.,Abudayyeh,O.O.,Barcena,C.,Hsu,P.D.,Habib,N.,Gootenberg,J.S.,Nishimasu,H.,et al.(2015).Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex.Nature 517,583-U332. Laird,P.W.,and Jaenisch,R.(1996).The role of DNA methylation in cancer genetics and epigenetics.Annual Review of Genetics 30,441-464. Landau,D.A.,Clement,K.,Ziller,M.J.,Boyle,P.,Fan,J.,Gu,H.,Stevenson,K.,Sougnez,C.,Wang,L.,Li,S.,et al.(2014).Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia.Cancer Cell 26,813-825. Lassar,A.B.,Paterson,B.M.,and Weintraub,H.(1986).Transfection of a DNA locus that mediates the conversion of 10T1 / 2 fibroblasts to myoblasts.Cell 47,649-656. Li,E.,Bestor,T.H.,and Jaenisch,R.(1992).Targeted mutation of the DNA methyltransferase gene results in embryonic lethality.Cell 69,915-926. Lin,Y.,Bloodgood,B.L.,Hauser,J.L.,Lapan,A.D.,Koon,A.C.,Kim,T.K.,Hu,L.S.,Malik,A.N.,and Greenberg,M.E.(2008).Activity-dependent regulation of inhibitory synapse development by Npas4.Nature 455,1198-1204. Lister,R.,Mukamel,E.A.,Nery,J.R.,Urich,M.,Puddifoot,C.A.,Johnson,N.D.,Lucero,J.,Huang,Y.,Dwork,A.J.,Schultz,M.D.,et al.(2013).Global Epigenomic Reconfiguration During Mammalian Brain Development.Science 341,629-+. Lister,R.,Pelizzola,M.,Dowen,R.H.,Hawkins,R.D.,Hon,G.,Tonti-Filippini,J.,Nery,J.R.,Lee,L.,Ye,Z.,Ngo,Q.M.,et al.(2009).Human DNA methylomes at base resolution show widespread epigenomic differences.Nature 462,315-322. Maeder,M.L.,Angstman,J.F.,Richardson,M.E.,Linder,S.J.,Cascio,V.M.,Tsai,S.Q.,Ho,Q.H.,Sander,J.D.,Reyon,D.,Bernstein,B.E.,et al.(2013).Targeted DNA demethylation and activation of endogenous genes using programmable TALE-TET1 fusion proteins.Nat Biotechnol 31,1137-1142. Mali,P.,Yang,L.,Esvelt,K.M.,Aach,J.,Guell,M.,DiCarlo,J.E.,Norville,J.E.,and Church,G.M.(2013).RNA-guided human genome engineering via Cas9.Science 339,823-826. Martinowich,K.,Hattori,D.,Wu,H.,Fouse,S.,He,F.,Hu,Y.,Fan,G.,and Sun,Y.E.(2003).DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation.Science 302,890-893. Narendra,V.,Rocha,P.P.,An,D.,Raviram,R.,Skok,J.A.,Mazzoni,E.O.,and Reinberg,D.(2015).CTCF establishes discrete functional chromatin domains at the Hox clusters during differentiation.Science 347,1017-1021. Nora,E.P.,Lajoie,B.R.,Schulz,E.G.,Giorgetti,L.,Okamoto,I.,Servant,N.,Piolot,T.,van Berkum,N.L.,Meisig,J.,Sedat,J.,et al.(2012).Spatial partitioning of the regulatory landscape of the X-inactivation centre.Nature 485,381-385. Phillips-Cremins,J.E.,Sauria,M.E.,Sanyal,A.,Gerasimova,T.I.,Lajoie,B.R.,Bell,J.S.,Ong,C.T.,Hookway,T.A.,Guo,C.,Sun,Y.,et al.(2013).Architectural protein subclasses shape 3D organization of genomes during lineage commitment.Cell 153,1281-1295. Phillips,J.E.,and Corces,V.G.(2009).CTCF:master weaver of the genome.Cell 137,1194-1211. Qi,L.S.,Larson,M.H.,Gilbert,L.A.,Doudna,J.A.,Weissman,J.S.,Arkin,A.P.,and Lim,W.A.(2013).Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression.Cell 152,1173-1183. Robertson,K.D.(2005).DNA methylation and human disease.Nat Rev Genet 6,597-610. Schultz,M.D.,He,Y.,Whitaker,J.W.,Hariharan,M.,Mukamel,E.A.,Leung,D.,Rajagopal,N.,Nery,J.R.,Urich,M.A.,Chen,H.,et al.(2015).Human body epigenome maps reveal noncanonical DNA methylation variation.Nature 523,212-216. Seitan,V.C.,Faure,A.J.,Zhan,Y.,McCord,R.P.,Lajoie,B.R.,Ing-Simmons,E.,Lenhard,B.,Giorgetti,L.,Heard,E.,Fisher,A.G.,et al.(2013).Cohesin-based chromatin interactions enable regulated gene expression within preexisting architectural compartments.Genome Res 23,2066-2077. Smith,ZD,and Meissner,A.(2013).DNA methylation:roles in mammalian development.Nat Rev Genet 14,204-220. Sofueva, S., Yaffe, E., Chan, WC, Georgopoulou, D., Vietri Rudan, M., Mira-Bontenbal, H., Pollard, S., Schroth, G., Tanay, A., and Hadjur, S. (2013).Cohesin-mediated interactions organize chromosomal domain architecture.EMBO J 32.3119–3 Stelzer,Y.,Shivalila,CS,Soldner,F.,Markoulaki,S.,and Jaenisch,R.(2015).Tracing dynamic changes of DNA methylation at single-cell resolution.Cell 163,218–229. Sweatt,JD(2013).The emerging field of neuroepigenetics.Neuron 80,624-632. Tang, Z., Luo, OJ, Li, X., Zheng, M., Zhu, JJ, Szalaj, P., Trzaskoma, P., Magalska, A., Wlodarczyk, J., Ruszczycki, B., et al Transcription.Cell 163,1611–1627. Vojta,A.,Dobrinic,P.,Tadic,V.,Bockor,L.,Korac,P.,Julg,B.,Klasic,M.,and Zoldos,V.(2016).Repurposing the CRISPR-Cas9 system for targeted DNA methylation.Nucleic Acids Res 44,5615-5628. Wang,H.,Maurano,M.T.,Qu,H.,Varley,K.E.,Gertz,J.,Pauli,F.,Lee,K.,Canfield,T.,Weaver,M.,Sandstrom,R.,et al.(2012).Widespread plasticity in CTCF occupancy linked to DNA methylation.Genome Res 22,1680-1688. Wilson,M.H.,Coates,C.J.,and George,A.L.,Jr.(2007).PiggyBac transposon-mediated gene transfer in human cells.Mol Ther 15,139-145. Wu,H.,Luo,J.,Yu,H.,Rattner,A.,Mo,A.,Wang,Y.,Smallwood,P.M.,Erlanger,B.,Wheelan,S.J.,and Nathans,J.(2014a).Cellular resolution maps of X chromosome inactivation:implications for neural development,function,and disease.Neuron 81,103-119. Wu,H.,and Zhang,Y.(2014).Reversing DNA methylation:mechanisms,genomics,and biological functions.Cell 156,45-68. Wu,X.,Scott,D.A.,Kriz,A.J.,Chiu,A.C.,Hsu,P.D.,Dadon,D.B.,Cheng,A.W.,Trevino,A.E.,Konermann,S.,Chen,S.,et al.(2014b).Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells.Nat Biotechnol 32,670-676. Xu,W.,Yang,H.,Liu,Y.,Yang,Y.,Wang,P.,Kim,S.H.,Ito,S.,Yang,C.,Wang,P.,Xiao,M.T.,et al.(2011).Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases.Cancer Cell 19,17-30. Xu,X.,Tao,Y.,Gao,X.,Zhang,L.,Li,X.,Zou,W.,Ruan,K.,Wang,F.,Xu,G.L.,and Hu,R.(2016).A CRISPR-based approach for targeted DNA demethylation.Cell discovery 2,16009.Yu,M.,Hon,G.C.,Szulwach,K.E.,Song,C.X.,Zhang,L.,Kim,A.,Li,X.,Dai,Q.,Shen,Y.,Park,B.,et al.(2012).Base-resolution analysis of 5-hydroxymethylcytosine in the mammalian genome.Cell 149,1368- 1380. Zhang,Y.,Liu,T.,Meyer,C.A.,Eeckhoute,J.,Johnson,D.S.,Bernstein,B.E.,Nusbaum,C.,Myers,R.M.,Brown,M.,Li,W.,et al.(2008).Model-based analysis of ChIP-Seq(MACS).Genome Biol 9,R137. Zuin, J., Dixon, JR, van der Reijden, MI, Ye, Z., Kolovos, P., Brouwer, RW, van de Corput, MP, van de Werken, HJ, Knoch, TA, van, IWF, et al. (2014). Cohesin and CTCF differentially affect chromatin architecture and gene expression in human cells. Proc Natl Acad Sci USA 111,996-1001. PCT Application No. PCT / US2014 / 034387, filed April 16, 2014, and U.S. Application No. 15 / 078,851, filed March 23, 2016
Claims
1. 1. A composition for altering expression of a gene adjacent to a chromatin loop in a cell, comprising: (a) a fusion protein or a nucleic acid encoding said fusion protein, said fusion protein comprising a catalytically inactive site-specific nuclease fused to an effector domain having methylation or demethylation activity; (b) a guide sequence or a nucleic acid encoding said guide sequence, wherein said guide sequence targets said fusion protein to a genomic sequence, and said genomic sequence comprises said chromatin loop comprising a CTCF binding site; A composition comprising:
2. The composition of claim 1 , wherein the effector domain having methylation activity comprises Dnmt3a.
3. The composition of claim 1 , wherein the effector domain having demethylation activity comprises Tet1.
4. The composition of any one of claims 1 to 3, wherein the catalytically inactive site-specific nuclease is a catalytically inactive Cas protein.
5. The composition of any one of claims 1 to 3, wherein the catalytically inactive site-specific nuclease is a catalytically inactive Cas9 protein.
6. The composition of any one of claims 1 to 3, wherein the catalytically inactive site-specific nuclease is a catalytically inactive Cpf1 protein.
7. The composition of any one of claims 1 to 6, wherein the guide sequence is a ribonucleic acid guide sequence.
8. 8. The composition of any one of claims 1 to 7, wherein the guide sequence is between 10 base pairs and 150 base pairs in length.
9. The composition of any one of claims 1 to 8, wherein the guide sequence comprises two or more guide sequences.
10. The composition of any one of claims 1 to 9, wherein the cell is a stem cell, a neuron, a post-mitotic cell, or a fibroblast.
11. The composition of any one of claims 1 to 10, wherein the cells are human cells.
12. The composition of any one of claims 1 to 11, wherein the fusion protein comprises one or more nuclear localization sequences.
13. The composition of claim 12, wherein at least one of the one or more nuclear localization sequences is fused between the catalytically inactive site-specific nuclease and the effector domain.
14. The composition of any one of claims 1 to 13, wherein expression of the gene is increased compared to expression of the gene in a cell without the composition.
15. The composition of any one of claims 1 to 13, wherein expression of the gene is reduced compared to expression of the gene in a cell without the composition.
16. The composition of any one of claims 1 to 15, wherein the gene is associated with a disease or condition.
17. 17. The composition of claim 16, wherein the disease or condition is cancer.
18. The composition of claim 14, wherein the gene is Nlrp12.
19. The composition of claim 14, wherein the gene is H2Q10.
